Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Lung Cancer

  Free Subscription


Articles published in J Thorac Oncol

Retrieve available abstracts of 967 articles:
HTML format



Single Articles


    August 2021
  1. AREDO JV, Wakelee HA, Han SS
    A Moving Target: Integration of Smoking Cessation Into Screening for Second Primary Lung Cancer.
    J Thorac Oncol. 2021;16:e59-e60.
    PubMed    


  2. PELOSI G, Pasini F
    Over-Time Risk of Lung Cancer Is Largely Owing to Continuing Smoking Exposition: A Good Reason to Quit.
    J Thorac Oncol. 2021;16:e57-e59.
    PubMed    


  3. SINGH N, Agrawal S, Jiwnani S, Khosla D, et al
    Lung Cancer in India.
    J Thorac Oncol. 2021;16:1250-1266.
    PubMed    


    July 2021
  4. DZIADZIUSZKO R, Mok T, Peters S, Han JY, et al
    Blood First Assay Screening Trial (BFAST) in Treatment-Naive Advanced or Metastatic Non-Small Cell Lung Cancer: Initial Results of the Phase 2 ALK-Positive Cohort.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02321.
    PubMed     Abstract available


  5. PATEL SA, Herynk MH, Cascone T, Saigal B, et al
    Estrogen promotes resistance to bevacizumab in murine models of non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02320.
    PubMed     Abstract available


  6. SOCINSKI MA, Nishio M, Jotte RM, Cappuzzo F, et al
    IMpower150 final overall survival analyses for atezolizumab plus bevacizumab and chemotherapy in first-line metastatic nonsquamous non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 23. pii: S1556-0864(21)02322.
    PubMed     Abstract available


  7. SMELTZER MP, Lee YS, Faris NR, Fehnel C, et al
    Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the United States.
    J Thorac Oncol. 2021 Jul 16. pii: S1556-0864(21)02299.
    PubMed     Abstract available


  8. STEWART CA, Gay CM, Ramkumar K, Cargill KR, et al
    Lung cancer models reveal SARS-CoV-2-induced EMT contributes to COVID-19 pathophysiology.
    J Thorac Oncol. 2021 Jul 15. pii: S1556-0864(21)02294.
    PubMed     Abstract available


  9. JASSEM J, de Marinis F, Giaccone G, Vergnenegre A, et al
    Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02286.
    PubMed     Abstract available


  10. AI X, Wang Q, Cheng Y, Liu X, et al
    Safety but Limited Efficacy of Ensartinib in ROS1-Positive Non-small Cell Lung Cancer: A Single-arm, Multicenter Phase II study.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02290.
    PubMed     Abstract available


  11. POWELL SF, Rodriguez-Abreu D, Langer CJ, Tafreshi A, et al
    Outcomes With Pembrolizumab Plus Platinum-Based Chemotherapy for Patients With Non-Small-Cell Lung Cancer and Stable Brain Metastases: Pooled Analysis of KEYNOTE-021, 189, and 407.
    J Thorac Oncol. 2021 Jul 12. pii: S1556-0864(21)02287.
    PubMed     Abstract available


  12. MYERS R, Brauer M, Dummer T, Atkar-Khattra S, et al
    High Ambient Air Pollution Exposure Among Never Smokers Versus Ever Smokers with Lung Cancer.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02256.
    PubMed     Abstract available


  13. WANG Y, Li J, Chang S, Dong Y, et al
    Risk and influencing factors for subsequent primary lung cancer after treatment of breast cancer: a systematic review and two meta-analyses based on four million cases.
    J Thorac Oncol. 2021 Jul 10. pii: S1556-0864(21)02293.
    PubMed     Abstract available


  14. ROLFO C, Mack P, Scagliotti GV, Aggarwal C, et al
    Liquid Biopsy for Advanced Non-Small Cell Lung Cancer: A Consensus Statement from The International Association for the Study of Lung Cancer (IASLC).
    J Thorac Oncol. 2021 Jul 8. pii: S1556-0864(21)02284.
    PubMed    


  15. HANN CL, Burns TF, Dowlati A, Morgensztern D, et al
    Brief Report: A Phase 1 Study Evaluating Rovalpituzumab Tesirine (Rova-T) in Frontline Treatment of Patients With Extensive-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02289.
    PubMed     Abstract available


  16. PARK HR, Kim TM, Lee Y, Kim S, et al
    Acquired resistance to third-generation EGFR tyrosine kinase inhibitors in patients with de novo EGFR(T790M)-mutant non-small cell lung cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02254.
    PubMed     Abstract available


  17. KUMAR A, Kumar S, Gilja S, Potter A, et al
    Reconsidering the American Joint Committee on Cancer 8(th) Edition TNM Staging Manual Classifications for T2b/T3 Non-small-cell Lung Cancer.
    J Thorac Oncol. 2021 Jul 6. pii: S1556-0864(21)02283.
    PubMed     Abstract available


  18. MOUNTZIOS G, Gkiozos I, Stratakos G, Pissakas G, et al
    Lung Cancer in Greece.
    J Thorac Oncol. 2021;16:1058-1066.
    PubMed    


    June 2021
  19. AKAMATSU H, Murakami H, Harada H, Shimizu J, et al
    Gefitinib with concurrent thoracic radiotherapy in unresectable locally advanced non-small cell lung cancer with EGFR mutation; West Japan Oncology Group 6911L.
    J Thorac Oncol. 2021 Jun 8. pii: S1556-0864(21)02190.
    PubMed     Abstract available


  20. SU CC, Wu JT, Neal JW, Popat RA, et al
    Impact of Low-Dose CT Screening for Primary Lung Cancer on Subsequent Risk of Brain Metastasis.
    J Thorac Oncol. 2021 Jun 3. pii: S1556-0864(21)02181.
    PubMed     Abstract available


  21. ANG YLE, Chia PL, Chua KLM, Devanand A, et al
    Lung Cancer in Singapore.
    J Thorac Oncol. 2021;16:906-911.
    PubMed    


  22. RAMI-PORTA R, Goldstraw P, Asamura H
    Commemorating the Silver Anniversary of the International Association for the Study of Lung Cancer International Workshop on Intrathoracic Staging.
    J Thorac Oncol. 2021;16:902-905.
    PubMed    


  23. GRASS GD, Scott JG, Sedor G, Kattan MW, et al
    Response to: Noncancer Cells in Tumor Samples May Bias the Predictive Genomically Adjusted Radiation Dose.
    J Thorac Oncol. 2021;16:e48-e49.
    PubMed    


  24. DU Y, Hu Z, Liang J, Zhan C, et al
    Noncancer Cells in Tumor Samples May Bias the Predictive Genomic-Adjusted Radiation Dose.
    J Thorac Oncol. 2021;16:e47.
    PubMed    


  25. RYAN BM
    In Response: Using Propensity Score Matching to Balance the Baseline Characteristics.
    J Thorac Oncol. 2021;16:e46.
    PubMed    


  26. LIANG J, Hu Z, Zhan C, Wang Q, et al
    Using Propensity Score Matching to Balance the Baseline Characteristics.
    J Thorac Oncol. 2021;16:e45-e46.
    PubMed    


  27. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Why Did the Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC Not Reveal a Difference?
    J Thorac Oncol. 2021;16:e42-e45.
    PubMed    


  28. BREEN WG, Brown PD, Laack NN
    Hippocampal Avoidance Prophylactic Cranial Irradiation for SCLC.
    J Thorac Oncol. 2021;16:e41-e42.
    PubMed    


  29. DEUTSCH E, Cengel KA, Galluzzi L, Levy A, et al
    Could Protons Promote Tumor Control by Avoiding Lymphopenia?
    J Thorac Oncol. 2021;16:e39-e41.
    PubMed    


  30. BAUMAN J, Borghaei H
    To Give or Not to Give: Consolidative Durvalumab in EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:894-896.
    PubMed    


  31. WARREN GW, Evans WK, Dresler C
    Critical Determinants of Cancer Treatment Outcomes: Smoking Must Be Addressed at the Highest Levels in Cancer Care.
    J Thorac Oncol. 2021;16:891-893.
    PubMed    


  32. CAMIDGE DR, Otterson GA, Clark JW, Ignatius Ou SH, et al
    Crizotinib in Patients With MET-Amplified NSCLC.
    J Thorac Oncol. 2021;16:1017-1029.
    PubMed     Abstract available


  33. FINN SP, Addeo A, Dafni U, Thunnissen E, et al
    Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project.
    J Thorac Oncol. 2021;16:990-1002.
    PubMed     Abstract available


  34. STEUER CE, Jegede OA, Dahlberg SE, Wakelee HA, et al
    Smoking Behavior in Patients With Early-Stage NSCLC: A Report From ECOG-ACRIN 1505 Trial.
    J Thorac Oncol. 2021;16:960-967.
    PubMed     Abstract available


    May 2021
  35. JAZIEH AR, Onal HC, Weng Tan DS, Soo RA, et al
    Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: Results of KINDLE, a multi-country observational study.
    J Thorac Oncol. 2021 May 26. pii: S1556-0864(21)02174.
    PubMed     Abstract available


  36. ZHOU C, Wu L, Fan Y, Wang Z, et al
    Sintilimab plus platinum and gemcitabine as first-line treatment for advanced or metastatic squamous non-small-cell lung cancer: results from a randomized, double-blind, phase 3 trial (ORIENT-12).
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02128.
    PubMed     Abstract available


  37. HERBST RS, Garon EB, Kim DW, Cho BC, et al
    5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02172.
    PubMed     Abstract available


  38. JOHNSON AM, Boland JM, Wrobel J, Klezcko EK, et al
    Cancer cell-specific MHCII expression as a determinant of the immune infiltrate organization and function in the non-small cell lung cancer tumor microenvironment.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02175.
    PubMed     Abstract available


  39. BARBI J, Patnaik SK, Pabla S, Zollo R, et al
    Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.
    J Thorac Oncol. 2021 May 25. pii: S1556-0864(21)02171.
    PubMed     Abstract available


  40. LU S, Wang J, Yu Y, Yu X, et al
    Tislelizumab Plus Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (RATIONALE 304): A Randomized Phase 3 Trial.
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02176.
    PubMed     Abstract available


  41. ZHAO H, Yao W, Min X, Gu K, et al
    Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706).
    J Thorac Oncol. 2021 May 22. pii: S1556-0864(21)02177.
    PubMed     Abstract available


  42. LOIOLA DE ALENCAR VT, Camandaroba MPG, Pirolli R, Fogassa CAZ, et al
    Immunotherapy as Single Treatment for Non-small-cell Lung Cancer Patients with Brain Metastases: a systematic review and meta-analysis - the META-L-BRAIN study.
    J Thorac Oncol. 2021 May 5. pii: S1556-0864(21)02131.
    PubMed     Abstract available


  43. OSAROGIAGBON RU, Ray MA, Faris NR, Smeltzer MP, et al
    Response to: "Lymph Node Dissection for Non-Small-Cell Lung Cancer at Whose Discretion?"
    J Thorac Oncol. 2021;16:e36-e37.
    PubMed    


  44. PIRKER R, Prosch H, Popper H, Klepetko W, et al
    Lung Cancer in Austria.
    J Thorac Oncol. 2021;16:725-733.
    PubMed    


  45. KIM CG, Cho BC, Lim SM
    Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?
    J Thorac Oncol. 2021;16:709-711.
    PubMed    


  46. LI M, Zhan C, Wang Q
    Is the Story of M Descriptors Fulfilled or Finished?
    J Thorac Oncol. 2021;16:e36-e37.
    PubMed    


  47. METOVIC J, Bianchi F, Barella M, Papotti M, et al
    SMARCA2 Deficiency While Preserving SMARCA4 and SMARCB1 in Lung Neuroendocrine Carcinomas.
    J Thorac Oncol. 2021;16:e32-e35.
    PubMed    


  48. DE CARLO E, Schiappacassi M, Del Conte A, Stanzione B, et al
    Combination of Chemotherapy and ALK Inhibitors in ALK-Positive NSCLC.
    J Thorac Oncol. 2021;16:e31-e32.
    PubMed    


  49. NISHIO M, Mendus D, Wang L, Socinski MA, et al
    Response to Letter to the Editor.
    J Thorac Oncol. 2021;16:e30-e31.
    PubMed    


  50. DI FEDERICO A, Nuvola G, Deiana C, Donati G, et al
    IMpower 132: Is the Second Exception to the Rule No Longer an Exception?
    J Thorac Oncol. 2021;16:e29-e30.
    PubMed    


  51. SEDOR G, Scott JG, Kattan MW, Torres-Roca JF, et al
    Letter Response.
    J Thorac Oncol. 2021;16:e28-e29.
    PubMed    


  52. MISTRY HB
    Simulating RTOG 0617 using Genomic Adjusted Radiation Dose: Comparing Apples With Oranges.
    J Thorac Oncol. 2021;16:e27.
    PubMed    


  53. RIMNER A, Wu AJ, Grills IS
    What Is the Impact of Hippocampus Avoidance-Prophylactic Cranial Irradiation on Neurocognitive Preservation?
    J Thorac Oncol. 2021;16:722-724.
    PubMed    


  54. WESTEEL V
    Surveillance After Curative-Intent Treatment for NSCLC: More to It Than Meets the Eye.
    J Thorac Oncol. 2021;16:719-721.
    PubMed    


  55. JULOORI A, Vokes EE
    Beyond PACIFIC: Uncharted Waters.
    J Thorac Oncol. 2021;16:715-718.
    PubMed    


  56. LIU SY, Wu YL
    Unmet Clinical Demand for Patients With Unresectable Stage III NSCLC Having Actionable Genetic Alterations.
    J Thorac Oncol. 2021;16:712-714.
    PubMed    


  57. ADJEI AA, Ignatius Ou SH, Ho C, Pujol JL, et al
    Increasing Transparency in Author Contributions to Manuscripts: Enhanced Policy on Ghost and Honorary Authorships.
    J Thorac Oncol. 2021;16:706-708.
    PubMed    


  58. MATSUI S, Le-Rademacher J, Mandrekar SJ
    Statistical Models in Clinical Studies.
    J Thorac Oncol. 2021;16:734-739.
    PubMed     Abstract available


  59. STIRLING RG, Chau C, Shareh A, Zalcberg J, et al
    Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2021;16:784-797.
    PubMed     Abstract available


  60. BELDERBOS JSA, De Ruysscher DKM, De Jaeger K, Koppe F, et al
    Phase 3 Randomized Trial of Prophylactic Cranial Irradiation With or Without Hippocampus Avoidance in SCLC (NCT01780675).
    J Thorac Oncol. 2021;16:840-849.
    PubMed     Abstract available


  61. HELLYER JA, Aredo JV, Das M, Ramchandran K, et al
    Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC.
    J Thorac Oncol. 2021;16:868-872.
    PubMed     Abstract available


  62. FAIVRE-FINN C, Vicente D, Kurata T, Planchard D, et al
    Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.
    J Thorac Oncol. 2021;16:860-867.
    PubMed     Abstract available


  63. NAGASAKA M, Zhu VW, Lim SM, Greco M, et al
    Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
    J Thorac Oncol. 2021;16:740-763.
    PubMed     Abstract available


  64. PASSARO A, Mok T, Peters S, Popat S, et al
    Recent Advances on the Role of EGFR Tyrosine Kinase Inhibitors in the Management of NSCLC With Uncommon, Non Exon 20 Insertions, EGFR Mutations.
    J Thorac Oncol. 2021;16:764-773.
    PubMed     Abstract available


    April 2021
  65. AI X, Pan Y, Shi J, Yang N, et al
    Efficacy and Safety of Niraparib as Maintenance Treatment in Patients with Extensive-Stage Small Cell Lung Cancer after First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02111.
    PubMed     Abstract available


  66. YONESHIMA Y, Morita S, Ando M, Nakamura A, et al
    Phase 3 trial comparing nab-paclitaxel with docetaxel for previously treated advanced non-small cell lung cancer.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02107.
    PubMed     Abstract available


  67. HWANG DM, Albaqer T, Santiago RC, Weiss J, et al
    Prevalence and heterogeneity of PD-L1 expression by 22C3 assay in routine population-based and reflexive clinical testing in lung cancer.
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02108.
    PubMed     Abstract available


  68. QIAO M, Jiang T, Liu X, Mao S, et al
    Immune checkpoint inhibitors in EGFR-mutated non-small cell lung cancer: Dusk or Dawn?
    J Thorac Oncol. 2021 Apr 26. pii: S1556-0864(21)02113.
    PubMed     Abstract available


  69. ANDRUSKA N, Stowe HB, Crockett C, Liu W, et al
    Stereotactic Radiation for Lung Cancer: A Practical Approach to Challenging Scenarios.
    J Thorac Oncol. 2021 Apr 23. pii: S1556-0864(21)02112.
    PubMed     Abstract available


  70. SAFIRI S, Sohrabi MR, Carson-Chahhoud K, Bettampadi D, et al
    Burden of tracheal, bronchus and lung cancer and its attributable risk factors in 204 countries and territories, 1990-2019.
    J Thorac Oncol. 2021 Apr 15. pii: S1556-0864(21)02110.
    PubMed     Abstract available


  71. PATAER A, Weissferdt A, Vaporciyan AA, Correa AM, et al
    Evaluation of Pathologic Response in Lymph Nodes of Lung Cancer Patients Receiving Neoadjuvant Chemotherapy.
    J Thorac Oncol. 2021 Apr 12. pii: S1556-0864(21)02109.
    PubMed     Abstract available


  72. BAUMEISTER SE, Baurecht H, Nolde M, Alayash Z, et al
    Cannabis use, pulmonary function, and lung cancer susceptibility: A Mendelian randomization study.
    J Thorac Oncol. 2021 Apr 11. pii: S1556-0864(21)02105.
    PubMed     Abstract available


  73. MEMMOTT RM, Wolfe AR, Carbone DP, Williams TM, et al
    Predictors of Response, Progression Free Survival, and Overall Survival in Lung Cancer Patients Treated with Immune Checkpoint Inhibitors.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02072.
    PubMed     Abstract available


  74. PARK K, Ozguroglu M, Vansteenkiste J, Spigel D, et al
    Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)01832.
    PubMed     Abstract available


  75. ALESSI JV, Ricciuti B, Spurr LF, Gupta H, et al
    SMARCA4 and other SWI/SNF family genomic alterations in non-small cell lung cancer: Clinicopathological characteristics and outcomes to immune checkpoint inhibition.
    J Thorac Oncol. 2021 Apr 9. pii: S1556-0864(21)02104.
    PubMed     Abstract available


  76. LIU L, Bai H, Wang C, Seery S, et al
    Efficacy and Safety of First-Line Immunotherapy Combinations for Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Network Meta-Analysis.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02071.
    PubMed     Abstract available


  77. ODINTSOV I, Mattar MS, Lui AJW, Offin M, et al
    Novel preclinical patient-derived lung cancer models reveal inhibition of HER3 and MTOR signaling as therapeutic strategies for NRG1 fusion-positive cancers.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02068.
    PubMed     Abstract available


  78. THOMAS PL, Groves SM, Zhang YK, Li J, et al
    Beyond PD-L1: B7-H6 emerges as a potential immunotherapy target in small cell lung cancer.
    J Thorac Oncol. 2021 Apr 8. pii: S1556-0864(21)02066.
    PubMed     Abstract available


  79. JOHNSON ML, Zvirbule Z, Laktionov K, Helland A, et al
    Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study.
    J Thorac Oncol. 2021 Apr 3. pii: S1556-0864(21)02067.
    PubMed     Abstract available


  80. LUO YH, Chiu CH, Scott Kuo CH, Chou TY, et al
    Lung Cancer in Republic of China.
    J Thorac Oncol. 2021;16:519-527.
    PubMed    


  81. GOTO T
    Lymph Node Dissection for NSCLC at Whose Discretion?
    J Thorac Oncol. 2021;16:e25.
    PubMed    


  82. PAZ-ARES L
    Response to: Bintrafusp Alfa in Second-Line Treatment of Patients With NSCLC.
    J Thorac Oncol. 2021;16:e24.
    PubMed    


  83. XU J, Nie H, Wan H
    Bintrafusp Alfa in the Second-Line Treatment of Patients With NSCLC.
    J Thorac Oncol. 2021;16:e23-e24.
    PubMed    


  84. QIU H, Li Q, Xiao Y, Wu D, et al
    A Novel Intergenic Region Between KLHL31 and LRRC1-ALK Exon 20 Fusion Variant in Advanced Lung Adenocarcinoma and its Remarkable Response to ALK Inhibitor.
    J Thorac Oncol. 2021;16:e21-e23.
    PubMed    


  85. NAGASAKA M, Ou SI
    Lorlatinib Should Be Considered as the Preferred First-Line Option in Patients With Advanced ALK-Rearranged NSCLC.
    J Thorac Oncol. 2021;16:532-536.
    PubMed    


  86. CAMIDGE DR
    Lorlatinib Should Not be Considered as the Preferred First-Line Option in Patients With Advanced ALK Rearranged NSCLC.
    J Thorac Oncol. 2021;16:528-531.
    PubMed    


  87. GADGEEL SM
    Patient-Reported Outcomes in the Era of Immunotherapy Trials.
    J Thorac Oncol. 2021;16:516-518.
    PubMed    


  88. FALKSON CB
    Postoperative Radiation for Completely Resected Stage II/III Thymoma: What Do We Know in 2021?
    J Thorac Oncol. 2021;16:515.
    PubMed    


  89. PATEL SP, Kelly K
    IMpower 132: Loses Power at the Finish Line.
    J Thorac Oncol. 2021;16:512-514.
    PubMed    


  90. PACHECO JM, Schenk EL
    CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC.
    J Thorac Oncol. 2021;16:509-511.
    PubMed    


  91. SEBASTIAN M, Stratmann JA, Eberhardt WEE
    Too Good to be True?
    J Thorac Oncol. 2021;16:507-508.
    PubMed    


  92. LE X
    Heterogeneity in MET-Aberrant NSCLC.
    J Thorac Oncol. 2021;16:504-506.
    PubMed    


  93. OU FS, Michiels S, Shyr Y, Adjei AA, et al
    Biomarker Discovery and Validation: Statistical Considerations.
    J Thorac Oncol. 2021;16:537-545.
    PubMed     Abstract available


  94. TATEISHI Y, Horita N, Namkoong H, Enomoto T, et al
    Postoperative Radiotherapy for Completely Resected Masaoka/Masaoka-Koga Stage II/III Thymoma Improves Overall Survival: An Updated Meta-Analysis of 4746 Patients.
    J Thorac Oncol. 2021;16:677-685.
    PubMed     Abstract available


  95. LE X, Negrao MV, Reuben A, Federico L, et al
    Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target.
    J Thorac Oncol. 2021;16:583-600.
    PubMed     Abstract available


  96. LAM VK, Zhang J, Wu CC, Tran HT, et al
    Genotype-Specific Differences in Circulating Tumor DNA Levels in Advanced NSCLC.
    J Thorac Oncol. 2021;16:601-609.
    PubMed     Abstract available


  97. VILLALBA JA, Shih AR, Sayo TMS, Kunitoki K, et al
    Accuracy and Reproducibility of Intraoperative Assessment on Tumor Spread Through Air Spaces in Stage 1 Lung Adenocarcinomas.
    J Thorac Oncol. 2021;16:619-629.
    PubMed     Abstract available


  98. MOONEN L, Derks JL, Hermans BCM, Bunnik IM, et al
    Preoperative Biopsy Diagnosis in Pulmonary Carcinoids, a Shot in the Dark.
    J Thorac Oncol. 2021;16:610-618.
    PubMed     Abstract available


    March 2021
  99. SCARFONE G, Fumagalli M, Imbimbo M, Ceruti T, et al
    First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report.
    J Thorac Oncol. 2021 Mar 29. pii: S1556-0864(21)01705.
    PubMed     Abstract available


  100. OSAROGIAGBON RU, Rami-Porta R, Tsao MS, Montuenga LM, et al
    The International Association for the Study of Lung Cancer (IASLC) Molecular Database Project: Objectives, Challenges and Opportunities.
    J Thorac Oncol. 2021 Mar 23. pii: S1556-0864(21)01781.
    PubMed    


  101. AREDO JV, Luo SJ, Gardner RM, Sanyal N, et al
    Tobacco Smoking and Risk of Second Primary Lung Cancer.
    J Thorac Oncol. 2021 Mar 12. pii: S1556-0864(21)01747.
    PubMed     Abstract available


  102. TANG WF, Wu M, Bao H, Xu Y, et al
    Timing and origins of local and distant metastases in lung cancer.
    J Thorac Oncol. 2021 Mar 12. pii: S1556-0864(21)01746.
    PubMed     Abstract available


  103. MINO-KENUDSON M, Le Stang N, Daigneault JB, Nicholson AG, et al
    IASLC Global Survey on PD-L1 Testing for Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Mar 1. pii: S1556-0864(21)01732.
    PubMed     Abstract available


  104. HENDRIKS LEL, Dingemans AC, De Ruysscher DKM, Aarts MJ, et al
    Lung Cancer in the Netherlands.
    J Thorac Oncol. 2021;16:355-365.
    PubMed    


  105. DY GK, Prasad D, Kumar P, Attwood K, et al
    A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating Nintedanib Versus Placebo as Prophylaxis Against Radiation Pneumonitis in Patients With Unresectable NSCLC Undergoing Chemoradiation Therapy.
    J Thorac Oncol. 2021;16:e19-e20.
    PubMed    


  106. YANG X, Li Y, Duan Q, Zhang Q, et al
    Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.
    J Thorac Oncol. 2021;16:e17-e19.
    PubMed    


  107. SHIELDS MD, Hicks JK, Boyle TA, Haura EB, et al
    Selpercatinib Overcomes CCDC6-RET-Mediated Resistance to Osimertinib.
    J Thorac Oncol. 2021;16:e15-e17.
    PubMed    


  108. UPRETY D
    Osimertinib Should Not Yet Be Considered the Standard of Care for EGFR-Mutant NSCLC in the Adjuvant Setting.
    J Thorac Oncol. 2021;16:371-374.
    PubMed    


  109. REMON J, Hendriks LEL
    Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:368-370.
    PubMed    


  110. ADJEI AA
    Controversies in Thoracic Oncology.
    J Thorac Oncol. 2021;16:366-367.
    PubMed    


  111. RAJAN A
    Immunotherapy for Thymic Cancers: A Convoluted Path Toward a Cherished Goal.
    J Thorac Oncol. 2021;16:352-354.
    PubMed    


  112. SONG L, Xu Q, Lizaso A, Zhang Y, et al
    Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC.
    J Thorac Oncol. 2021;16:349-351.
    PubMed    


  113. SONG Z, Lu C, Xu CW, Zheng Z, et al
    Noncanonical Gene Fusions Detected at the DNA Level Necessitate Orthogonal Diagnosis Methods Before Targeted Therapy.
    J Thorac Oncol. 2021;16:344-348.
    PubMed    


  114. WANG X, Piantadosi S, Le-Rademacher J, Mandrekar SJ, et al
    Statistical Considerations for Subgroup Analyses.
    J Thorac Oncol. 2021;16:375-380.
    PubMed    


  115. NILSSON MB, Robichaux J, Herynk MH, Cascone T, et al
    Altered Regulation of HIF-1alpha in Naive- and Drug-Resistant EGFR-Mutant NSCLC: Implications for a Vascular Endothelial Growth Factor-Dependent Phenotype.
    J Thorac Oncol. 2021;16:439-451.
    PubMed     Abstract available


  116. NG TL, Johnson A, Nemenoff RA, Hsieh E, et al
    Prospective Observational Study Revealing Early Pulmonary Function Changes Associated With Brigatinib Initiation.
    J Thorac Oncol. 2021;16:486-491.
    PubMed     Abstract available


  117. LI W, Guo L, Liu Y, Dong L, et al
    Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
    J Thorac Oncol. 2021;16:404-418.
    PubMed     Abstract available


  118. GIACCONE G, Kim C
    Durable Response in Patients With Thymic Carcinoma Treated With Pembrolizumab After Prolonged Follow-Up.
    J Thorac Oncol. 2021;16:483-485.
    PubMed     Abstract available


  119. SECHI E, Zekeridou A
    Neurologic Complications of Immune Checkpoint Inhibitors in Thoracic Malignancies.
    J Thorac Oncol. 2021;16:381-394.
    PubMed     Abstract available


    February 2021
  120. MALHOTRA J, Nikolinakos P, Leal T, Lehman J, et al
    A Phase I/II Study of Rovalpituzumab Tesirine in Combination With Nivolumab +/- Ipilimumab in Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2021 Feb 27. pii: S1556-0864(21)01745.
    PubMed     Abstract available


  121. YAMADA Y, Simon-Keller K, Belharazem-Vitacolonnna D, Bohnenberger H, et al
    A tuft cell-like signature is highly prevalent in thymic squamous cell carcinoma and delineates new molecular subsets among the major lung cancer histotypes.
    J Thorac Oncol. 2021 Feb 17. pii: S1556-0864(21)01708.
    PubMed     Abstract available


  122. BLACKHALL F, Jao K, Greillier L, Cho BC, et al
    Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01709.
    PubMed     Abstract available


  123. OSAROGIAGBON RU, Smeltzer MP, Faris NR, Ray MA, et al
    Outcomes Following Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01658.
    PubMed     Abstract available


  124. YUN JK, Lee GD, Choi S, Kim YH, et al
    A Validation Study on the Recommended Change in Residual Tumor Descriptors Proposed by the International Association for the Study of Lung Cancer for Patients with pN2 Non-small Cell Lung Cancer.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01668.
    PubMed     Abstract available


  125. ZHANG Y, Luo G, Etxeberria J, Hao Y, et al
    Global patterns and trends in lung cancer incidence: a population-based study.
    J Thorac Oncol. 2021 Feb 16. pii: S1556-0864(21)01700.
    PubMed     Abstract available


  126. YANG Y, Huang J, Wang T, Zhou J, et al
    Decoding the Evolutionary Response to Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer Patients by Dynamic Circulating Tumor DNA Sequencing.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01662.
    PubMed     Abstract available


  127. RAY MA, Fehnel C, Akinbobola O, Faris NR, et al
    Comparative Effectiveness of a Lymph Node Collection kit Versus 'Heightened Awareness' on Lung Cancer Surgery Quality and Outcomes.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01665.
    PubMed     Abstract available


  128. RADONIC T, Geurts-Giele WRR, Samsom KG, Roemen GMJM, et al
    RET FISH analysis is a sensitive but highly unspecific screening method for RET fusions in lung cancer.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01666.
    PubMed     Abstract available


  129. AREDO JV, Mambetsariev I, Hellyer JA, Amini A, et al
    Durvalumab for Stage III EGFR-Mutated Non-Small Cell Lung Cancer After Definitive Chemoradiotherapy.
    J Thorac Oncol. 2021 Feb 12. pii: S1556-0864(21)01702.
    PubMed     Abstract available


  130. HENDERSON LM, Durham DD, Tammemagi MC, Benefield T, et al
    Lung Cancer Screening with Low Dose Computed Tomography in Patients With and Without Prior History of Cancer in the National Lung Screening Trial.
    J Thorac Oncol. 2021 Feb 10. pii: S1556-0864(21)01703.
    PubMed     Abstract available


  131. YE L, Creaney J, Redwood A, Robinson B, et al
    The current lung cancer neoantigen landscape and implications for therapy.
    J Thorac Oncol. 2021 Feb 10. pii: S1556-0864(21)01698.
    PubMed     Abstract available


  132. ILIE M, MaziEres J, Chamorey E, Heeke S, et al
    Prospective multi-center validation of the detection of ALK rearrangements of circulating tumor cells for non-invasive longitudinal management of patients with advanced non-small cell lung cancer.
    J Thorac Oncol. 2021 Feb 3. pii: S1556-0864(21)01664.
    PubMed     Abstract available


  133. DAGOGO-JACK I, Moonsamy P, Gainor JF, Lennerz JK, et al
    A Phase II Study of Capmatinib in Patients with MET-Altered Lung Cancer Previously Treated with a MET Inhibitor.
    J Thorac Oncol. 2021 Feb 2. pii: S1556-0864(21)01650.
    PubMed     Abstract available


  134. BARTLETT EC, Silva M, Callister ME, Devaraj A, et al
    False negative results in lung cancer screening - Evidence and Controversies.
    J Thorac Oncol. 2021 Feb 2. pii: S1556-0864(21)01652.
    PubMed     Abstract available


  135. JOSEPH N, Choudhury A
    Dosimetric Predictors of Radiotherapy-Induced Lymphocytopenia in Lung Cancer.
    J Thorac Oncol. 2021;16:e11-e12.
    PubMed    


  136. LEIGHL NB
    Meeting Immunotherapy Resistance in Lung Cancer.
    J Thorac Oncol. 2021;16:187-190.
    PubMed    


  137. LEE J, Ahn MJ
    A Response to the Letter to the Editor: Osimertinib Leads the Way Towards Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
    J Thorac Oncol. 2021;16:e14.
    PubMed    


  138. ZHENG MM, Li YS, Sun H, Wu YL, et al
    Osimertinib Leads the Way Toward Improving Outcomes of EGFR-Mutant NSCLC With Leptomeningeal Metastases.
    J Thorac Oncol. 2021;16:e12-e14.
    PubMed    


  139. TSUI DCC, Camidge DR
    Molecular Profiling of the Cerebrospinal Fluid in Leptomeningeal NSCLC: The Shape of Things to Come?
    J Thorac Oncol. 2021;16:194-196.
    PubMed    


  140. SEQUIST LV, Skates SJ, Haas W
    A New Era of Protein-Based Assays for Cancer Early Detection.
    J Thorac Oncol. 2021;16:191-193.
    PubMed    


  141. FERRARA R, Campochiaro C, Garassino MC
    Shifting From a "One Size Fits All" to a Tailored Approach for Immune-Related Adverse Events.
    J Thorac Oncol. 2021;16:183-186.
    PubMed    


  142. PADDA SK, Reckamp KL
    Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-a Rational Approach.
    J Thorac Oncol. 2021;16:178-182.
    PubMed    


  143. MOK T, Peters S, Camidge DR, Noe J, et al
    Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
    J Thorac Oncol. 2021;16:259-268.
    PubMed     Abstract available


  144. LI B, Zhang Y, Miao L, Ma L, et al
    Esophagectomy With Three-Field Versus Two-Field Lymphadenectomy for Middle and Lower Thoracic Esophageal Cancer: Long-Term Outcomes of a Randomized Clinical Trial.
    J Thorac Oncol. 2021;16:310-317.
    PubMed     Abstract available


  145. BANFILL K, Giuliani M, Aznar M, Franks K, et al
    Cardiac Toxicity of Thoracic Radiotherapy: Existing Evidence and Future Directions.
    J Thorac Oncol. 2021;16:216-227.
    PubMed     Abstract available


  146. GJYSHI O, Xu T, Elhammali A, Boyce-Fappiano D, et al
    Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC.
    J Thorac Oncol. 2021;16:269-277.
    PubMed     Abstract available


  147. PETERS S, Felip E, Dafni U, Tufman A, et al
    Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology P
    J Thorac Oncol. 2021;16:278-288.
    PubMed     Abstract available


  148. JIANG T, Fang Z, Tang S, Cheng R, et al
    Mutational Landscape and Evolutionary Pattern of Liver and Brain Metastasis in Lung Adenocarcinoma.
    J Thorac Oncol. 2021;16:237-249.
    PubMed     Abstract available


  149. OSTRIN EJ, Bantis LE, Wilson DO, Patel N, et al
    Contribution of a Blood-Based Protein Biomarker Panel to the Classification of Indeterminate Pulmonary Nodules.
    J Thorac Oncol. 2021;16:228-236.
    PubMed     Abstract available


  150. LE X, Nilsson M, Goldman J, Reck M, et al
    Dual EGFR-VEGF Pathway Inhibition: A Promising Strategy for Patients With EGFR-Mutant NSCLC.
    J Thorac Oncol. 2021;16:205-215.
    PubMed     Abstract available


  151. MOI L, Bouchaab H, Mederos N, Nguyen-Ngoc T, et al
    Personalized Cytokine-Directed Therapy With Tocilizumab for Refractory Immune Checkpoint Inhibitor-Related Cholangiohepatitis.
    J Thorac Oncol. 2021;16:318-326.
    PubMed     Abstract available


    January 2021
  152. RECK M, Ciuleanu TE, Lee JS, Schenker M, et al
    First-Line Nivolumab Plus Ipilimumab vs Chemotherapy in Advanced Non-Small Cell Lung Cancer With Tumor PD-L1 >/= 1%: Patient-Reported Outcomes From CheckMate 227 Part 1.
    J Thorac Oncol. 2021 Jan 21. pii: S1556-0864(21)00041.
    PubMed     Abstract available


  153. CARBONE M, Lednicky J, Xiao SY, Venditti M, et al
    Coronavirus Infectious Disease Epidemic (COVID-19): where we are, what can be done and hope for.
    J Thorac Oncol. 2021 Jan 7. pii: S1556-0864(20)31140.
    PubMed     Abstract available


  154. LI L, Ling Y, Guo C, Guo L, et al
    Necrosis Is Not the Main Part of Immune-Related Pathologic Response to Neoadjuvant Immunotherapy in Squamous Cell Lung Cancer.
    J Thorac Oncol. 2021;16:e7-e9.
    PubMed    


  155. PUJOL JL, Thomas PA, Giraud P, Denis MG, et al
    Lung Cancer in France.
    J Thorac Oncol. 2021;16:21-29.
    PubMed    


  156. HAMANN HA, Williamson TJ, Studts JL, Ostroff JS, et al
    Lung Cancer Stigma Then and Now: Continued Challenges Amid a Landscape of Progress.
    J Thorac Oncol. 2021;16:17-20.
    PubMed    


  157. SHOJAEE S, Nana-Sinkam P
    One Metformin a Day, Keeps Lung Cancer Away! Or Does It?
    J Thorac Oncol. 2021;16:11-13.
    PubMed    


  158. TRAVIS WD, Dacic S, Sholl LM, Wistuba II, et al
    Pathologic Assessment of Lung Squamous Cell Carcinoma After Neoadjuvant Immunotherapy.
    J Thorac Oncol. 2021;16:e9-e10.
    PubMed    


  159. CALLSTROM MR, de Baere T
    Response to Is Cryoablation Really Safe and Efficacious: Analyzing Results Within SOLSTICE Trial.
    J Thorac Oncol. 2021;16:e6-e7.
    PubMed    


  160. SHARMA A, Kamal VK
    Is Cryoablation Really Safe and Efficacious? Analyzing Results From the SOLSTICE Trial.
    J Thorac Oncol. 2021;16:e5.
    PubMed    


  161. BAIRD AM, Finn SP, Gray SG, Sheils O, et al
    Epigenetic Modifier UHRF1 May Be a Potential Target in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:14-16.
    PubMed    


  162. LEE JJ, Yin G
    Principles and Reporting of Bayesian Trials.
    J Thorac Oncol. 2021;16:30-36.
    PubMed     Abstract available


  163. SANDS J, Tammemagi MC, Couraud S, Baldwin DR, et al
    Lung Screening Benefits and Challenges: A Review of The Data and Outline for Implementation.
    J Thorac Oncol. 2021;16:37-53.
    PubMed     Abstract available


  164. SATO H, Offin M, Kubota D, Yu HA, et al
    Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers.
    J Thorac Oncol. 2021;16:113-126.
    PubMed     Abstract available


  165. DIMOU A, Grewe P, Sidney J, Sette A, et al
    HLA Class I Binding of Mutant EGFR Peptides in NSCLC Is Associated With Improved Survival.
    J Thorac Oncol. 2021;16:104-112.
    PubMed     Abstract available


  166. REARDON ES, Shukla V, Xi S, Gara SK, et al
    UHRF1 Is a Novel Druggable Epigenetic Target in Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2021;16:89-103.
    PubMed     Abstract available


    December 2020
  167. NISHIO M, Barlesi F, West H, Ball S, et al
    Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial.
    J Thorac Oncol. 2020 Dec 14. pii: S1556-0864(20)31100.
    PubMed     Abstract available


  168. CHU T, Zhong R, Zhong H, Zhang B, et al
    Phase Ib Study of Sintilimab Plus Anlotinib as First-line Therapy in Patients with Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2020 Dec 14. pii: S1556-0864(20)31101.
    PubMed     Abstract available


  169. KRON A, Scheffler M, Heydt C, Ruge L, et al
    Genetic Heterogeneity of MET-aberrant Non-Small Cell Lung Cancer and its Impact on the Outcome of Immunotherapy.
    J Thorac Oncol. 2020 Dec 9. pii: S1556-0864(20)31091.
    PubMed     Abstract available


  170. PAN D, Hu AY, Antonia SJ, Li CY, et al
    A Gene Mutation Signature Predicting Immunotherapy Benefits in Non-Small Cell Lung Cancer Patients.
    J Thorac Oncol. 2020 Dec 8. pii: S1556-0864(20)31096.
    PubMed     Abstract available


  171. HELLYER JA, Padda SK, Diehn M, Wakelee HA, et al
    Clinical implications of KEAP1-NFE2L2 mutations in non-small cell lung cancer.
    J Thorac Oncol. 2020 Dec 8. pii: S1556-0864(20)31089.
    PubMed     Abstract available


  172. SCOTT JG, Sedor G, Scarborough JA, Kattan MW, et al
    Personalizing Radiotherapy Prescription Dose Using Genomic Markers of Radiosensitivity and Normal Tissue Toxicity in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Dec 7. pii: S1556-0864(20)31046.
    PubMed     Abstract available


  173. JOHN T, Cooper WA, Wright G, Siva S, et al
    Lung Cancer in Australia.
    J Thorac Oncol. 2020;15:1809-1814.
    PubMed    


  174. ROSSI G, Caruso D, Stella F, Davoli F, et al
    Histologic Confounding Findings in Coronavirus disease 2019 (COVID-19) Pathology.
    J Thorac Oncol. 2020;15:e192-e193.
    PubMed    


  175. CAI Y, Kuang D, Zhang N
    Response to Letter to the Editor.
    J Thorac Oncol. 2020;15:e193-e194.
    PubMed    


  176. YANG Y, Zhou H, Zhang L
    Response to Letter to the Editor: Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: A Randomized, Double-Blind, Phase 3 Study (ORIENT-11).
    J Thorac Oncol. 2020;15:e191-e192.
    PubMed    


  177. CUI L, Zhao N, Zhang Z, Jiao X, et al
    Comparing Immunotherapies in Combination With Chemotherapy for Previously Untreated Advanced Nonsquamous NSCLC.
    J Thorac Oncol. 2020;15:e189-e191.
    PubMed    


  178. CASO R, Jones DR
    Response to the Letter to the Editor: Clinical and Pathologic Implications of Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e188-e189.
    PubMed    


  179. XU X, Mao Y, Ding Q, Chen Y, et al
    Clinical and Pathologic Implications of Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e187-e188.
    PubMed    


  180. YATABE Y
    Reassessing the SCLC Subtypes.
    J Thorac Oncol. 2020;15:1819-1822.
    PubMed    


  181. PUNEKAR SR, Shum E
    Expanding the Role of Immunotherapy to Limited-Stage SCLC.
    J Thorac Oncol. 2020;15:1806-1808.
    PubMed    


  182. AHN BC, Zhu VW, Lim SM
    The Next Target for NSCLC: Let It Be "RET".
    J Thorac Oncol. 2020;15:1803-1805.
    PubMed    


  183. MAMDANI H, Schwartz AG
    Genomic Characterization of NSCLC in African Americans: A Step Toward "Race-Aware" Precision Medicine.
    J Thorac Oncol. 2020;15:1800-1802.
    PubMed    


  184. ARAUZ RF, Byun JS, Tandon M, Sinha S, et al
    Whole-Exome Profiling of NSCLC Among African Americans.
    J Thorac Oncol. 2020;15:1880-1892.
    PubMed     Abstract available


  185. YANG JC, Camidge DR, Yang CT, Zhou J, et al
    Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial.
    J Thorac Oncol. 2020;15:1907-1918.
    PubMed     Abstract available


  186. DUAN J, Xu J, Wang Z, Bai H, et al
    Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment.
    J Thorac Oncol. 2020;15:1857-1870.
    PubMed     Abstract available


  187. ESAI SELVAN M, Zauderer MG, Rudin CM, Jones S, et al
    Inherited Rare, Deleterious Variants in ATM Increase Lung Adenocarcinoma Risk.
    J Thorac Oncol. 2020;15:1871-1879.
    PubMed     Abstract available


  188. CASO R, Sanchez-Vega F, Tan KS, Mastrogiacomo B, et al
    The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:1844-1856.
    PubMed     Abstract available


    November 2020
  189. OWONIKOKO TK, Dwivedi B, Chen Z, Zhang C, et al
    YAP1 Expression in Small Cell Lung Cancer Defines a Distinct Subtype with T-cell Inflamed Phenotype.
    J Thorac Oncol. 2020 Nov 25. pii: S1556-0864(20)31028.
    PubMed     Abstract available


  190. NISHIO M, Yoshida T, Kumagai T, Hida T, et al
    Brigatinib in Japanese Patients With ALK-Positive Non-Small Cell Lung Cancer Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial.
    J Thorac Oncol. 2020 Nov 25. pii: S1556-0864(20)31026.
    PubMed     Abstract available


  191. SPIGEL D, Jotte R, Nemunaitis J, Shum M, et al
    Brief Report: Randomized Phase 2 Studies of Checkpoint Inhibitors Alone or in Combination with Pegilodecakin in Patients with Metastatic Non-Small-Cell Lung Cancer (CYPRESS-1 and CYPRESS-2).
    J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30805.
    PubMed     Abstract available


  192. FURUTA H, Araki M, Masago K, Sagae Y, et al
    Novel resistance mechanisms including L1196Q, P1094H, and R1248_D1249insertion in three patients with non-small-cell lung cancer following ALK tyrosine kinase inhibitor treatment.
    J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30803.
    PubMed     Abstract available


  193. CHUN SG, Simone CB 2nd, Amini A, Chetty IJ, et al
    American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-stage Small Cell Lung Cancer 2020.
    J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30846.
    PubMed     Abstract available


  194. FAN Y, Zhao J, Wang Q, Huang D, et al
    Camrelizumab Plus Apatinib in Extensive-Stage Small-Cell Lung Cancer (PASSION): A Multicenter, Two-Stage, Phase 2 Trial.
    J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30806.
    PubMed     Abstract available


  195. MAZIERES J, Rittmeyer A, Gadgeel S, Hida T, et al
    Atezolizumab vs Docetaxel in Pretreated Patients with Non-Small Cell Lung Cancer: Final Results From the Randomized Phase II POPLAR and Phase III OAK Clinical Trials.
    J Thorac Oncol. 2020 Nov 6. pii: S1556-0864(20)30802.
    PubMed     Abstract available


  196. OSAROGIAGBON RU, Ray MA, Faris NR, Smeltzer MP, et al
    Response to Clinical Thoughts on Mediastinal Node Management in Early-Stage Lung Cancer.
    J Thorac Oncol. 2020;15:e185-e186.
    PubMed    


  197. CHEN D, Mao Y, Chen Y, Chen C, et al
    Clinical Thoughts on Mediastinal Node Management in Early-Stage Lung Cancer.
    J Thorac Oncol. 2020;15:e183-e184.
    PubMed    


  198. REUNGWETWATTANA T, Oranratnachai S, Puataweepong P, Tangsujaritvijit V, et al
    Lung Cancer in Thailand.
    J Thorac Oncol. 2020;15:1714-1721.
    PubMed    


  199. TANNER NT, Rivera MP
    Improving Inequities in Lung Cancer Screening: Risk Prediction Models and the Potential to Achieve a Great Equalizer Effect.
    J Thorac Oncol. 2020;15:1711-1713.
    PubMed    


  200. ADJEI AA
    A Call to Arms: Reducing Disparities in Lung Cancer Care Worldwide.
    J Thorac Oncol. 2020;15:1700-1702.
    PubMed    


  201. BAKHRIBAH H, Alfayea T
    Immunotherapy and Coronavirus Disease 2019: Challenges and Possibilities.
    J Thorac Oncol. 2020;15:1709-1710.
    PubMed    


  202. LU S, Li Z
    Adverse Effects of Combined Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2020;15:e182-e183.
    PubMed    


  203. LI Z, Deng J, Yan F, Ma Y, et al
    Letter to the Editor About the Adverse Effect of Combined Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2020;15:e181-e182.
    PubMed    


  204. HEGDE A, Velcheti V
    Osimertinib for Leptomeningeal Disease in EGFR-Mutated NSCLC.
    J Thorac Oncol. 2020;15:1705-1708.
    PubMed    


  205. ALEXANDER M, Wrangle J
    Can We MIRror the Efficacy of Immune Checkpoints With miRNAs?
    J Thorac Oncol. 2020;15:1703-1704.
    PubMed    


  206. RICE SJ, Hyland V, Behera M, Ramalingam SS, et al
    Guidance on the Clinical Management of Electronic Cigarette or Vaping-Associated Lung Injury.
    J Thorac Oncol. 2020;15:1727-1737.
    PubMed     Abstract available


  207. OU FS, Le-Rademacher JG, Ballman KV, Adjei AA, et al
    Guidelines for Statistical Reporting in Medical Journals.
    J Thorac Oncol. 2020;15:1722-1726.
    PubMed     Abstract available


    October 2020
  208. ZHENG MM, Li YS, Tu HY, Jiang BY, et al
    Genotyping of cerebrospinal fluid associated with osimertinib response and resistance for leptomeningeal metastases in EGFR-mutated non-small cell lung cancer.
    J Thorac Oncol. 2020 Oct 26. pii: S1556-0864(20)30816.
    PubMed     Abstract available


  209. REMON J, Reguart N, Garcia-Campelo R, Conde E, et al
    Lung Cancer in Spain.
    J Thorac Oncol. 2020 Oct 24. pii: S1556-0864(20)30812.
    PubMed    


  210. GAUDREAU PO, Negrao MV, Mitchell KG, Reuben A, et al
    Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Oct 20. pii: S1556-0864(20)30813.
    PubMed     Abstract available


  211. HERBST RS, Arkenau HT, Bendell J, Arrowsmith E, et al
    Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Oct 14. pii: S1556-0864(20)30809.
    PubMed     Abstract available


  212. RAMI-PORTA R, Wittekind C, Goldstraw P
    Complete Resection in Lung Cancer Surgery: From Definition to Validation and Beyond.
    J Thorac Oncol. 2020 Oct 13. pii: S1556-0864(20)30727.
    PubMed    


  213. STINCHCOMBE TE, Doebele RC, Wang X, Gerber DE, et al
    Brief report: Preliminary clinical and molecular analysis results from a single arm phase 2 trial of brigatinib in patients with disease progression after next-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors in advanced ALK + no
    J Thorac Oncol. 2020 Oct 8. pii: S1556-0864(20)30764.
    PubMed     Abstract available


  214. KIDANE B, Levin DP
    Identification and Resolution of Asymptomatic COVID-19 Pneumonitis and Colitis: Serial Assessment of Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography for Evaluation of Lung Cancer.
    J Thorac Oncol. 2020 Oct 5. pii: S1556-0864(20)30725.
    PubMed    


  215. SEITLINGER J, Banga Nkomo D, Streit A, Stasiak F, et al
    Letter to the Editor Concerning the Article From Cai et al. Focusing on Coronavirus Disease 2019 Impact on Lung Cancer Resection, Published in June 2020.
    J Thorac Oncol. 2020;15:e172-e173.
    PubMed    


  216. GAO S, Li N, Wang S, Zhang F, et al
    Lung Cancer in People's Republic of China.
    J Thorac Oncol. 2020;15:1567-1576.
    PubMed    


  217. LIM E
    What Is the Optimum Lymph Node Management in Patients Undergoing Surgery for Lung Cancer?
    J Thorac Oncol. 2020;15:1565-1566.
    PubMed    


  218. SCHILD SE
    Optimizing the Radiotherapy of Lung Cancer.
    J Thorac Oncol. 2020;15:1559-1560.
    PubMed    


  219. LAM VK, Forde PM
    Another Brick in the Wall: Sintilimab Plus Chemotherapy in Advanced Lung Cancer.
    J Thorac Oncol. 2020;15:1556-1558.
    PubMed    


  220. RIGNEY M, Rapsomaniki E, Carter-Harris L, King JC, et al
    Brief Report: Ten Year Cross-sectional Analysis of Public, Oncologist, and Patient Attitudes About Lung Cancer and Associated Stigma.
    J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30757.
    PubMed     Abstract available


  221. HIGGINS KA, Simone CB 2nd, Amini A, Chetty IJ, et al
    American Radium Society , Appropriate Use Criteria on Radiation Therapy for Extensive-stage Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30759.
    PubMed     Abstract available


  222. BAINE MK, Hsieh MS, Lai WV, Egger JV, et al
    Small Cell Lung Carcinoma Subtypes Defined by ASCL1, NEUROD1, POU2F3 and YAP1: Comprehensive Immunohistochemical and Histopathologic Characterization.
    J Thorac Oncol. 2020 Oct 1. pii: S1556-0864(20)30755.
    PubMed     Abstract available


  223. KUNIMASA K, Honma K, Matsumoto M, Nishino K, et al
    Dermatopathic Lymphadenopathy Mimicking Disease Progression During Osimertinib Treatment.
    J Thorac Oncol. 2020;15:e178-e180.
    PubMed    


  224. MATSUDA K, Kashima J, Yatabe Y
    The Isoform Matters in NUT Carcinoma: A Diagnostic Pitfall of p40 Immunohistochemistry.
    J Thorac Oncol. 2020;15:e176-e178.
    PubMed    


  225. DAGOGO-JACK I
    Durable Response to Dabrafenib Combined With Trametinib in a Patient With NSCLC Harboring a BRAF G469A Mutation.
    J Thorac Oncol. 2020;15:e174-e176.
    PubMed    


  226. CAI Y, Gao Y, Zhang N
    Response to Letter to the Editor.
    J Thorac Oncol. 2020;15:e173-e174.
    PubMed    


  227. PIGNATARO D, Bertaglia V, Bironzo P, Olmetto E, et al
    Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules.
    J Thorac Oncol. 2020;15:e170-e172.
    PubMed    


  228. HASSAN R, Miettinen M
    Response to Letter to Editor by Cornelissen et al.
    J Thorac Oncol. 2020;15:e169-e170.
    PubMed    


  229. CORNELISSEN R, Dubbink HJ, von der Thusen JH
    ALK in Mesothelioma: To FISH or Not to FISH?
    J Thorac Oncol. 2020;15:e168-e169.
    PubMed    


  230. MORENO AC, Lin SH
    Authors' Reply to Yajing Du's Letter to the Editor on "Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC".
    J Thorac Oncol. 2020;15:e166-e168.
    PubMed    


  231. DU Y, Zhan C, Li M, Qiao T, et al
    Promising Stereotactic Body Radiotherapy in NSCLC.
    J Thorac Oncol. 2020;15:e165-e166.
    PubMed    


  232. COLEMAN N, Woolf D, Welsh L, McDonald F, et al
    EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib.
    J Thorac Oncol. 2020;15:e162-e165.
    PubMed    


  233. WANG YY, Tian XC, Zhu L, Bai XH, et al
    Concomitant Radiation Recall Dermatitis and Radiation Recall Pneumonitis Induced by Pembrolizumab.
    J Thorac Oncol. 2020;15:e160-e162.
    PubMed    


  234. LI M, Xu Z, Zhan C, Wang Q, et al
    A Few Clouds Over the Eighth Edition T Categorization System.
    J Thorac Oncol. 2020;15:e159-e160.
    PubMed    


  235. CHU QSC
    How Is Receptor Activator of Nuclear Factor-kappabeta/Receptor Activator of Nuclear Factor-kappabeta Ligand Targeting Ranked as an Immuno-Oncology Target for NSCLC: a Pathway Unclear as yet?
    J Thorac Oncol. 2020;15:1561-1564.
    PubMed    


  236. SINGH S, Bergsland EK, Card CM, Hope TA, et al
    Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Updat
    J Thorac Oncol. 2020;15:1577-1598.
    PubMed     Abstract available


  237. WANG X, Palaskas NL, Yusuf SW, Abe JI, et al
    Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer.
    J Thorac Oncol. 2020;15:1682-1690.
    PubMed     Abstract available


  238. PETERS S, Danson S, Hasan B, Dafni U, et al
    A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLE
    J Thorac Oncol. 2020;15:1647-1656.
    PubMed     Abstract available


  239. MOREIRA AL, Ocampo PSS, Xia Y, Zhong H, et al
    A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2020;15:1599-1610.
    PubMed     Abstract available


  240. NEGRAO MV, Raymond VM, Lanman RB, Robichaux JP, et al
    Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.
    J Thorac Oncol. 2020;15:1611-1623.
    PubMed     Abstract available


    September 2020
  241. AWAD MM, Gadgeel SM, Borghaei H, Patnaik A, et al
    Brief Report: Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2020 Sep 28. pii: S1556-0864(20)30761.
    PubMed     Abstract available


  242. KANG J, Jeong SM, Shin DW, Cho M, et al
    Associations of aspirin, statins, and metformin with lung cancer risk and related mortality: time-dependent analysis of population-based nationally representative data.
    J Thorac Oncol. 2020 Sep 12. pii: S1556-0864(20)30712.
    PubMed     Abstract available


  243. GEMMA A, Kusumoto M, Sakai F, Endo M, et al
    Real-world evaluation of factors for interstitial lung disease incidence and radiologic characteristics in patients with epidermal growth factor receptor T790M-positive non-small cell lung cancer treated with osimertinib in Japan.
    J Thorac Oncol. 2020 Sep 11. pii: S1556-0864(20)30717.
    PubMed     Abstract available


  244. WELSH JW, Heymach JV, Guo C, Menon H, et al
    Phase I/II Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Sep 8. pii: S1556-0864(20)30713.
    PubMed     Abstract available


  245. BRAUN M, Fuchs V, Kian W, Roisman L, et al
    Nivolumab Induced Hepatocanalicular Cholestasis and Liver Rejection in a Patient With Lung Cancer and Liver Transplant.
    J Thorac Oncol. 2020;15:e149-e150.
    PubMed    


  246. GEDVILAITE V, Danila E, Cicenas S, Smailyte G, et al
    Lung Cancer in Lithuania.
    J Thorac Oncol. 2020;15:1401-1405.
    PubMed    


  247. AHN MJ
    Molecular Testing in Lung Cancer: Still Big Gap in Implementation for Real-World Use.
    J Thorac Oncol. 2020;15:1399-1400.
    PubMed    


  248. ZHOU F, Zhou C
    Treatment Algorithm for Advanced ALK-Rearranged NSCLC: Reply.
    J Thorac Oncol. 2020;15:e157-e158.
    PubMed    


  249. URBANSKA EM, Sorensen JB, Santoni-Rugiu E
    Treatment Algorithm for Advanced ALK-Rearranged NSCLC.
    J Thorac Oncol. 2020;15:e156-e157.
    PubMed    


  250. HAURA EB, Hicks JK, Boyle TA
    Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib.
    J Thorac Oncol. 2020;15:e154-e156.
    PubMed    


  251. ZHENG J, Sun W, Chen W, Zhou J, et al
    Sustained Response to Crizotinib After Resistance to First-Line Alectinib Treatment in Two Patients With ALK-Rearranged NSCLC.
    J Thorac Oncol. 2020;15:e150-e153.
    PubMed    


  252. OKUDA K, Nakanishi R
    Circulating Cancer-Associated Cells for the Early Detection and Decision-Making Concerning Effective Therapeutic Strategies for NSCLC.
    J Thorac Oncol. 2020;15:1397-1398.
    PubMed    


  253. LYCAN TW JR, Petty WJ
    Adverse Event Reporting at Professional Conferences: We Need Better Standards and Bigger Posters.
    J Thorac Oncol. 2020;15:1394-1396.
    PubMed    


  254. GOTO Y
    Current Understanding and Biomarker Application of Programmed Death-Ligand 1 Expression in Tumors.
    J Thorac Oncol. 2020;15:1392-1393.
    PubMed    


  255. ADDEO A, Banna LG, Friedlaender A
    Filtering Data About Treatment-Induced Renal Injury: From Biology to Practice.
    J Thorac Oncol. 2020;15:1389-1391.
    PubMed    


  256. KERN JA, Kim J, Foster DG, Mishra R, et al
    Role of mTOR As an Essential Kinase in SCLC.
    J Thorac Oncol. 2020;15:1522-1534.
    PubMed     Abstract available


  257. DAHLBERG SE, Korn EL, Le-Rademacher J, Mandrekar SJ, et al
    Clinical Versus Statistical Significance in Studies of Thoracic Malignancies.
    J Thorac Oncol. 2020;15:1406-1408.
    PubMed    


  258. OYAMA T, Goto T, Amemiya K, Hirotsu Y, et al
    Squamous Cell Carcinoma of the Lung With Micropapillary Pattern.
    J Thorac Oncol. 2020;15:1541-1544.
    PubMed    


  259. SHOLL LM, Hirsch FR, Hwang D, Botling J, et al
    The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee.
    J Thorac Oncol. 2020;15:1409-1424.
    PubMed     Abstract available


  260. DUMOULIN DW, Visser S, Cornelissen R, van Gelder T, et al
    Renal Toxicity From Pemetrexed and Pembrolizumab in the Era of Combination Therapy in Patients With Metastatic Nonsquamous Cell NSCLC.
    J Thorac Oncol. 2020;15:1472-1483.
    PubMed     Abstract available


  261. ZHU VW, Lin YT, Kim DW, Loong HH, et al
    An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLC.
    J Thorac Oncol. 2020;15:1484-1496.
    PubMed     Abstract available


    August 2020
  262. TAN AC, Seet AOL, Lai GGY, Lim TH, et al
    Molecular characterisation and clinical outcomes in RET rearranged non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2020 Aug 28. pii: S1556-0864(20)30671.
    PubMed     Abstract available


  263. CALABRESE F, Fortarezza F, Giraudo C, Pezzuto F, et al
    Two sorts of microthrombi in a COVID-19 patient with lung cancer.
    J Thorac Oncol. 2020 Aug 28. pii: S1556-0864(20)30668.
    PubMed    


  264. IKEDA S, Kato T, Kenmotsu H, Ogura T, et al
    A phase II study of atezolizumab for pretreated non-small cell lung cancer with idiopathic interstitial pneumonias.
    J Thorac Oncol. 2020 Aug 25. pii: S1556-0864(20)30678.
    PubMed     Abstract available


  265. PASQUINELLI MM, Tammemagi MC, Kovitz KL, Durham ML, et al
    Risk Prediction Model versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria - Reducing Race Disparities.
    J Thorac Oncol. 2020 Aug 17. pii: S1556-0864(20)30638.
    PubMed     Abstract available


  266. ADAMEK M, Biernat W, Chorostowska-Wynimko J, Didkowska JA, et al
    Lung Cancer in Poland.
    J Thorac Oncol. 2020;15:1271-1276.
    PubMed    


  267. GU Z, Liu Y, Qiu B, Liu H, et al
    Risk Stratification Is Helpful in Designing Follow-Up Strategy and Future Studies on Adjuvant Therapies: Response to the External Validation on the Chinese Alliance for Research in Thymomas Predictive Model of Recurrence.
    J Thorac Oncol. 2020;15:e139-e141.
    PubMed    


  268. CHIAPPETTA M, Sperduti I, Lococo F, Margaritora S, et al
    Does Follow-Up Duration Affect the Effectiveness of a Predictive Nomogram Model for Thymic Malignancy Recurrences? Results From an External Validation.
    J Thorac Oncol. 2020;15:e137-e139.
    PubMed    


  269. DAGOGO-JACK I, Mino-Kenudson M
    Reply to the Letter to the Editor From Zhou et al.
    J Thorac Oncol. 2020;15:e136-e137.
    PubMed    


  270. ZHOU H, Shen J, Liu J, Fang W, et al
    Efficacy of Immune Checkpoint Inhibitors in SMARCA4-Mutant NSCLC.
    J Thorac Oncol. 2020;15:e133-e136.
    PubMed    


  271. GENDARME S, Chouaid C
    Monitoring Subsolid Pulmonary Nodules in High-Risk Patients Is Even More Cost-Effective When Combined With a Stop-Smoking Program.
    J Thorac Oncol. 2020;15:1268-1270.
    PubMed    


  272. URUGA H, Mino-Kenudson M
    Is the Programmed Death-Ligand 1 73-10 Immunohistochemistry Assay Compatible With the 22C3 Assay?
    J Thorac Oncol. 2020;15:1265-1267.
    PubMed    


  273. PEROL M
    Multidisciplinary Approach of Immune Checkpoint Inhibitor-Related Pneumonitis: A Key to Address Knowledge and Management Gaps.
    J Thorac Oncol. 2020;15:1261-1264.
    PubMed    


  274. STINCHCOMBE TE
    IMpower 131: The Exception to the Rule.
    J Thorac Oncol. 2020;15:1258-1260.
    PubMed    


  275. KOKORIAN R, Grainville T, Robert L, Corre R, et al
    Coeliac-Like Disease Is a Rare Immune-Related Complication Induced by Nivolumab in NSCLC.
    J Thorac Oncol. 2020;15:e147-e148.
    PubMed    


  276. ARAKAWA S, Yoshida T, Nakayama Y, Motoi N, et al
    Small Cell Cancer Transformation of Lung Adenocarcinoma During Durvalumab Treatment After Chemoradiotherapy.
    J Thorac Oncol. 2020;15:e145-e146.
    PubMed    


  277. COLEMAN N, Yousaf N, Arkenau HT, Welsh L, et al
    Lorlatinib Salvages Central Nervous System-Only Relapse on Entrectinib in ROS1-Positive NSCLC.
    J Thorac Oncol. 2020;15:e142-e144.
    PubMed    


  278. ZHENG Q, Fang W, Huang Y, Gan J, et al
    Identification of a Novel KIF5B-RET, ABHD17C-RET Double-Fusion Variant in Lung Adenocarcinoma and Response to Cabozantinib.
    J Thorac Oncol. 2020;15:e132-e133.
    PubMed    


  279. MANDREKAR SJ, Le-Rademacher J, Adjei AA
    Introducing the Journal of Thoracic Oncology Statistical Series.
    J Thorac Oncol. 2020;15:1257.
    PubMed    


  280. AN MW, Duong Q, Le-Rademacher J, Mandrekar SJ, et al
    Principles of Good Clinical Trial Design.
    J Thorac Oncol. 2020;15:1277-1280.
    PubMed     Abstract available


  281. JEENE PM, Vermeulen BD, Rozema T, Braam PM, et al
    Short-Course External Beam Radiotherapy Versus Brachytherapy for Palliation of Dysphagia in Esophageal Cancer: A Matched Comparison of Two Prospective Trials.
    J Thorac Oncol. 2020;15:1361-1368.
    PubMed     Abstract available


  282. WANG Y, Yang N, Zhang Y, Li Li, et al
    Effective Treatment of Lung Adenocarcinoma Harboring EGFR-Activating Mutation, T790M, and cis-C797S Triple Mutations by Brigatinib and Cetuximab Combination Therapy.
    J Thorac Oncol. 2020;15:1369-1375.
    PubMed     Abstract available


  283. KIM-WANNER SZ, Assenov Y, Nair MB, Weichenhan D, et al
    Genome-Wide DNA Methylation Profiling in Early Stage I Lung Adenocarcinoma Reveals Predictive Aberrant Methylation in the Promoter Region of the Long Noncoding RNA PLUT: An Exploratory Study.
    J Thorac Oncol. 2020;15:1338-1350.
    PubMed     Abstract available


  284. HAMMER MM, Palazzo LL, Paquette A, Eckel AL, et al
    Cost-Effectiveness of Follow-Up for Subsolid Pulmonary Nodules in High-Risk Patients.
    J Thorac Oncol. 2020;15:1298-1305.
    PubMed     Abstract available


    July 2020
  285. YANG Y, Wang Z, Fang J, Yu Q, et al
    Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous non-small cell lung cancer: a randomized, double-blind, phase 3 study (ORIENT-11).
    J Thorac Oncol. 2020 Jul 31. pii: S1556-0864(20)30595.
    PubMed     Abstract available


  286. PEARSALL SM, Humphrey S, Revill M, Morgan D, et al
    The rare YAP1 subtype of Small Cell Lung Cancer revisited in a biobank of 39 Circulating Tumour Cell Patient Derived eXplant models (CDX): A brief report.
    J Thorac Oncol. 2020 Jul 25. pii: S1556-0864(20)30588.
    PubMed     Abstract available


  287. BUENO R, Richards WG, Harpole DH, Ballman KV, et al
    Multi-institutional prospective validation of prognostic mRNA signatures in early stage squamous lung cancer (Alliance).
    J Thorac Oncol. 2020 Jul 24. pii: S1556-0864(20)30558.
    PubMed     Abstract available


  288. ROLFO C, Cardona AF, Ruiz-Patino A, Ariza S, et al
    Atypical skin manifestations during immune checkpoint blockage in COVID19-infected lung cancer patients.
    J Thorac Oncol. 2020 Jul 9. pii: S1556-0864(20)30543.
    PubMed     Abstract available


  289. LEE J, La Choi Y, Han J, Park S, et al
    Osimertinib improves overall survival in EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastases regardless of T790M mutational status.
    J Thorac Oncol. 2020 Jul 8. pii: S1556-0864(20)30505.
    PubMed     Abstract available


  290. KILADZE I, Mariamidze E, Jeremic B
    Lung Cancer in Georgia.
    J Thorac Oncol. 2020;15:1113-1118.
    PubMed    


  291. SMELTZER MP, Osarogiagbon RU
    Out of the Darkness, Into Light: The Scientific Rigor of Lung Cancer Clinical Trials in the Age of Enlightenment.
    J Thorac Oncol. 2020;15:1110-1112.
    PubMed    


  292. LIN JJ, Solomon BJ
    Reply to "Emergence of High Level of MET Amplification During Treatment With Selpercatinib in KIF5B-RET NSCLC".
    J Thorac Oncol. 2020;15:e127-e128.
    PubMed    


  293. ZHU VW, Madison R, Schrock AB, Ou SI, et al
    Emergence of High Level of MET Amplification as Off-Target Resistance to Selpercatinib Treatment in KIF5B-RET NSCLC.
    J Thorac Oncol. 2020;15:e124-e127.
    PubMed    


  294. EMOTO K, Tan KS, Rekhtman N, Adusumilli PS, et al
    The Newly Described Filigree Pattern Is an Expansion of the Micropapillary Adenocarcinoma Concept Rather Than a Proposed New Subtype.
    J Thorac Oncol. 2020;15:e121-e124.
    PubMed    


  295. THUNNISSEN E, Flieder D
    Morphologic Logic: "Filigree" and "Classical" Micropapillary Pattern Are Orientation-Dependent Views of the Same Lesion.
    J Thorac Oncol. 2020;15:e120-e121.
    PubMed    


  296. TRAVIS WD, Aly RG, Rekhtman N, Tan KS, et al
    Spread Through Air Spaces Is Prognostic in Neuroendocrine Lung Tumors and Can Be Distinguished From Artifacts.
    J Thorac Oncol. 2020;15:e118-e120.
    PubMed    


  297. THUNNISSEN E, Marchevsky A, Rossi G, Russell PA, et al
    RE: Spread Through Air Spaces (STAS) is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung.
    J Thorac Oncol. 2020;15:e116-e117.
    PubMed    


  298. JEAN D, Delaunay T, Meiller C, Boisgerault N, et al
    Reply to: Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2020;15:e113-e116.
    PubMed    


  299. YANG H, Xu D, Gao Y, Schmid RA, et al
    Oncolytic Viral Therapy for Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2020;15:e111-e113.
    PubMed    


  300. GAUTSCHI O, Bubendorf L, Leyvraz S, Menon R, et al
    Challenges in the Diagnosis of NTRK Fusion-Positive Cancers.
    J Thorac Oncol. 2020;15:e108-e110.
    PubMed    


  301. SUTHERLAND KD, Vissers JHA
    Balancing the Count: Harmonizing Panel-Based Tumor Mutational Burden Assessment.
    J Thorac Oncol. 2020;15:1106-1109.
    PubMed    


  302. HSIAO SJ, Ou SI
    Is Retention of the 5' Nononcogenic ALK Fusion Variant a Novel Poor Prognostic Factor in ALK-Positive NSCLC?
    J Thorac Oncol. 2020;15:1103-1105.
    PubMed    


  303. LOONG HH, Li MSC, Tang GCH, Lau YM, et al
    Have We Revealed the Achilles' Heel of Brigatinib? Implications on Clinical Practice.
    J Thorac Oncol. 2020;15:1100-1102.
    PubMed    


  304. JETT JR, Kim ES
    Response to Letter to the Editor.
    J Thorac Oncol. 2020;15:e110-e111.
    PubMed    


  305. BARSKY AR, Kim MM, Williams GR, Lally BE, et al
    Proton-Beam Therapy: At the Heart of Cardiac Dose-Sparing in Mediastinal Radiotherapy for Thymic Carcinoma.
    J Thorac Oncol. 2020;15:1240-1242.
    PubMed    


  306. CALLSTROM MR, Woodrum DA, Nichols FC, Palussiere J, et al
    Multicenter Study of Metastatic Lung Tumors Targeted by Interventional Cryoablation Evaluation (SOLSTICE).
    J Thorac Oncol. 2020;15:1200-1209.
    PubMed     Abstract available


  307. STENZINGER A, Endris V, Budczies J, Merkelbach-Bruse S, et al
    Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study.
    J Thorac Oncol. 2020;15:1177-1189.
    PubMed     Abstract available


    June 2020
  308. PAZ-ARES L, Vicente D, Tafreshi A, Robinson A, et al
    A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non-Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407.
    J Thorac Oncol. 2020 Jun 26. pii: S1556-0864(20)30500.
    PubMed     Abstract available


  309. RAY MA, Smeltzer MP, Faris N, Osarogiagbon RU, et al
    Survival after mediastinal node dissection, systematic sampling or neither for early-stage non-small-cell lung cancer.
    J Thorac Oncol. 2020 Jun 20. pii: S1556-0864(20)30479.
    PubMed     Abstract available


  310. SHUKUYA T, Ghai V, Amann JM, Okimoto T, et al
    Circulating miRNAs and extracellular vesicle containing miRNAs as response biomarkers of anti PD-1/PD-L1 therapy in non-small-cell lung cancer.
    J Thorac Oncol. 2020 Jun 18. pii: S1556-0864(20)30467.
    PubMed     Abstract available


  311. ABRAVAN A, Faivre-Finn C, Kennedy J, McWilliam A, et al
    Radiotherapy-related lymphopenia affects overall survival in patients with lung cancer.
    J Thorac Oncol. 2020 Jun 14. pii: S1556-0864(20)30478.
    PubMed     Abstract available


  312. UPRETY D, Mandrekar SJ, Wigle D, Roden AC, et al
    Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer - Current Concepts and Future Approaches.
    J Thorac Oncol. 2020 Jun 6. pii: S1556-0864(20)30425.
    PubMed     Abstract available


  313. RUIZ R, Galvez-Nino M, Poquioma E, Limache-Garcia A, et al
    Lung Cancer in Peru.
    J Thorac Oncol. 2020;15:891-898.
    PubMed    


  314. WANG F, Adjei AA
    Does the Lung Cancer Field Need Another Third-Generation EGFR Tyrosine Kinase Inhibitor?
    J Thorac Oncol. 2020;15:881-883.
    PubMed    


  315. MCGINNIS GJ, Ning MS, Nitsch PL, O'Reilly MS, et al
    Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy.
    J Thorac Oncol. 2020;15:1085-1087.
    PubMed    


  316. NICHOLSON AG, Sauter JL, Galateau-Salle F
    In Reply.
    J Thorac Oncol. 2020;15:e94-e95.
    PubMed    


  317. AUJAYEB A, Taylor L
    Is the Deciduoid Variant of Pleural Mesothelioma Significant?
    J Thorac Oncol. 2020;15:e94.
    PubMed    


  318. ARAI S, Yano S
    In Reply.
    J Thorac Oncol. 2020;15:e93.
    PubMed    


  319. CORTINOVIS D, Gemelli M, Cappuzzo F
    Alectinib Resistance Through Amphiregulin Overexpression: Is Osimertinib the Best Candidate?
    J Thorac Oncol. 2020;15:e92-e93.
    PubMed    


  320. HASSAN R, Sengupta M, Murai J, Pommier Y, et al
    Response to Letter to the Editor by Yang et al.
    J Thorac Oncol. 2020;15:e91.
    PubMed    


  321. YANG H, Xu D, Gao Y, Schmid RA, et al
    The Association of BAP1 Loss-of-Function With the Defect in Homologous Recombination Repair and Sensitivity to PARP-Targeted Therapy.
    J Thorac Oncol. 2020;15:e88-e90.
    PubMed    


  322. MAZZOTTA M, Marinelli D, Maugeri-Sacca M
    KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed. Reply to "KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis".
    J Thorac Oncol. 2020;15:e87-e88.
    PubMed    


  323. ZHANG C, Zhang C, Li J, Wang H, et al
    KEAP1-NFE2L2-Mutant NSCLC and Immune Checkpoint Inhibitors: A Large Database Analysis.
    J Thorac Oncol. 2020;15:e85-e86.
    PubMed    


  324. DAGOGO-JACK I, Lennerz JK
    Personalized Diagnostic Workflows: The Next Wave of Precision Medicine in NSCLC.
    J Thorac Oncol. 2020;15:888-890.
    PubMed    


  325. CARBONE M
    Transitional Mesothelioma and Artificial Intelligence: Do We Need One More Subtype? and Do We Need Computers to Identify Them?
    J Thorac Oncol. 2020;15:884-887.
    PubMed    


  326. NAGASAKA M, Ou SI
    Is NRG2alpha Fusion a "Doppelganger" to NRG1alpha/beta Fusions in Oncology?
    J Thorac Oncol. 2020;15:878-880.
    PubMed    


  327. ZHANG C, Yan LX, Jiang BY, Wu YL, et al
    Feasibility and Safety of Neoadjuvant Alectinib in a Patient With ALK-Positive Locally Advanced NSCLC.
    J Thorac Oncol. 2020;15:e95-e99.
    PubMed    


  328. CHURG A, Dacic S, Galateau-Salle F, Attanoos R, et al
    Malignant Mesothelioma In Situ: Clinical and Pathologic Implications.
    J Thorac Oncol. 2020;15:899-901.
    PubMed    


  329. ZHANG J, Zou C, Zhou C, Luo Y, et al
    A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib.
    J Thorac Oncol. 2020;15:1073-1077.
    PubMed    


  330. REMON J, Passiglia F, Ahn MJ, Barlesi F, et al
    Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
    J Thorac Oncol. 2020;15:914-947.
    PubMed     Abstract available


  331. GALATEAU SALLE F, Le Stang N, Tirode F, Courtiol P, et al
    Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center.
    J Thorac Oncol. 2020;15:1037-1053.
    PubMed     Abstract available


  332. DECESARIS CM, McCarroll R, Mishra MV, Glass E, et al
    Assessing Outcomes of Patients Treated With Re-Irradiation Utilizing Proton Pencil-Beam Scanning for Primary or Recurrent Malignancies of the Esophagus and Gastroesophageal Junction.
    J Thorac Oncol. 2020;15:1054-1064.
    PubMed     Abstract available


  333. GOODMAN CD, Nijman SFM, Senan S, Nossent EJ, et al
    A Primer on Interstitial Lung Disease and Thoracic Radiation.
    J Thorac Oncol. 2020;15:902-913.
    PubMed     Abstract available


  334. KOHSAKA S, Hayashi T, Nagano M, Ueno T, et al
    Identification of Novel CD74-NRG2alpha Fusion From Comprehensive Profiling of Lung Adenocarcinoma in Japanese Never or Light Smokers.
    J Thorac Oncol. 2020;15:948-961.
    PubMed     Abstract available


  335. ZHAO S, Fang W, Pan H, Yang Y, et al
    Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:962-972.
    PubMed     Abstract available


  336. LOTSBERG ML, Wnuk-Lipinska K, Terry S, Tan TZ, et al
    AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells.
    J Thorac Oncol. 2020;15:973-999.
    PubMed     Abstract available


  337. SHI Y, Zhang S, Hu X, Feng J, et al
    Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation.
    J Thorac Oncol. 2020;15:1015-1026.
    PubMed     Abstract available


    May 2020
  338. BEST SA, Hess J, Souza-Fonseca-Guimaraes F, Cursons J, et al
    Harnessing natural killer immunity in metastatic small cell lung cancer.
    J Thorac Oncol. 2020 May 26. pii: S1556-0864(20)30394.
    PubMed     Abstract available


  339. OUYANG W, Hu J, Zhang H, Xie C, et al
    The Management of Patients With Lung Cancer During the Outbreak of Coronavirus Disease 2019.
    J Thorac Oncol. 2020 May 23. pii: S1556-0864(20)30385.
    PubMed    


  340. HEEKE S, Benzaquen J, Hofman V, Long-Mira E, et al
    Brief Report: Comparison of three sequencing panels used for the assessment of tumor mutational burden in non-small cell lung cancer demonstrates low comparability.
    J Thorac Oncol. 2020 May 22. pii: S1556-0864(20)30417.
    PubMed     Abstract available


  341. SMELTZER MP, Wynes MW, Lantuejoul S, Soo R, et al
    The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer.
    J Thorac Oncol. 2020 May 14. pii: S1556-0864(20)30383.
    PubMed     Abstract available


  342. DINGEMANS AC, Soo RA, Jazieh AR, Rice SJ, et al
    Treatment guidance for lung cancer patients during the COVID-19 pandemic.
    J Thorac Oncol. 2020 May 13. pii: S1556-0864(20)30382.
    PubMed     Abstract available


  343. MANJUNATH Y, Mitchem JB, Suvilesh KN, Avella DM, et al
    Circulating giant tumor-macrophage fusion cells are independent prognosticators in non-small cell lung cancer patients.
    J Thorac Oncol. 2020 May 13. pii: S1556-0864(20)30381.
    PubMed     Abstract available


  344. AL-SAMKARI H, Leiva O, Dagogo-Jack I, Shaw A, et al
    Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 May 10. pii: S1556-0864(20)30380.
    PubMed     Abstract available


  345. HONG L, Negrao MV, Dibaj SS, Chen R, et al
    Programmed Death Ligand 1 Heterogeneity and its Impact on Benefit from Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2020 May 7. pii: S1556-0864(20)30373.
    PubMed     Abstract available


  346. ZHU J, Zhang Y, Gao XH, Xi EP, et al
    COVID-19 or Lung Cancer: A differential diagnostic experience and management model from Wuhan.
    J Thorac Oncol. 2020 May 6. pii: S1556-0864(20)30377.
    PubMed    


  347. LEE JC, Blazak JK
    The Use of Positron Emission Tomography in Coronavirus Disease 2019 Cases.
    J Thorac Oncol. 2020 May 5. pii: S1556-0864(20)30374.
    PubMed    


  348. CHANG HL, Chen YH, Yang CJ
    Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI)-Associated Interstitial Lung Disease During the COVID-19 Pandemic.
    J Thorac Oncol. 2020 May 5. pii: S1556-0864(20)30376.
    PubMed    


  349. DAI J, Sun L, Jin K, Jiang G, et al
    Identifiable and Unidentifiable Factors Influencing Lymph Node Examination and Adjuvant Chemotherapy in Stage I Lung Cancer.
    J Thorac Oncol. 2020;15:e78-e79.
    PubMed    


  350. TIAN S, Xiao SY
    Pathology of 2019 Novel Coronavirus Pneumonia: A Dynamic Disease Process.
    J Thorac Oncol. 2020;15:e67-e68.
    PubMed    


  351. BOGOS K, Kiss Z, Galffy G, Tamasi L, et al
    Lung Cancer in Hungary.
    J Thorac Oncol. 2020;15:692-699.
    PubMed    


  352. JOOB B, Wiwanitkit V
    Pulmonary Pathology of Early Phase 2019 Novel Coronavirus Pneumonia.
    J Thorac Oncol. 2020;15:e67.
    PubMed    


  353. WO Y, Wang Y, Lu T, Sun D, et al
    Evaluated Lymph Node Number in Population-Based Analyses: Significant Prognostic Factor, but Assess With Caution.
    J Thorac Oncol. 2020;15:e77-e78.
    PubMed    


  354. FRIEDBERG JS, Culligan MJ, Tsao AS, Rusch V, et al
    Reply to Waller et al. Standardizing Surgical Treatment for Mesothelioma.
    J Thorac Oncol. 2020;15:e75-e77.
    PubMed    


  355. WALLER DA, Bilancia R, Bille A, Tenconi S, et al
    Standardizing Surgical Treatment of Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2020;15:e73-e74.
    PubMed    


  356. WANG Z, Duan J, Wang J, Wang G, et al
    In Reply: A Modified Algorithm Adjusting Both High and Minor Allele-Frequency to Redefine Blood-Based Tumor Mutational Burden for Optimal Prediction of Clinical Benefits From Programmed Cell Death-Protein 1 Immunotherapy.
    J Thorac Oncol. 2020;15:e72-e73.
    PubMed    


  357. LIU Z, Xie Z, Cai X, He J, et al
    A Modified Algorithm Adjusting Both High and Minor Allele Frequency Mutation to Redefine Blood-Based Tumor Mutational Burden (bTMB) for Optimal Prediction of Clinical Benefits From Immune Checkpoint Inhibitor Therapy.
    J Thorac Oncol. 2020;15:e69-e72.
    PubMed    


  358. PEIKERT T
    Personalized Oncolytic Therapy: The Next Step Toward the Successful Clinical Application of Vaccine-Strain Measles Viruses for Cancer Therapy?
    J Thorac Oncol. 2020;15:689-691.
    PubMed    


  359. DE MIGUEL FJ
    An Elaborate STING Operation to Take Down NSCLC: Combination of Immunotherapies and Chemotherapies.
    J Thorac Oncol. 2020;15:686-688.
    PubMed    


  360. DENG L, Cheng H
    Uncommon as an Individual, Not That Uncommon as a Whole.
    J Thorac Oncol. 2020;15:681-685.
    PubMed    


  361. YASUDA H
    Targeting Co-Occurring Genomic Alterations in MET Exon 14 Skipping Mutation-Positive NSCLC.
    J Thorac Oncol. 2020;15:679-680.
    PubMed    


  362. CARBONE M, Green JB, Bucci EM, Lednicky JA, et al
    Coronaviruses: Facts, Myths, and Hypotheses.
    J Thorac Oncol. 2020;15:675-678.
    PubMed    


  363. WARREN GW, Alberg AJ, Cummings KM, Dresler C, et al
    Smoking Cessation After a Cancer Diagnosis Is Associated With Improved Survival.
    J Thorac Oncol. 2020;15:705-708.
    PubMed    


  364. JAMME P, Fernandes M, Copin MC, Descarpentries C, et al
    Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
    J Thorac Oncol. 2020;15:741-751.
    PubMed     Abstract available


  365. DELLA CORTE CM, Sen T, Gay CM, Ramkumar K, et al
    STING Pathway Expression Identifies NSCLC With an Immune-Responsive Phenotype.
    J Thorac Oncol. 2020;15:777-791.
    PubMed     Abstract available


  366. VAGHJIANI RG, Takahashi Y, Eguchi T, Lu S, et al
    Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:792-802.
    PubMed     Abstract available


  367. RATHKEY D, Khanal M, Murai J, Zhang J, et al
    Sensitivity of Mesothelioma Cells to PARP Inhibitors Is Not Dependent on BAP1 but Is Enhanced by Temozolomide in Cells With High-Schlafen 11 and Low-O6-methylguanine-DNA Methyltransferase Expression.
    J Thorac Oncol. 2020;15:843-859.
    PubMed     Abstract available


  368. DOMBLIDES C, Leroy K, Monnet I, Mazieres J, et al
    Efficacy of Immune Checkpoint Inhibitors in Lung Sarcomatoid Carcinoma.
    J Thorac Oncol. 2020;15:860-866.
    PubMed     Abstract available


  369. DELAUNAY T, Achard C, Boisgerault N, Grard M, et al
    Frequent Homozygous Deletions of Type I Interferon Genes in Pleural Mesothelioma Confer Sensitivity to Oncolytic Measles Virus.
    J Thorac Oncol. 2020;15:827-842.
    PubMed     Abstract available


    April 2020
  370. KUMAR S, Chmura S, Robinson C, Lin SH, et al
    Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic.
    J Thorac Oncol. 2020 Apr 28. pii: S1556-0864(20)30331.
    PubMed     Abstract available


  371. GROTE HJ, Feng Z, Schlichting M, Helwig C, et al
    PD-L1 Immunohistochemistry Assay Comparison Studies in Non-Small Cell Lung Cancer: Characterization of the 73-10 Assay.
    J Thorac Oncol. 2020 Apr 27. pii: S1556-0864(20)30327.
    PubMed     Abstract available


  372. SIMONS EA, Smith DE, Gao D, Camidge DR, et al
    Variation in toxicity reporting methods for early phase lung cancer treatment trials at oncology conferences.
    J Thorac Oncol. 2020 Apr 27. pii: S1556-0864(20)30335.
    PubMed     Abstract available


  373. CAFAROTTI S
    SARS-COV2 INFECTION AND LUNG CANCER PATIENTS: the potential role of IL17 target therapy.
    J Thorac Oncol. 2020 Apr 27. pii: S1556-0864(20)30330.
    PubMed     Abstract available


  374. SANZ-SANTOS J, Rami-Porta R, Call S
    Lessons already learnt from the Covid-19 pandemic.
    J Thorac Oncol. 2020 Apr 22. pii: S1556-0864(20)30326.
    PubMed    


  375. WARREN G, Adjei AA
    A CALL FOR RAPID SUBMISSION OF DATA FOR AGGREGATE REVIEW: Can daily radiotherapy imaging be used as a potential screen for COVID-19?
    J Thorac Oncol. 2020 Apr 21. pii: S1556-0864(20)30318.
    PubMed    


  376. OUYANG W, Yu J, Zhang J, Xie C, et al
    Alert to Potential Contagiousness: A Case of Lung Cancer with Asymptomatic SARS-CoV-2 Infection.
    J Thorac Oncol. 2020 Apr 16. pii: S1556-0864(20)30300.
    PubMed    


  377. TORLAKOVIC E, Albadine R, Bigras G, Boag A, et al
    Canadian Multicentre Project on Standardization of PD-L1 22C3 Immunohistochemistry Laboratory Developed Tests for Pembrolizumab Therapy in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Apr 15. pii: S1556-0864(20)30293.
    PubMed     Abstract available


  378. CAFAROTTI S, Patella M
    LUNG CANCER SURGICAL MANAGEMENT DURING THE OUTBREAK OF COVID-19.
    J Thorac Oncol. 2020 Apr 11. pii: S1556-0864(20)30291.
    PubMed    


  379. SUZUKI Y, Karayama M, Uto T, Fujii M, et al
    Assessment of Immune-Related Interstitial Lung Disease in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors: A Multi-Center Prospective Study.
    J Thorac Oncol. 2020 Apr 11. pii: S1556-0864(20)30297.
    PubMed     Abstract available


  380. CAI Y, Hao Z, Gao Y, Ping W, et al
    COVID-19 in the perioperative period of lung resection: a brief report from a single thoracic surgery department in Wuhan, China.
    J Thorac Oncol. 2020 Apr 11. pii: S1556-0864(20)30298.
    PubMed     Abstract available


  381. SUPPLI MH, Riisgaard de Blanck S, Elgaard T, Josipovic M, et al
    Early appearance of COVID-19 associated pulmonary infiltrates during daily radiotherapy imaging for lung cancer.
    J Thorac Oncol. 2020 Apr 10. pii: S1556-0864(20)30299.
    PubMed    


  382. RUSSANO M, Citarella F, Vincenzi B, Tonini G, et al
    COVID-19 or Lung Cancer: what should we treat?
    J Thorac Oncol. 2020 Apr 10. pii: S1556-0864(20)30294.
    PubMed    


  383. JOTTE R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, et al
    Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous Non-Small-Cell Lung Cancer (IMpower131): Results From a Randomized Phase III Trial.
    J Thorac Oncol. 2020 Apr 7. pii: S1556-0864(20)30292.
    PubMed     Abstract available


  384. YANG H
    Co-Occurring LKB1 Deficiency Determinates the Susceptibility to ERK-Targeted Therapy in RAS-Mutant Lung Cancer.
    J Thorac Oncol. 2020;15:e58-59.
    PubMed    


  385. KAIRA K, Ogiwara Y, Naruse I
    Occurrence of Ventricular Fibrillation in a Patient With Lung Cancer Receiving Osimertinib.
    J Thorac Oncol. 2020;15:e54-e55.
    PubMed    


  386. GRINBERG RD, Refaely Y, Cohen LB, Shaham D, et al
    Lung Cancer in Israel.
    J Thorac Oncol. 2020;15:493-498.
    PubMed    


  387. TREMBLAY A
    Reply and Commentary to "Smoking Cessation Interventions in the Setting of Low-Dose Computed Tomography: Are They Effective?"
    J Thorac Oncol. 2020;15:e61-e62.
    PubMed    


  388. SANGUANKEO A
    Smoking Cessation Interventions in the Setting of Low-Dose Computed Tomography: Are They Effective?
    J Thorac Oncol. 2020;15:e60.
    PubMed    


  389. CAIOLA E, Broggini M, Marabese M
    LKB1ness Dictates ERK Inhibitors Response in NSCLC.
    J Thorac Oncol. 2020;15:e59.
    PubMed    


  390. EGUREN-SANTAMARIA I, Sanmamed MF, Gil-Bazo I
    Are Immune Checkpoint Inhibitors Effective Against Uncommon Oncogene-Driven NSCLC Subtypes?
    J Thorac Oncol. 2020;15:489-492.
    PubMed    


  391. ZHOU F, Zhou C
    Treatment Algorithm for Advanced ALK-Rearranged NSCLC: A Marathon Rather Than a Sprint.
    J Thorac Oncol. 2020;15:485-488.
    PubMed    


  392. SOLOMON B
    Identifying Mechanisms of Resistance to ALK Tyrosine Kinase Inhibitors Using Analysis of Circulating Tumor DNA.
    J Thorac Oncol. 2020;15:482-484.
    PubMed    


  393. XIA B, Ou SI
    Simultaneous RET Solvent-Front and Gatekeeper Resistance Mutations In Trans: A Rare TKI-Specific Therapeutic Challenge?
    J Thorac Oncol. 2020;15:479-481.
    PubMed    


  394. BU K, Lu Y, Liu X, Cheng C, et al
    Lysocardiolipin Acyltransferase 1-Anaplastic Lymphoma Receptor Tyrosine Kinase: A Novel Crizotinib-Sensitive Fusion Gene in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e55-e57.
    PubMed    


  395. LV Y, Ling F, Zhang J, Xiao M, et al
    A Novel Intergenic LSM14A-RET Fusion Variant in a Patient With Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e52-e53.
    PubMed    


  396. XU J, Jiang Q, Xu H, Liu A, et al
    Two Patients Having NSCLC With Novel Duplication Mutation in Their EGFR Gene (p.I740_K745dupIPVAIK) and Their Response to Osimertinib.
    J Thorac Oncol. 2020;15:e49-e51.
    PubMed    


  397. SOLOMON BJ, Tan L, Lin JJ, Wong SQ, et al
    RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
    J Thorac Oncol. 2020;15:541-549.
    PubMed     Abstract available


  398. AHN MJ, Chiu CH, Cheng Y, Han JY, et al
    Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis.
    J Thorac Oncol. 2020;15:637-648.
    PubMed     Abstract available


  399. YAGI Y, Aly RG, Tabata K, Barlas A, et al
    Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:589-600.
    PubMed     Abstract available


  400. GUO R, DuBoff M, Jayakumaran G, Kris MG, et al
    Novel Germline Mutations in DNA Damage Repair in Patients with Malignant Pleural Mesotheliomas.
    J Thorac Oncol. 2020;15:655-660.
    PubMed     Abstract available


  401. KIM H, Goo JM, Kim YT, Park CM, et al
    Validation of the Eighth Edition Clinical T Categorization System for Clinical Stage IA, Resected Lung Adenocarcinomas: Prognostic Implications of the Ground-Glass Opacity Component.
    J Thorac Oncol. 2020;15:580-588.
    PubMed     Abstract available


  402. RODEN AC, Fang W, Shen Y, Carter BW, et al
    Distribution of Mediastinal Lesions Across Multi-Institutional, International, Radiology Databases.
    J Thorac Oncol. 2020;15:568-579.
    PubMed     Abstract available


  403. NOE J, Lovejoy A, Ou SI, Yaung SJ, et al
    ALK Mutation Status Before and After Alectinib Treatment in Locally Advanced or Metastatic ALK-Positive NSCLC: Pooled Analysis of Two Prospective Trials.
    J Thorac Oncol. 2020;15:601-608.
    PubMed     Abstract available


    March 2020
  404. POLVERARI G, Arena V, Ceci F, Pelosi E, et al
    (18)F-FDG uptake in Asymptomatic SARS-CoV-2 (COVID-19) patient, referred to PET/CT for Non-Small Cells Lung Cancer restaging.
    J Thorac Oncol. 2020 Mar 31. pii: S1556-0864(20)30286.
    PubMed    


  405. BONOMI L, Ghilardi L, Arnoldi E, Tondini CA, et al
    A rapid fatal evolution of Coronavirus Disease-19 (COVID-19) in an advanced lung cancer patient with a long time response to nivolumab.
    J Thorac Oncol. 2020 Mar 31. pii: S1556-0864(20)30285.
    PubMed    


  406. DE SOUZA GUTIERRES B, Aguiar PN Jr, Dourado BB, Alves AL, et al
    Evidence Strength of Pharmaceutical Industry Funded Clinical Trials in Metastatic Non-Small Cell Lung Cancer: A Comparison with Other Sources of Funding.
    J Thorac Oncol. 2020 Mar 23. pii: S1556-0864(20)30196.
    PubMed     Abstract available


  407. MEZQUITA L, Jove M, Nadal E, Kfoury M, et al
    Brief report: High prevalence of somatic oncogenic driver alterations in non-small cell lung cancer patients with Li-Fraumeni Syndrome.
    J Thorac Oncol. 2020 Mar 13. pii: S1556-0864(20)30197.
    PubMed     Abstract available


  408. PAZ-ARES L, Kim TM, Vicente D, Felip E, et al
    Bintrafusp alfa, a bifunctional fusion protein targeting TGF-beta and PD-L1, in second-line treatment of patients with non-small cell lung cancer: results from an expansion cohort of a phase 1 trial.
    J Thorac Oncol. 2020 Mar 12. pii: S1556-0864(20)30195.
    PubMed     Abstract available


  409. LURIENNE L, Cervesi J, Duhalde L, de Gunzburg J, et al
    Non-small-cell lung cancer immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis.
    J Thorac Oncol. 2020 Mar 12. pii: S1556-0864(20)30194.
    PubMed     Abstract available


  410. LI W, Liu Y, Li W, Chen L, et al
    Intergenic breakpoints identified by DNA sequencing confound targetable kinase fusion detection in non-small cell lung cancer.
    J Thorac Oncol. 2020 Mar 6. pii: S1556-0864(20)30189.
    PubMed     Abstract available


  411. ZHANG H, Huang Y, Xie C
    The Treatment and Outcome of a Lung Cancer Patient Infected with SARS-CoV-2.
    J Thorac Oncol. 2020 Mar 5. pii: S1556-0864(20)30191.
    PubMed    


  412. NG TL, Narasimhan N, Gupta N, Venkatakrishnan K, et al
    Early-Onset Pulmonary Events Associated With Brigatinib Use in Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Mar 2. pii: S1556-0864(20)30133.
    PubMed     Abstract available


  413. RAJADURAI P, How SH, Liam CK, Sachithanandan A, et al
    Lung Cancer in Malaysia.
    J Thorac Oncol. 2020;15:317-323.
    PubMed    


  414. LI T
    Managing the Isolated Central Nervous System Progression in Patients With Oncogene-Driven Metastatic NSCLC: Does Circulating Tumor DNA Add to Management?
    J Thorac Oncol. 2020;15:314-316.
    PubMed    


  415. MACAYA I, Entrialgo-Cadierno R, Valencia K, Vicent S, et al
    Liver Kinase B1 (LKB1) Loss Has its p-ERKs: ERK Inactivation as a Vulnerability in NSCLC With LKB1 Mutations.
    J Thorac Oncol. 2020;15:311-313.
    PubMed    


  416. MENIS J, Reck M
    Checkpoint Inhibitors in SCLC: How Much Can We Trust in Randomized Cohorts of Phase I/II Trials?
    J Thorac Oncol. 2020;15:308-310.
    PubMed    


  417. DE-RUI HUANG D, Chih-Hsin Yang J
    Checkpoint Inhibitor Combined With Tyrosine Kinase Inhibitor-the End or Beginning?
    J Thorac Oncol. 2020;15:305-307.
    PubMed    


  418. ZHANG Q, Jiang T, Xiao M, Zhang J, et al
    Identification of a Novel Osimertinib-Sensitive Mutation, EGFR H773L, in a Chinese Patient With NSCLC.
    J Thorac Oncol. 2020;15:e46-e48.
    PubMed    


  419. WANG L, Yao S, Teng L, Zhang W, et al
    Melanoregulin-Anaplastic Lymphoma Kinase (ALK), a Novel ALK Rearrangement That Responds to Crizotinib in Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e44-e46.
    PubMed    


  420. FUKUDO M, Sasaki T, Ohsaki Y
    PD-1 Blockers: Staying Long in the Body and Delayed Toxicity Risks.
    J Thorac Oncol. 2020;15:e42-e44.
    PubMed    


  421. KANEMURA H, Hayashi H, Hagiwara S, Otani T, et al
    Severe Immune-Related Hepatitis Treated With Plasma Exchange.
    J Thorac Oncol. 2020;15:e39-e42.
    PubMed    


  422. MAO W, Chen R, Zhang J, Zheng M, et al
    TMED2-ALK, a Novel ALK Fusion Gene Identified in a Patient With Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e37-e39.
    PubMed    


  423. FANG W, Huang Y, Gan J, Zheng Q, et al
    Emergence of EGFR G724S After Progression on Osimertinib Responded to Afatinib Monotherapy.
    J Thorac Oncol. 2020;15:e36-e37.
    PubMed    


  424. FANG W, Huang Y, Gan J, He B, et al
    Nintedanib Effect in Osimertinib-Induced Interstitial Pneumonia.
    J Thorac Oncol. 2020;15:e34-e35.
    PubMed    


  425. OH S, Lim JH, Park N, Choi S, et al
    Dual Inhibition of EGFR and BRAF Can Be Harmful in Patients Harboring an EGFR-Activating Mutation.
    J Thorac Oncol. 2020;15:e32-e34.
    PubMed    


  426. WANG H, Tian R, Gao P, Wang Q, et al
    Tocilizumab for Fulminant Programmed Death 1 Inhibitor-Associated Myocarditis.
    J Thorac Oncol. 2020;15:e31-e32.
    PubMed    


  427. MOLINA-VILA MA, Stahel RA, Dafni U, Jordana-Ariza N, et al
    Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial.
    J Thorac Oncol. 2020;15:416-425.
    PubMed     Abstract available


  428. PELOSI G, Sabella G, Cannone M, Balladore E, et al
    Parietal Pleura-Based Malignant Perivascular Epithelioid Cell Neoplasm Protruding Into Serous Cavity: A Hitherto Unrecognized Occurrence.
    J Thorac Oncol. 2020;15:462-466.
    PubMed    


  429. OSAROGIAGBON RU, Faris NR, Stevens W, Fehnel C, et al
    Beyond Margin Status: Population-Based Validation of the Proposed International Association for the Study of Lung Cancer Residual Tumor Classification Recategorization.
    J Thorac Oncol. 2020;15:371-382.
    PubMed     Abstract available


  430. RUFFINI E, Fang W, Guerrera F, Huang J, et al
    The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors.
    J Thorac Oncol. 2020;15:436-447.
    PubMed     Abstract available


  431. MIAN I, Abdullaev Z, Morrow B, Kaplan RN, et al
    Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.
    J Thorac Oncol. 2020;15:457-461.
    PubMed     Abstract available


  432. LIU H, Gu Z, Qiu B, Detterbeck FC, et al
    A Recurrence Predictive Model for Thymic Tumors and Its Implication for Postoperative Management: a Chinese Alliance for Research in Thymomas Database Study.
    J Thorac Oncol. 2020;15:448-456.
    PubMed     Abstract available


    February 2020
  433. TIAN S, Hu W, Niu L, Liu H, et al
    Pulmonary pathology of early phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer.
    J Thorac Oncol. 2020 Feb 27. pii: S1556-0864(20)30132.
    PubMed     Abstract available


  434. CAO P, Jeon J, Levy DT, Jayasekera J, et al
    Potential Impact of Cessation Interventions at the Point of Lung Cancer Screening on Lung Cancer and Overall Mortality in the United States.
    J Thorac Oncol. 2020 Feb 27. pii: S1556-0864(20)30130.
    PubMed     Abstract available


  435. ZHANG Y, Zeng L, Zhou C, Li Y, et al
    Detection of non-reciprocal/reciprocal ALK translocation as poor predictive marker in first-line crizotinib-treated ALK-rearranged non-small cell lung cancer patients.
    J Thorac Oncol. 2020 Feb 26. pii: S1556-0864(20)30129.
    PubMed     Abstract available


  436. GAO S, Li N, Gao S, Xue Q, et al
    Neoadjuvant PD-1 inhibitor (Sintilimab) in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Feb 6. pii: S1556-0864(20)30057.
    PubMed     Abstract available


  437. BACKMAN M, La Fleur L, Kurppa P, Djureinovic D, et al
    Characterization of patterns of immune cell infiltration in non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2020 Feb 3. pii: S1556-0864(20)30015.
    PubMed     Abstract available


  438. POIRIER JT, George J, Owonikoko TK, Berns A, et al
    New approaches to small cell lung cancer therapy : from the laboratory to the clinic.
    J Thorac Oncol. 2020 Feb 1. pii: S1556-0864(20)30056.
    PubMed     Abstract available


  439. JIANG H, Xiao M, Qi C, Cai S, et al
    A Novel Oncogenic RET Fusion Variant in Non-Small Cell Lung Cancer: RELCH-RET.
    J Thorac Oncol. 2020;15:e27-e28.
    PubMed    


  440. MATHIAS C, Prado GF, Mascarenhas E, Ugalde PA, et al
    Lung Cancer in Brazil.
    J Thorac Oncol. 2020;15:170-175.
    PubMed    


  441. HENDRIKS LEL, Menis J, De Ruysscher DKM, Reck M, et al
    Combination of Immunotherapy and Radiotherapy-The Next Magic Step in the Management of Lung Cancer?
    J Thorac Oncol. 2020;15:166-169.
    PubMed    


  442. PUJOL JL, Roch B
    Is Darbepoietin Alfa Linked to Mortality During Non-Small Cell Lung Cancer Chemotherapy?
    J Thorac Oncol. 2020;15:159-162.
    PubMed    


  443. SANDS JM, Milan MSD, Oxnard GR
    Blood-Based Disease Assessment in SCLC: A Perpetual Proof of Concept or a Clinically Important Tool?
    J Thorac Oncol. 2020;15:163-165.
    PubMed    


  444. JOHKOH T
    Take a Look at Clinical Data in Detail, Analyze Them, and Develop a New Diagnostic Method.
    J Thorac Oncol. 2020;15:158.
    PubMed    


  445. LE TALLEC E, Lescoat A, Ballerie A, Cador B, et al
    Eosinophilic Fasciitis Triggered by Nivolumab: A Remarkable Efficacy of the mTOR Inhibitor Sirolimus.
    J Thorac Oncol. 2020;15:e29-e30.
    PubMed    


  446. KABBASH MS, Edmund J, Ghafoor A, Hassan R, et al
    Intracardiac Involvement by Primary Malignant Mesothelioma: A Report of Two Cases.
    J Thorac Oncol. 2020;15:e25-e27.
    PubMed    


  447. LU R, Qi C, Xiao M, Cai S, et al
    STRN3-NTRK1: A Novel NTRK1 Oncogenic Fusion in a Patient with Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e23-e24.
    PubMed    


  448. REKHTMAN N, Montecalvo J, Chang JC, Alex D, et al
    SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic Sarcomas.
    J Thorac Oncol. 2020;15:231-247.
    PubMed     Abstract available


  449. SUH YJ, Lee HJ, Sung P, Yoen H, et al
    A Novel Algorithm to Differentiate Between Multiple Primary Lung Cancers and Intrapulmonary Metastasis in Multiple Lung Cancers With Multiple Pulmonary Sites of Involvement.
    J Thorac Oncol. 2020;15:203-215.
    PubMed     Abstract available


  450. GRAY JE, Villegas A, Daniel D, Vicente D, et al
    Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.
    J Thorac Oncol. 2020;15:288-293.
    PubMed     Abstract available


    January 2020
  451. COHEN D, Hondelink LM, Solleveld-Westerink N, Uljee SM, et al
    Optimizing mutation and fusion detection in Non-Small Cell Lung Cancer by sequential DNA and RNA sequencing.
    J Thorac Oncol. 2020 Jan 31. pii: S1556-0864(20)30093.
    PubMed     Abstract available


  452. TRAVIS WD, Dacic S, Wistuba I, Sholl L, et al
    IASLC MULTIDISCIPLINARY RECOMMENDATIONS FOR PATHOLOGIC ASSESSMENT OF LUNG CANCER RESECTION SPECIMENS FOLLOWING NEOADJUVANT THERAPY.
    J Thorac Oncol. 2020 Jan 28. pii: S1556-0864(20)30026.
    PubMed     Abstract available


  453. DAGOGO-JACK I, Schrock AB, Kem M, Jessop N, et al
    Clinicopathologic Characteristics of BRG1-Deficient Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2020 Jan 24. pii: S1556-0864(20)30023.
    PubMed     Abstract available


  454. ARAI S, Takeuchi S, Fukuda K, Taniguchi H, et al
    Osimertinib overcomes alectinib resistance caused by amphiregulin in a leptomeningeal carcinomatosis model of ALK-rearranged lung cancer.
    J Thorac Oncol. 2020 Jan 20. pii: S1556-0864(20)30022.
    PubMed     Abstract available


  455. GUISIER F, Dubos-Arvis C, Vinas F, Doubre H, et al
    Efficacy and safety of anti-PD-1 immunotherapy in patients with advanced Non Small Cell Lung Cancer with BRAF, HER2 or MET mutation or RET-translocation. GFPC 01-2018.
    J Thorac Oncol. 2020 Jan 13. pii: S1556-0864(20)30020.
    PubMed     Abstract available


  456. CHIH-HSIN YANG J, Schuler M, Popat S, Miura S, et al
    Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Database of 693 Cases.
    J Thorac Oncol. 2020 Jan 10. pii: S1556-0864(20)30014.
    PubMed     Abstract available


  457. GAINOR JF, Stevens SE, Willers H, Shih HA, et al
    Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification.
    J Thorac Oncol. 2020;15:e8-e10.
    PubMed    


  458. WANG X, Lai Y, Dai W, He J, et al
    Mutation Profile of Tibetan Lung Cancer Revealed by Whole Exome Sequencing.
    J Thorac Oncol. 2020;15:e10-e13.
    PubMed    


  459. VAN EEDEN R, Tunmer M, Geldenhuys A, Nayler S, et al
    Lung Cancer in South Africa.
    J Thorac Oncol. 2020;15:22-28.
    PubMed    


  460. DAVIES KD, Merrick DT
    Skipping Expected Mechanisms of MET-Mediated Oncogenesis.
    J Thorac Oncol. 2020;15:9-11.
    PubMed    


  461. SCHOENFELD AJ, Yu HA
    The Evolving Landscape of Resistance to Osimertinib.
    J Thorac Oncol. 2020;15:18-21.
    PubMed    


  462. NESTLE U, Adebahr S, van Herk M
    Retrospective Analyses of Registry Data for Technical Radiation Oncology Questions: Apples Versus Pears or Solid Evidence?
    J Thorac Oncol. 2020;15:15-17.
    PubMed    


  463. ARULANANDA S, John T
    Gefitinib and Pemetrexed Improve Survival in EGFR-Mutated NSCLC - Tarring all Patients With the Same Brush?
    J Thorac Oncol. 2020;15:12-14.
    PubMed    


  464. PENG Y, Zhang L, Zeng T, Liu L, et al
    Characterization of Hyperprogression After Immunotherapy in a Lung Adenocarcinoma Patient With Strong Expression of Programmed Death Ligand 1.
    J Thorac Oncol. 2020;15:e4-e8.
    PubMed    


  465. HIRANO S, Hayama N, Tabeta H, Kuroki T, et al
    Drastic Response of Rechallenge of Nivolumab in a Patient with NSCLC Who Progressed on the First Nivolumab Treatment.
    J Thorac Oncol. 2020;15:e20-e22.
    PubMed    


  466. VAN TURENHOUT ST, Berghuis M, Snaebjornsson P, Wilgenhof S, et al
    Cytomegalovirus in Steroid-Refractory Immune Checkpoint Inhibition-Related Colitis.
    J Thorac Oncol. 2020;15:e15-e20.
    PubMed    


  467. GAUTSCHI O, Menon R, Bertrand M, Murer C, et al
    Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma.
    J Thorac Oncol. 2020;15:e13-e15.
    PubMed    


  468. WANG Z, Jia Q, Tang X, Yan L, et al
    Transformation to Lung Adenocarcinoma From Complete Remission-Experienced SCLC.
    J Thorac Oncol. 2020;15:e1-e3.
    PubMed    


  469. SCAGLIOTTI G, Moro-Sibilot D, Kollmeier J, Favaretto A, et al
    A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation-Positive NSCLC Patients.
    J Thorac Oncol. 2020;15:80-90.
    PubMed     Abstract available


  470. BALDACCI S, Figeac M, Antoine M, Descarpentries C, et al
    High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.
    J Thorac Oncol. 2020;15:120-124.
    PubMed     Abstract available


  471. MIKUBO M, Seto K, Kitamura A, Nakaguro M, et al
    Calculating the Tumor Nuclei Content for Comprehensive Cancer Panel Testing.
    J Thorac Oncol. 2020;15:130-137.
    PubMed     Abstract available


  472. TAN VS, Correa RJM, Rodrigues GB, Palma DA, et al
    Intraluminal Superior Vena Cava Invasion.
    J Thorac Oncol. 2020;15:144-145.
    PubMed    


  473. SCHENK EL, Mandrekar SJ, Dy GK, Aubry MC, et al
    A Randomized Double-Blind Phase II Study of the Seneca Valley Virus (NTX-010) versus Placebo for Patients with Extensive-Stage SCLC (ES SCLC) Who Were Stable or Responding after at Least Four Cycles of Platinum-Based Chemotherapy: North Central Cancer
    J Thorac Oncol. 2020;15:110-119.
    PubMed     Abstract available


  474. NICHOLSON AG, Sauter JL, Nowak AK, Kindler HL, et al
    EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach.
    J Thorac Oncol. 2020;15:29-49.
    PubMed     Abstract available


    December 2019
  475. CHUNG HC, Piha-Paul SA, Lopez-Martin J, Schellens JHM, et al
    Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic Small-Cell Lung Cancer: Results From the KEYNOTE-028 and KEYNOTE-158 Studies.
    J Thorac Oncol. 2019 Dec 20. pii: S1556-0864(19)33850.
    PubMed     Abstract available


  476. LANTUEJOUL S, Tsao MS, Cooper WA, Girard N, et al
    PD-L1 Testing for Lung Cancer in 2019: Perspective from the IASLC Pathology Committee.
    J Thorac Oncol. 2019 Dec 20. pii: S1556-0864(19)33847.
    PubMed     Abstract available


  477. HWANG JK, Page BJ, Flynn D, Passmore L, et al
    Validation of the eighth edition TNM lung cancer staging system; a brief report.
    J Thorac Oncol. 2019 Dec 18. pii: S1556-0864(19)33846.
    PubMed     Abstract available


  478. ALDEA M, Hendriks L, Mezquita L, Jovelet C, et al
    Circulating tumor DNA analysis for oncogene-addicted non-small cell lung cancer patients with isolated central nervous system progression.
    J Thorac Oncol. 2019 Dec 13. pii: S1556-0864(19)33716.
    PubMed     Abstract available


  479. WANG Z, Duan J, Wang G, Zhao J, et al
    Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for non-small cell lung cancer patients treated with PD-1/PD-L1 inhibitors.
    J Thorac Oncol. 2019 Dec 12. pii: S1556-0864(19)33720.
    PubMed     Abstract available


  480. PARK S, Lee SH, Park K
    In Reply: DDR Pathway Alteration, Tumor Mutation Burden and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole-Exome and Targeted-Gene Sequencing.
    J Thorac Oncol. 2019;14:e279-e280.
    PubMed    


  481. LUO P, Lin A, Li K, Wei T, et al
    DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing.
    J Thorac Oncol. 2019;14:e276-e279.
    PubMed    


  482. PASSIGLIA F, Calandri M, Guerrera F, Malapelle U, et al
    Lung Cancer in Italy.
    J Thorac Oncol. 2019;14:2046-2052.
    PubMed    


  483. PASTORINO U, Tagliabue E
    Non-Human Determinants of Lung Cancer Outcome: A Target for Inhibition of Pro-Metastatic Effect of Surgery, Triggered by Postoperative Bacterial Pneumonia.
    J Thorac Oncol. 2019;14:2039-2041.
    PubMed    


    November 2019
  484. WILLIAMS GH, Nicholson AG, Snead DRJ, Thunnissen E, et al
    Inter-observer Reliability of Programmed Cell Death Ligand-1 Scoring Using the VENTANA PD-L1 (SP263) Assay in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33664.
    PubMed     Abstract available


  485. NISHIO M, Felip E, Orlov S, Park K, et al
    Final Overall Survival, Other Efficacy and Safety Results from ASCEND-3: Phase II Study of Ceritinib in ALKi-Naive Patients With ALK-Rearranged Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33660.
    PubMed     Abstract available


  486. LIN SH, Lin Y, Yao L, Kalhor N, et al
    Phase II trial of concurrent atezolizumab with chemoradiation in unresectable non-small cell lung cancer.
    J Thorac Oncol. 2019 Nov 25. pii: S1556-0864(19)33659.
    PubMed     Abstract available


  487. HUBER RM, Hansen KH, Paz-Ares Rodriguez L, West HL, et al
    Brigatinib in Crizotinib-Refractory ALK+ Non-Small Cell Lung Cancer: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA Trial.
    J Thorac Oncol. 2019 Nov 19. pii: S1556-0864(19)33645.
    PubMed     Abstract available


  488. TAN WL, Chua KLM, Lin CC, Lee VHF, et al
    Asian Thoracic Oncology Research Group expert consensus statement on optimal management of stage III non-small cell lung cancer.
    J Thorac Oncol. 2019 Nov 13. pii: S1556-0864(19)33640.
    PubMed     Abstract available


  489. EDWARDS JG, Chansky K, van Schil P, Nicholson AG, et al
    The IASLC Lung Cancer Staging Project: Analysis of Resection Margin Status and Proposals for Residual Tumor (R) Descriptors for Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Nov 12. pii: S1556-0864(19)33637.
    PubMed     Abstract available


  490. BROOKS ED, Verma V, Senan S, De Baere T, et al
    Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Nov 8. pii: S1556-0864(19)33634.
    PubMed     Abstract available


  491. SHARMA GG, Cortinovis D, Agustoni F, Arosio G, et al
    A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib.
    J Thorac Oncol. 2019;14:e257-e259.
    PubMed    


  492. LI J, Li C, Cheng B, He J, et al
    The Relative Impact of Family History of Different Cancers on Lung Cancer Risk.
    J Thorac Oncol. 2019;14:e248-e249.
    PubMed    


  493. JAZIEH AR, Algwaiz G, Errihani H, Elghissassi I, et al
    Lung Cancer in the Middle East and North Africa Region.
    J Thorac Oncol. 2019;14:1884-1891.
    PubMed    


    October 2019
  494. LIN JJ, Schoenfeld AJ, Zhu VW, Yeap BY, et al
    Efficacy of platinum/pemetrexed combination chemotherapy in ALK-positive non-small cell lung cancer refractory to second-generation ALK inhibitors.
    J Thorac Oncol. 2019 Oct 26. pii: S1556-0864(19)33573.
    PubMed     Abstract available


  495. OWONIKOKO TK, Niu H, Nackaerts K, Csoszi T, et al
    Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for Small-Cell Lung Cancer: Primary and Correlative Biomarker Analyses.
    J Thorac Oncol. 2019 Oct 23. pii: S1556-0864(19)33572.
    PubMed     Abstract available


  496. CAIOLA E, Iezzi A, Tomanelli M, Bonaldi E, et al
    LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitors.: ERK inhibitors in LKB1 mutated NSCLC.
    J Thorac Oncol. 2019 Oct 18. pii: S1556-0864(19)33568.
    PubMed     Abstract available


  497. FELIP E, de Braud FG, Maur M, Loong HH, et al
    Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC.
    J Thorac Oncol. 2019 Oct 18. pii: S1556-0864(19)33564.
    PubMed     Abstract available


  498. READY NE, Ott PA, Hellmann MD, Zugazagoitia J, et al
    Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.
    J Thorac Oncol. 2019 Oct 17. pii: S1556-0864(19)33531.
    PubMed     Abstract available


  499. MOHAN S, Foy V, Ayub M, Leong HS, et al
    Profiling of circulating free DNA using targeted and genome wide sequencing in patients with Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Oct 16. pii: S1556-0864(19)33566.
    PubMed     Abstract available


  500. GASCON P, Nagarkar R, Smakal M, Syrigos KN, et al
    A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin alfa for Chemotherapy-Induced Anemia in Patients With Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Oct 16. pii: S1556-0864(19)33563.
    PubMed     Abstract available


  501. HAN D, Heuvelmans MA, van der Aalst CM, van Smoorenburg LH, et al
    New Fissure-attached Nodules in Lung Cancer Screening: A Brief Report from The NELSON Study.
    J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33521.
    PubMed     Abstract available


  502. ALMOTLAK AA, Farooqui M, Siegfried JM
    Inhibiting pathways predicted from a steroid hormone gene signature yields synergistic anti-tumor effects in non-small cell lung cancer.
    J Thorac Oncol. 2019 Oct 10. pii: S1556-0864(19)33523.
    PubMed     Abstract available


  503. CHIH-HSIN YANG J, Cheng Y, Murakami H, Yang PC, et al
    A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33332.
    PubMed    


  504. ZUGAZAGOITIA J, Liu Y, Toki M, McGuire J, et al
    Quantitative assessment of CMTM6 in the tumor microenvironment and association with response to PD-1 pathway blockade in advanced-stage non-small-cell lung cancer.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33342.
    PubMed     Abstract available


  505. WELSH JW, Heymach JV, Chen D, Verma V, et al
    Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33525.
    PubMed     Abstract available


  506. BROWN H, Vansteenkiste J, Nakagawa K, Cobo M, et al
    Brief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.
    J Thorac Oncol. 2019 Oct 9. pii: S1556-0864(19)33334.
    PubMed     Abstract available


  507. SANCHIS-BORJA M, Parrot A, Sroussi D, Rivin Del Campo E, et al
    Dramatic Radiation Recall Pneumonitis Induced by Osimertinib after Palliative Thoracic Radiotherapy for Lung Cancer.
    J Thorac Oncol. 2019;14:e224-e226.
    PubMed    


  508. GUAN R, Lin A, Luo P, Zhang J, et al
    Association between Circulating Inflammatory Proteins and Clinical Prognosis in Chinese Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e222-e224.
    PubMed    


  509. ARRIETA O, Zatarain-Barron ZL, Aldaco F, Barron F, et al
    Lung Cancer in Mexico.
    J Thorac Oncol. 2019;14:1695-1700.
    PubMed    


  510. GRANNIS FW JR
    Lung Cancer Incidence and Mortality with Extended Follow-up during Screening.
    J Thorac Oncol. 2019;14:1692-1694.
    PubMed    


    September 2019
  511. HSU CC, Liao BC, Liao WY, Markovets A, et al
    Exon-16-skipping HER2 as a novel mechanism of osimertinib-resistance in EGFR L858R/T790M-positive non-small-cell lung cancer.
    J Thorac Oncol. 2019 Sep 23. pii: S1556-0864(19)33307.
    PubMed     Abstract available


  512. GAGNE A, Wang E, Bastien N, Orain M, et al
    Impact of Specimen Characteristics on PD-L1 Testing in Non-Small Cell Lung Cancer: Validation of the IASLC PD-L1 Testing Guidelines.
    J Thorac Oncol. 2019 Sep 5. pii: S1556-0864(19)33186.
    PubMed     Abstract available


  513. FANG W, Huang Y, Gan J, Hong S, et al
    A Patient with EGFR Exon 20 Insertion-Mutant Non-Small Cell Lung Cancer Responded to Osimertinib plus Cetuximab Combination Therapy.
    J Thorac Oncol. 2019;14:e201-e202.
    PubMed    


  514. BUROTTO M, Aren O, Renner A, Samtani S, et al
    Lung Cancer in Chile.
    J Thorac Oncol. 2019;14:1504-1509.
    PubMed    


  515. ARENBERG D
    Micronodules Detected on Lung Cancer Screening CT Scans.
    J Thorac Oncol. 2019;14:1501-1503.
    PubMed    


    August 2019
  516. MORENO AC, Fellman B, Hobbs BP, Liao Z, et al
    Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients with Early-Stage Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Aug 31. pii: S1556-0864(19)33191.
    PubMed     Abstract available


  517. GILL RR, Tsao AS, Kindler HL, Richards WG, et al
    Radiologic Considerations And Standardization Of Malignant Pleural Mesothelioma (MPM) Imaging Within Clinical Trials: Consensus Statement From The NCI Thoracic Malignancy Steering Committee - International Association For The Study Of Lung Cancer - Me
    J Thorac Oncol. 2019 Aug 27. pii: S1556-0864(19)30695.
    PubMed     Abstract available


  518. SEN T, Della Corte CM, Milutinovic S, Cardnell RJ, et al
    Combination treatment of the oral CHK1 inhibitor, SRA737 and low dose gemcitabine, enhances the effect of PD-L1 blockade by modulating the immune microenvironment in small cell lung cancer.
    J Thorac Oncol. 2019 Aug 27. pii: S1556-0864(19)30692.
    PubMed     Abstract available


  519. OHUE Y, Kurose K, Karasaki T, Isobe M, et al
    Serum Antibody against NY-ESO-1 and XAGE1 Antigens Potentially Predicts Clinical Responses to Anti-PD-1 Therapy in Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2019 Aug 23. pii: S1556-0864(19)30691.
    PubMed     Abstract available


  520. HORN L, Whisenant JG, Wakelee H, Reckamp KL, et al
    Monitoring therapeutic response and resistance: analysis of circulating tumor DNA in patients with ALK+ lung cancer.
    J Thorac Oncol. 2019 Aug 22. pii: S1556-0864(19)30665.
    PubMed     Abstract available


  521. PARK BJ, Kim TH, Shin S, Kim HK, et al
    Recommended change in the N descriptor proposed by the International Association for the Study of Lung Cancer: a validation study.
    J Thorac Oncol. 2019 Aug 20. pii: S1556-0864(19)30670.
    PubMed     Abstract available


  522. SPAGGIARI L, Sedda G, Maisonneuve P, Tessitore A, et al
    A brief report on survival after robotic lobectomy for early-stage lung cancer.
    J Thorac Oncol. 2019 Aug 19. pii: S1556-0864(19)30666.
    PubMed     Abstract available


  523. FU F, Zhang Y, Wen Z, Zheng D, et al
    Distinct prognostic factors in patients with stage I non-small cell lung cancer with radiologic part solid or solid lesions.
    J Thorac Oncol. 2019 Aug 19. pii: S1556-0864(19)30664.
    PubMed     Abstract available


  524. DINGEMANS AC, Hendriks LEL, Berghmans T, Levy A, et al
    Definition of synchronous oligo-metastatic non-small cell lung cancer - a consensus report.
    J Thorac Oncol. 2019 Aug 6. pii: S1556-0864(19)30655.
    PubMed     Abstract available


  525. GOWING SD, Chow SC, Cools-Lartigue JJ, Chen CB, et al
    Gram-Negative Pneumonia Augments Non-Small Cell Lung Cancer Metastasis Through Host Toll-like Receptor 4 Activation.
    J Thorac Oncol. 2019 Aug 2. pii: S1556-0864(19)30653.
    PubMed     Abstract available


  526. STIRLING R, Zalcberg J
    Peeling the Onion of Health Care Disparity in Lung Cancer.
    J Thorac Oncol. 2019;14:e167-e168.
    PubMed    


  527. JAIN A, Fujioka N, Patel M
    Immune Checkpoint Inhibitors in ROS1-Rearranged Non-Small Cell Lung Cancer: A Report of Two Cases.
    J Thorac Oncol. 2019;14:e165-e167.
    PubMed    


  528. WATANABE Y, Kikuchi R, Iwai Y, Ito M, et al
    Varicella Zoster Virus Encephalitis Mimicking Nivolumab-Induced Autoimmune Neuropathy in a Patient with Lung Cancer.
    J Thorac Oncol. 2019;14:e163-e165.
    PubMed    


  529. ZHOU H, Liu J, Zhang Y, Huang Y, et al
    Autoimmune Diseases and Lung Cancer: A Mendelian Randomization Study.
    J Thorac Oncol. 2019;14:e161-e163.
    PubMed    


  530. ZWITTER M, Cufer T, Vrankar M, Kern I, et al
    Lung Cancer in Slovenia.
    J Thorac Oncol. 2019;14:1327-1331.
    PubMed    


  531. BERNICKER EH, Quigley EMM
    The Gut Microbiome Influences Responses to Programmed Death 1 Therapy in Chinese Lung Cancer Patients - the Benefits of Diversity.
    J Thorac Oncol. 2019;14:1319-1322.
    PubMed    


  532. GAY CM, Byers LA
    PARP Inhibition Combined with Immune Checkpoint Blockade in SCLC: Oasis in an Immune Desert or Mirage?
    J Thorac Oncol. 2019;14:1323-1326.
    PubMed    


    July 2019
  533. MAKIMOTO G, Ohashi K, Tomida S, Nishii K, et al
    Brief Report: Rapid Acquisition of Alectinib Resistance in ALK-positive Lung Cancer with High Tumor Mutation Burden.
    J Thorac Oncol. 2019 Jul 30. pii: S1556-0864(19)30602.
    PubMed     Abstract available


  534. YANG SC, Kuo CW, Lai WW, Lin CC, et al
    Dynamic Changes of Health Utility in Lung Cancer Patients Receiving Different Treatments: A 7-Year Follow-up.
    J Thorac Oncol. 2019 Jul 25. pii: S1556-0864(19)30588.
    PubMed     Abstract available


  535. CONDE E, Hernandez S, Martinez R, Angulo B, et al
    Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Non-Small Cell Lung Carcinoma Patients: the ROSING Study.
    J Thorac Oncol. 2019 Jul 23. pii: S1556-0864(19)30562.
    PubMed     Abstract available


  536. EDELMAN MJ, Redman MW, Albain KS, McGary EC, et al
    Brief Report: SWOG S1400C (NCT02154490)-A Phase II Study of Palbociclib for Previously Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-study).
    J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30557.
    PubMed     Abstract available


  537. BENITEZ JC, Mezquita L, Colle R, Tselikas KL, et al
    Hepatic Intra-Arterial Chemotherapy with Immunotherapy in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jul 11. pii: S1556-0864(19)30556.
    PubMed    


  538. FUJINO T, Kobayashi Y, Suda K, Koga T, et al
    Sensitivity and Resistance of MET Exon 14 Mutations in Lung Cancer to Eight MET Tyrosine Kinase Inhibitors In Vitro.
    J Thorac Oncol. 2019 Jul 3. pii: S1556-0864(19)30551.
    PubMed     Abstract available


  539. CANEPA M, Patel NR, Griffith RC, Ng TT, et al
    KRAS Mutation for Staging Resected Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e153-e155.
    PubMed    


  540. WANG H, Zhang L, Liu W
    Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e141-e143.
    PubMed    


  541. HO C, Lefresne S, Liberman M, McGuire A, et al
    Lung Cancer in Canada.
    J Thorac Oncol. 2019;14:1128-1133.
    PubMed    


  542. FOSTER CC, Pitroda SP, Weichselbaum RR
    Beyond Palliation: The Rationale for Metastasis-Directed Therapy for Metastatic Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jul 1. pii: S1556-0864(19)30410.
    PubMed    


  543. REKHTMAN N, Travis WD
    Large No More: The Journey of Pulmonary Large Cell Carcinoma from Common to Rare Entity.
    J Thorac Oncol. 2019;14:1125-1127.
    PubMed    


  544. LAI WV, Rudin CM
    Analyzing the Thin Tail: Searching for Biomarkers of Exceptional Survival in SCLC.
    J Thorac Oncol. 2019;14:1122-1124.
    PubMed    


  545. KOUNO S, Atagi S
    Immunotherapy for NSCLC With Brain Metastases: What Can We Learn From Real-World Data?
    J Thorac Oncol. 2019;14:1119-1121.
    PubMed    


    June 2019
  546. BAUER TM, Besse B, Martinez-Marti A, Trigo JM, et al
    Phase I, Open-Label, Dose-Escalation Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of GSK2879552 in Relapsed/Refractory Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30503.
    PubMed     Abstract available


  547. NAITO T, Udagawa H, Sato J, Horinouchi H, et al
    A minimum of 100 tumor cells in a single biopsy sample is required to assess programmed cell death ligand 1 expression in predicting patient response to nivolumab treatment in non-squamous non-small cell lung carcinoma.
    J Thorac Oncol. 2019 Jun 28. pii: S1556-0864(19)30501.
    PubMed     Abstract available


  548. CHAE YK, Viveiros P, Lopes G, Sukhadia B, et al
    Clinical and immunological implications of frameshift mutations in lung cancer.
    J Thorac Oncol. 2019 Jun 22. pii: S1556-0864(19)30496.
    PubMed     Abstract available


  549. MUNDEN RF, Chiles C, Boiselle PM, Sicks JD, et al
    Micronodules Detected on CT during the NLST: Prevalence and Relation to Positive Studies and Lung Cancer.
    J Thorac Oncol. 2019 Jun 20. pii: S1556-0864(19)30481.
    PubMed     Abstract available


  550. GUO R, Berry LD, Aisner DL, Sheren J, et al
    MET IHC is a Poor Screen for MET Amplification or MET exon 14 mutations in Lung Adenocarcinomas: Data from a Tri-Institutional Cohort of the Lung Cancer Mutation Consortium.
    J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30474.
    PubMed     Abstract available


  551. BALATA H, Fong KM, Hendriks LE, Lam S, et al
    Prevention and Early Detection for Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    J Thorac Oncol. 2019 Jun 19. pii: S1556-0864(19)30476.
    PubMed     Abstract available


  552. BLACK WC, Chiles C, Church TR, Gareen IF, et al
    Lung Cancer Incidence and Mortality with Extended Follow-up in the National Lung Screening Trial National Lung Screening Trial Writing Team (1).
    J Thorac Oncol. 2019 Jun 13. pii: S1556-0864(19)30473.
    PubMed     Abstract available


  553. IAMS WT, Shiuan E, Meador CB, Roth M, et al
    Improved prognosis and increased tumor infiltrating lymphocytes in small cell lung cancer patients with neurologic paraneoplastic syndromes.
    J Thorac Oncol. 2019 Jun 12. pii: S1556-0864(19)30463.
    PubMed     Abstract available


  554. AGGARWAL C, Redman MW, Lara PN Jr, Borghaei H, et al
    Brief Report: SWOG S1400D (NCT02965378), a Phase II Study of the Fibroblast Growth Factor Receptor Inhibitor AZD4547 in Previously-treated Patients with Fibroblast Growth Factor Pathway-Activated Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study)
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30462.
    PubMed     Abstract available


  555. KIM Y, Kim CH, Lee HY, Lee SH, et al
    Comprehensive Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitor.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30454.
    PubMed     Abstract available


  556. LAIRD J, Lok BH, Carney B, Kossatz S, et al
    PET Imaging of a [(18)F]-radiolabeled PARP Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in Small Cell Lung Cancer Patient-Derived Xenografts.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30453.
    PubMed     Abstract available


  557. GIAJLEVRA N, Levra MG, Durieux V, Novello S, et al
    Defining synchronous oligometastatic non-small cell lung cancer: a systematic review.
    J Thorac Oncol. 2019 Jun 10. pii: S1556-0864(19)30458.
    PubMed     Abstract available


  558. GONG L, Qin J, Xie F, Han N, et al
    The Evolutionary Difference Between Extracranial Lesions and Leptomeningeal Metastasis in a Patient With Afatinib-Resistant Lung Cancer.
    J Thorac Oncol. 2019;14:e120-e123.
    PubMed    


  559. JAZIEH AR, Algwaiz G, Alshehri SM, Alkattan K, et al
    Lung Cancer in Saudi Arabia.
    J Thorac Oncol. 2019;14:957-962.
    PubMed    


  560. ADJEI AA
    Lung Cancer Worldwide.
    J Thorac Oncol. 2019;14:956.
    PubMed    


  561. MILLER AB
    Improving Surveillance following Treatment for Lung Cancer.
    J Thorac Oncol. 2019;14:955.
    PubMed    


  562. RUTKOWSKI J, Saad ED, Burzykowski T, Buyse M, et al
    Chronological Trends in Progression-free, Overall and Post-progression Survival in First-line Therapy for Advanced Non-small-cell Lung Cancer.
    J Thorac Oncol. 2019 Jun 1. pii: S1556-0864(19)30415.
    PubMed     Abstract available


  563. SHEPSHELOVICH D, Xu W, Lu L, Fares A, et al
    Body mass index (BMI), BMI change, and overall survival in small cell and non-small cell lung cancer patients: a pooled analysis of the International Lung Cancer Consortium.
    J Thorac Oncol. 2019 Jun 1. pii: S1556-0864(19)30416.
    PubMed     Abstract available


  564. HANDRA-LUCA A
    Alveolar Septa Muscle: Subclinical Pulmonary Hypertension-Related Change or Malformation?
    J Thorac Oncol. 2019;14:e124-e125.
    PubMed    


  565. ROTHSCHILD SI
    KRAS and Immune Checkpoint Inhibitors-Serendipity Raising Expectations.
    J Thorac Oncol. 2019;14:951-954.
    PubMed    


    May 2019
  566. LANGER CJ, Redman MW, Wade JL 3rd, Aggarwal C, et al
    Brief Report: SWOG S1400B (NCT02785913), A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study).
    J Thorac Oncol. 2019 May 31. pii: S1556-0864(19)30414.
    PubMed     Abstract available


  567. PARK S, Lee H, Lee B, Lee SH, et al
    DNA Damage Response and Repair Pathway Alteration and Its Association with Tumor Mutation Burden and Platinum-Based Chemotherapy in Small Cell Lung Cancer.
    J Thorac Oncol. 2019 May 21. pii: S1556-0864(19)30381.
    PubMed     Abstract available


  568. GOMEZ DR, Rimner A, Simone CB 2nd, Cho BCJ, et al
    The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applie
    J Thorac Oncol. 2019 May 21. pii: S1556-0864(19)30380.
    PubMed     Abstract available


  569. SPIGEL DR, McCleod M, Jotte RM, Einhorn L, et al
    Safety, Efficacy, and Patient-reported Health-related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged >/=70 Years or with Poor Performance Status (CheckMate 153).
    J Thorac Oncol. 2019 May 20. pii: S1556-0864(19)30376.
    PubMed     Abstract available


  570. LEE Y, Kim TM, Kim DW, Kim S, et al
    Pre-clinical Modeling of Osimertinib for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
    J Thorac Oncol. 2019 May 17. pii: S1556-0864(19)30369.
    PubMed     Abstract available


  571. FLIPPOT R, Biondani P, Auclin E, Xiao D, et al
    Activity of epidermal growth factor tyrosine kinase inhibitors in non-small cell lung carcinoma with refractory leptomeningeal metastases.
    J Thorac Oncol. 2019 May 17. pii: S1556-0864(19)30370.
    PubMed     Abstract available


  572. MURPHY SJ, Harris FR, Kosari F, Terra S, et al
    Using genomics to differentiate multiple primaries from metastatic lung cancer.
    J Thorac Oncol. 2019 May 16. pii: S1556-0864(19)30374.
    PubMed     Abstract available


  573. MUPPA P, Parrilha Terra SB, Sharma A, Mansfield AS, et al
    Immune Cell Infiltration May be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer.
    J Thorac Oncol. 2019 May 9. pii: S1556-0864(19)30356.
    PubMed     Abstract available


  574. TREMBLAY A, Taghizadeh N, Huang J, Kasowski D, et al
    A Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening Program.
    J Thorac Oncol. 2019 May 8. pii: S1556-0864(19)30359.
    PubMed     Abstract available


  575. CANNON-ALBRIGHT LA, Carr SR, Akerley W
    Population-based Relative Risks for Lung Cancer Based on Complete Family History of Lung Cancer.
    J Thorac Oncol. 2019 May 7. pii: S1556-0864(19)30316.
    PubMed     Abstract available


  576. VARGHESE C, Rajagopalan S, Karwoski RA, Bartholmai BJ, et al
    Computed Tomography based Score Indicative of Lung Cancer Aggression (SILA) Predicts the Degree of Histological Tissue Invasion and Patient Survival in Lung Adenocarcinoma Spectrum.
    J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30355.
    PubMed     Abstract available


  577. THOMAS A, Vilimas R, Trindade C, Erwin-Cohen R, et al
    Durvalumab in Combination with Olaparib in Patients with Relapsed Small Cell Lung Cancer: Results from a Phase II Study.
    J Thorac Oncol. 2019 May 4. pii: S1556-0864(19)30361.
    PubMed     Abstract available


  578. KATSUMATA S, Aokage K, Ishii G, Nakasone S, et al
    Prognostic impact of the number of metastatic lymph nodes on the eighth edition of the TNM classification of non-small cell lung cancer.
    J Thorac Oncol. 2019 May 2. pii: S1556-0864(19)30313.
    PubMed     Abstract available


  579. MEHLMAN C, Chaabane N, Lacave R, Kerrou K, et al
    Ceritinib ALK T1151R Resistance Mutation in Lung Cancer With Initial Response to Brigatinib.
    J Thorac Oncol. 2019;14:e95-e96.
    PubMed    


  580. ZHANG J, Wang J, Qian Z, Han Y, et al
    CCR5 is Associated With Immune Cell Infiltration and Prognosis of Lung Cancer.
    J Thorac Oncol. 2019;14:e102-e103.
    PubMed    


  581. AHN MJ
    Combination of Osimertinib with Durvalumab in Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer: Is There Room for Reinvestigation?
    J Thorac Oncol. 2019;14:766-767.
    PubMed    


  582. CHIAPPETTA M, Petracca Ciavarella L, Margaritora S
    Can Pemetrexed Also Have a Potential Role Preoperatively in the Management of Advanced Thymic Epithelial Tumors?
    J Thorac Oncol. 2019;14:e89.
    PubMed    


  583. MITSUDOMI T
    BRAF Fusion - Another Mechanism of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors.
    J Thorac Oncol. 2019;14:764-765.
    PubMed    


  584. GROEN HJM, Hiltermann TJN
    Air Pollution and Adenocarcinoma in Never-Smokers.
    J Thorac Oncol. 2019;14:761-763.
    PubMed    


  585. DAVIES KD, Villalobos VM, Aisner DL
    Ready or Not, Here I Come: Inflammatory Myofibroblastic Tumors With Kinase Alterations Revealed Through Molecular Hide and Seek.
    J Thorac Oncol. 2019;14:758-760.
    PubMed    


    April 2019
  586. JIN Y, Dong H, Xia L, Yang Y, et al
    The diversity of gut microbiome is associated with favorable responses to anti-PD-1 immunotherapy in Chinese non-small cell lung cancer patients.
    J Thorac Oncol. 2019 Apr 23. pii: S1556-0864(19)30286.
    PubMed     Abstract available


  587. REMON J, Reguart N, Auclin E, Besse B, et al
    Immune-Related Adverse Events and Outcomes in Patients with Advanced Non-Small Cell Lung Cancer: A Predictive Marker of Efficacy?
    J Thorac Oncol. 2019 Apr 23. pii: S1556-0864(19)30202.
    PubMed    


  588. HUNG RJ, Spitz MR, Houlston RS, Schwartz AG, et al
    Lung Cancer Risk in Never Smokers of European Descent is Associated with Genetic Variation in the 5P15.33 TERT-CLPTM1L Region.
    J Thorac Oncol. 2019 Apr 19. pii: S1556-0864(19)30289.
    PubMed     Abstract available


  589. DAI J, Liu M, Yang Y, Li Q, et al
    Optimal Lymph Nodes Examination and Adjuvant Chemotherapy for Stage I Lung Cancer.
    J Thorac Oncol. 2019 Apr 19. pii: S1556-0864(19)30290.
    PubMed     Abstract available


  590. MANOHARAN P, Salem A, Mistry H, Gornall M, et al
    [18F]fludeoxyglucose PET/CT in small-cell lung cancer: Analysis of the CONVERT randomized controlled trial.
    J Thorac Oncol. 2019 Apr 16. pii: S1556-0864(19)30282.
    PubMed     Abstract available


  591. REMON J, Ahn MJ, Girard N, Johnson M, et al
    Advanced Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    J Thorac Oncol. 2019 Apr 16. pii: S1556-0864(19)30280.
    PubMed     Abstract available


  592. SORICH MJ, Rowland A, Karapetis CS, Hopkins AM, et al
    Evaluation of the lung immune prognostic index for prediction of survival and response in patients treated with atezolizumab for non-small cell lung cancer: pooled analysis of clinical trials.
    J Thorac Oncol. 2019 Apr 15. pii: S1556-0864(19)30285.
    PubMed     Abstract available


  593. MICHELS S, Massuti B, Schildhaus HU, Franklin J, et al
    Safety and efficacy of crizotinib in patients with advanced or metastatic ROS1-rearranged lung cancer (EUCROSS): A European phase 2 clinical trial.
    J Thorac Oncol. 2019 Apr 9. pii: S1556-0864(19)30276.
    PubMed     Abstract available


  594. KRATZ JR, Haro GJ, Cook NR, He J, et al
    Incorporation of a Molecular Prognostic Classifier Improves Conventional Non-Small Cell Lung Cancer Staging.
    J Thorac Oncol. 2019 Apr 5. pii: S1556-0864(19)30270.
    PubMed     Abstract available


  595. MEANEY C, Mitchell KA, Zingone A, Brown D, et al
    Circulating Inflammation Proteins Associated with Lung Cancer in African Americans.
    J Thorac Oncol. 2019 Apr 3. pii: S1556-0864(19)30269.
    PubMed     Abstract available


  596. LI C, Liang H, Zhong N, He J, et al
    Optimal Starting Age for Lung Cancer Screening With Low-Dose Computed Tomography: A Population Level Analysis.
    J Thorac Oncol. 2019;14:e82-e84.
    PubMed    


  597. QIN J, Wang J, Lin X, Wang J, et al
    Erlotinib Resistance with EGFR L858R/Y891D Double Mutation in a Patient with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e65-e68.
    PubMed    


  598. ARJYAL L
    Concurrent Chemoradiation in Elderly Patients with Limited-Stage Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:e63.
    PubMed    


  599. LU S, Li Z
    Rethinking Our Approach of Combining Novel Agents With Standard Chemotherapy in Small Cell Lung Cancer.
    J Thorac Oncol. 2019;14:580-582.
    PubMed    


  600. WANG Z, Wu YL
    Re-emerging C797S In Trans and Rechallenge of Osimertinib With Erlotinib.
    J Thorac Oncol. 2019;14:e81-e82.
    PubMed    


  601. CHRISTODOULOU M, Faivre-Finn C
    Author's Reply to the: Letter to the Editor.
    J Thorac Oncol. 2019;14:e63-e64.
    PubMed    


  602. MACKINTOSH JA, Marshall HM, Fong KM
    A Targeted Approach to the Complications of Targeted Therapy.
    J Thorac Oncol. 2019;14:577-579.
    PubMed    


  603. MOLNAR TF, Szipocs A, Szalai Z
    Neoadjuvant Crizotinib for ALK Re-arranged NSCLC?
    J Thorac Oncol. 2019;14:574-576.
    PubMed    


    March 2019
  604. BOUSEMA JE, van Dorp M, Noyez VJJM, Dijkgraaf MGW, et al
    Unforeseen N2 disease following negative endosonography with or without confirmatory mediastinoscopy in resectable non-small cell lung cancer: a systematic review and meta-analysis.
    J Thorac Oncol. 2019 Mar 21. pii: S1556-0864(19)30211.
    PubMed    


  605. CAMIDGE DR, Dziadziuszko R, Peters S, Mok T, et al
    Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-positive Advanced Non-small-cell Lung Cancer in the Global Phase III ALEX Study.
    J Thorac Oncol. 2019 Mar 19. pii: S1556-0864(19)30210.
    PubMed     Abstract available


  606. OSAROGIAGBON RU, Veronesi G, Fang W, Ekman S, et al
    Early Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    J Thorac Oncol. 2019 Mar 6. pii: S1556-0864(19)30199.
    PubMed     Abstract available


  607. LEE J, Maeng CH, Song JU
    The Role of Prophylactic Cranial Irradiation in Patients With Extensive-Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2019;14:e60-e61.
    PubMed    


  608. KOGURE Y, Ishii Y, Oki M
    Cytokine Release Syndrome with Pseudoprogression in a Patient with Advanced Non-Small Cell Lung Cancer Treated with Pembrolizumab.
    J Thorac Oncol. 2019;14:e55-e57.
    PubMed    


  609. LAM S
    Lung Cancer Screening in Never-Smokers.
    J Thorac Oncol. 2019;14:336-337.
    PubMed    


  610. FERRARA R, Caramella C, Besse B, Champiat S, et al
    Pseudoprogression in Non-Small Cell Lung Cancer upon Immunotherapy: Few Drops in the Ocean?
    J Thorac Oncol. 2019;14:328-331.
    PubMed    


  611. RAMAEKERS B, De Ruysscher D
    Quality of Life After Stereotactic Radiotherapy for Early-Stage Lung Cancer: Mission Accomplished?
    J Thorac Oncol. 2019;14:326-327.
    PubMed    


  612. BUCKNELL NW, Ball D
    PCI in Small Cell-Review the Cohorts.
    J Thorac Oncol. 2019;14:e59-e60.
    PubMed    


  613. RIHAWI K, Giannarelli D, Galetta D, Delmonte A, et al
    BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience.
    J Thorac Oncol. 2019;14:e57-e59.
    PubMed    


  614. LE T, Minna JD, Gerber DE
    Checkpoint Inhibitor Pneumonitis: Too Clinically Serious For Benefit?
    J Thorac Oncol. 2019;14:332-335.
    PubMed    


    February 2019
  615. DZIADZIUSZKO R, Smit EF, Dafni U, Wolf J, et al
    Afatinib in non-small cell lung cancer with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP).
    J Thorac Oncol. 2019 Feb 27. pii: S1556-0864(19)30148.
    PubMed     Abstract available


  616. SHUKUYA T, Yamada T, Koenig MJ, Xu J, et al
    The effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibition in non-small cell lung cancer.
    J Thorac Oncol. 2019 Feb 27. pii: S1556-0864(19)30150.
    PubMed     Abstract available


  617. CAMIDGE DR, Kim EE, Usari T, Polli A, et al
    Renal Effects of Crizotinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Feb 26. pii: S1556-0864(19)30146.
    PubMed     Abstract available


  618. HENDRIKS LEL, Henon C, Auclin E, Mezquita L, et al
    Outcome of non-small cell lung cancer patients with brain metastases treated with checkpoint inhibitors.
    J Thorac Oncol. 2019 Feb 16. pii: S1556-0864(19)30117.
    PubMed     Abstract available


  619. NEGRAO MV, Lam VK, Reuben A, Rubin ML, et al
    PD-L1 expression, tumor mutational burden and cancer gene mutations are stronger predictors of benefit from immune checkpoint blockade than HLA class I genotype in non-small cell lung cancer.
    J Thorac Oncol. 2019 Feb 16. pii: S1556-0864(19)30116.
    PubMed     Abstract available


  620. LIZEE T, Basch E, Tremolieres P, Voog E, et al
    Cost-effectiveness of web-based patient-reported outcome surveillance in lung cancer patients.
    J Thorac Oncol. 2019 Feb 15. pii: S1556-0864(19)30113.
    PubMed     Abstract available


  621. AGGARWAL R, Lam AC, McGregor M, Menezes R, et al
    Outcomes of Long-term Interval Rescreening with Low-Dose CT for Lung Cancer in Different Risk Cohorts.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30112.
    PubMed     Abstract available


  622. HSU WH, Zhao X, Zhu J, Kim IK, et al
    Chk1 inhibition enhances cisplatin cytotoxicity and overcomes cisplatin resistance in small cell lung cancer by promoting mitotic cell death.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30108.
    PubMed     Abstract available


  623. LEE JW, Zhang Y, Eoh KJ, Sharma R, et al
    The Combination of MEK inhibitor with Immunomodulatory Antibodies Targeting PD-1 and PD-L1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    J Thorac Oncol. 2019 Feb 13. pii: S1556-0864(19)30111.
    PubMed     Abstract available


  624. ZIMMERMAN S, Das A, Wang S, Julian R, et al
    2017-2018 Scientific Advances in Thoracic Oncology: Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Feb 11. pii: S1556-0864(19)30099.
    PubMed     Abstract available


  625. JEANSON A, Tomasini P, Souquet-Bressand M, Brandone N, et al
    Brief report: efficacy of immune checkpoint inhibitors in KRAS-mutant Non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2019 Feb 6. pii: S1556-0864(19)30040.
    PubMed     Abstract available


  626. EL OSTA B, Behera M, Kim S, Berry LD, et al
    Characteristics and outcomes of patients with metastatic KRAS mutant lung adenocarcinomas: The Lung Cancer Mutation Consortium experience.
    J Thorac Oncol. 2019 Feb 5. pii: S1556-0864(19)30097.
    PubMed     Abstract available


  627. ZHAO X, Kallakury B, Chahine JJ, Hartmann D, et al
    Surgical resection of small cell lung carcinoma: prognostic factors and the tumor microenvironment.
    J Thorac Oncol. 2019 Feb 5. pii: S1556-0864(19)30096.
    PubMed     Abstract available


  628. IJSSELDIJK MA, Shoni M, Siegert C, Wiering BM, et al
    Survival after SBRT for Clinically diagnosed or Biopsy-proven Early-stage Non-small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2019 Feb 2. pii: S1556-0864(19)30094.
    PubMed     Abstract available


  629. TABBO F, D'Aveni A, Tota D, Pignataro D, et al
    Pulmonary Arterial Hypertension in ALK Receptor Tyrosine Kinase-Positive Lung Cancer Patient: Adverse Event or Disease Spread?
    J Thorac Oncol. 2019;14:e38-e40.
    PubMed    


  630. VARKARIS A, Sehgal K, Rangachari D, Costa DB, et al
    Complete and Sustained Response of Brain Metastases to Programmed Death 1 Antibody Monotherapy in Treatment-naive Programmed Death Ligand 1-Positive Lung Cancer.
    J Thorac Oncol. 2019;14:e34-e36.
    PubMed    


  631. WATANABE K, Kage H, Shinozaki-Ushiku A, Kohsaka S, et al
    Spontaneous Transdifferentiation from Small Cell Lung Carcinoma to Squamous Cell Carcinoma.
    J Thorac Oncol. 2019;14:e31-e34.
    PubMed    


  632. BOGART JA, Mix M
    Management of the Brain in Small Cell Lung Cancer: Are Patients Paying a Lot Now Instead of a Little Later?
    J Thorac Oncol. 2019;14:153-156.
    PubMed    


  633. TSOU TC, Gowen K, Ali SM, Miller VA, et al
    Variable Response to ALK Inhibitors in NSCLC with a Novel MYT1L-ALK Fusion.
    J Thorac Oncol. 2019;14:e29-e30.
    PubMed    


  634. GOLDMAN JW, Garon EB
    Nivolumab in Previously Treated SCLC: Encouraging, but Still Awaiting the Complete Story.
    J Thorac Oncol. 2019;14:160-162.
    PubMed    


  635. CARBONE M, Yang H, Gaudino G
    Does Chromothripsis Make Mesothelioma an Immunogenic Cancer?
    J Thorac Oncol. 2019;14:157-159.
    PubMed    


    January 2019
  636. KIM ES, Roy UB, Ersek JL, King J, et al
    Updates Regarding Biomarker Testing for Non-Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable.
    J Thorac Oncol. 2019 Jan 29. pii: S1556-0864(19)30003.
    PubMed    


  637. RECK M, Horn L, Novello S, Barlesi F, et al
    Phase II Study of Roniciclib in Combination with Cisplatin/Etoposide or Carboplatin/Etoposide as First-Line Therapy in Patients with Extensive-Disease Small-Cell Lung Cancer.
    J Thorac Oncol. 2019 Jan 21. pii: S1556-0864(19)30029.
    PubMed     Abstract available


  638. TSENG CH, Tsuang BJ, Chiang CJ, Ku KC, et al
    The relationship between air pollution and lung cancer in non-smokers in Taiwan.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30026.
    PubMed     Abstract available


  639. DAGOGO-JACK I, Rooney M, Nagy RJ, Lin JJ, et al
    Molecular Analysis of Plasma from Patients with ROS1-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30027.
    PubMed     Abstract available


  640. PUJOL JL, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al
    A Randomized Non-Comparative Phase 2 Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients with Small Cell Lung Cancer: Results from the IFCT-1603 Trial.
    J Thorac Oncol. 2019 Jan 18. pii: S1556-0864(19)30025.
    PubMed     Abstract available


  641. DAGOGO-JACK I, Robinson H, Mino-Kenudson M, Farago AF, et al
    Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients with Minimal Smoking History.
    J Thorac Oncol. 2019 Jan 17. pii: S1556-0864(19)30024.
    PubMed     Abstract available


  642. WU YL, Lu S, Cheng Y, Zhou C, et al
    Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced Non-Small Cell Lung Cancer: CheckMate 078 Randomized Phase III Clinical Trial.
    J Thorac Oncol. 2019 Jan 16. pii: S1556-0864(19)30020.
    PubMed     Abstract available


  643. QUINTANAL-VILLALONGA A, Molina-Pinelo S, Cirauqui C, Ojeda-Marquez L, et al
    FGFR1 cooperates with EGFR in lung cancer oncogenesis, and their combined inhibition shows improved efficacy.
    J Thorac Oncol. 2019 Jan 9. pii: S1556-0864(19)30008.
    PubMed     Abstract available


  644. DAVIES KD, Lomboy A, Lawrence CA, Yourshaw M, et al
    Brief Report: DNA-based versus RNA-based detection of MET exon 14 skipping events in lung cancer.
    J Thorac Oncol. 2019 Jan 9. pii: S1556-0864(19)30007.
    PubMed     Abstract available


  645. LU S, Yu Y, Li Z, Yu R, et al
    Brief Report: EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
    J Thorac Oncol. 2019 Jan 2. pii: S1556-0864(18)33515.
    PubMed     Abstract available


  646. LEE YL, Hsu JF, Yang CJ
    Tracheoesophageal Fistula in a Patient with Advanced Non-Small Cell Lung Cancer Who Received Chemoradiotherapy and Ramucirumab.
    J Thorac Oncol. 2019;14:e17-e18.
    PubMed    


  647. VAN LOON J, Dingemans AC
    Is Concurrent Chemoradiotherapy Also the Best Treatment for Elderly Patients with Limited-Stage Small Cell Lung Cancer? - What the CONVERT Data Can Tell Us.
    J Thorac Oncol. 2019;14:13-15.
    PubMed    


  648. ABADA PB
    Tracheoesophageal Fistula in a Patient With Advanced NSCLC Who Received Chemoradiotherapy and Ramucirumab.
    J Thorac Oncol. 2019;14:e19.
    PubMed    


  649. DRESLER C, Warren GW, Arenberg D, Yang P, et al
    Indeed, Nuance Matters.
    J Thorac Oncol. 2019;14:e16-e17.
    PubMed    


  650. STIEFEL F, Bourquin C
    Nuance Matters.
    J Thorac Oncol. 2019;14:e15.
    PubMed    


  651. MCCOACH CE
    A Cautionary Analysis of Immunotherapy Prior to Targeted Therapy.
    J Thorac Oncol. 2019;14:8-10.
    PubMed    


  652. DAVID EA, Atay SM, McFadden PM, Kim AW, et al
    Sublobar or Suboptimal: Does Tumor Spread through Air Spaces Signify the End of Sublobar Resections for T1N0 Adenocarcinomas?
    J Thorac Oncol. 2019;14:11-12.
    PubMed    


    December 2018
  653. PACHECO JM, Gao D, Smith D, Purcell WT, et al
    Natural history and factors associated with overall survival in stage IV ALK rearranged non-small-cell lung cancer.
    J Thorac Oncol. 2018 Dec 29. pii: S1556-0864(18)33533.
    PubMed     Abstract available


  654. YATABE Y, Dacic S, Borczuk AC, Warth A, et al
    Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer.
    J Thorac Oncol. 2018 Dec 17. pii: S1556-0864(18)33514.
    PubMed     Abstract available


  655. IAMS WT, Beckermann KE, Almodovar K, Hernandez J, et al
    Small cell lung cancer transformation as a mechanism of resistance to PD-1 therapy in KRAS mutant lung adenocarcinoma: A report of two cases.
    J Thorac Oncol. 2018 Dec 10. pii: S1556-0864(18)33511.
    PubMed    


  656. SEIJO LM, Peled N, Ajona D, Boeri M, et al
    Biomarkers in lung cancer screening: achievements, promises and challenges.
    J Thorac Oncol. 2018 Dec 4. pii: S1556-0864(18)33501.
    PubMed     Abstract available


  657. YANG JC, Gadgeel SM, Sequist LVD, Wu CL, et al
    Brief Report: Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer With Sensitizing EGFR Mutation.
    J Thorac Oncol. 2018 Dec 4. pii: S1556-0864(18)33506.
    PubMed     Abstract available


    November 2018
  658. HECHTNER M, Eichler M, Wehler B, Buhl R, et al
    Quality of life in Non-Small Cell Lung Cancer survivors - a multicenter cross-sectional study.
    J Thorac Oncol. 2018 Nov 30. pii: S1556-0864(18)33497.
    PubMed     Abstract available


  659. SURESH K, Psoter KJ, Voong KR, Shankar B, et al
    Impact of Checkpoint Inhibitor Pneumonitis on Survival in Non-Small Cell Lung Cancer Patients receiving Immune Checkpoint Immunotherapy.
    J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33493.
    PubMed     Abstract available


  660. ERNANI V, Appiah AK, Marr A, Zhang C, et al
    Adjuvant Systemic Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer (NSCLC) Treated with Stereotactic Body Radiation Therapy (SBRT).
    J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33495.
    PubMed     Abstract available


  661. QU Y, Emoto K, Eguchi T, Aly RG, et al
    Pathologic assessment after neoadjuvant chemotherapy for non-small cell lung cancer: Importance and implications of distinguishing adenocarcinoma from squamous cell carcinoma.
    J Thorac Oncol. 2018 Nov 29. pii: S1556-0864(18)33494.
    PubMed     Abstract available


  662. LICHTENSTEIN M, Nipp RD, Muzikansky A, Goodwin K, et al
    Impact of Age on Outcomes with Immunotherapy in Patients with Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Nov 23. pii: S1556-0864(18)33454.
    PubMed     Abstract available


  663. KARACHALIOU N, Bracht JWP, Bruno MF, Drozdowskyj A, et al
    BRIEF REPORT: Association of PALB2 Messenger RNA Expression with platinum-docetaxel efficacy in advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Nov 22. pii: S1556-0864(18)33450.
    PubMed     Abstract available


  664. FUJIMOTO D, Yoshioka H, Kataoka Y, Morimoto T, et al
    Pseudoprogression in previously treated patients with non-small cell lung cancer who received nivolumab monotherapy: A multicenter retrospective cohort study.
    J Thorac Oncol. 2018 Nov 20. pii: S1556-0864(18)33418.
    PubMed     Abstract available


  665. KANG HR, Cho JY, Lee SH, Lee YJ, et al
    Role of low-dose computerized tomography in lung cancer screening among never-smokers.
    J Thorac Oncol. 2018 Nov 13. pii: S1556-0864(18)33417.
    PubMed     Abstract available


  666. ZHANG C, Li SL, Nie Q, Dong S, et al
    Neoadjuvant Crizotinib in Resectable Locally Advanced Non-Small-Cell Lung Cancer with ALK-rearrangement: A Brief Report.
    J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33410.
    PubMed     Abstract available


  667. SINICROPI-YAO SL, Amann JM, Lopez DLY, Cerciello F, et al
    Co-expression analysis reveals mechanisms underlying the varied roles of NOTCH1 in non-small cell lung cancer.
    J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33411.
    PubMed     Abstract available


  668. BLAAUWGEERS H, Damhuis R, Lissenberg-Witte B, de Langen AJ, et al
    A population-based study of outcomes in surgically resected T3N0 non-small cell lung cancer in the Netherlands, defined using TNM-7 and TNM-8; justification of changes and an argument to incorporate histology in the staging algorithm?
    J Thorac Oncol. 2018 Nov 5. pii: S1556-0864(18)33413.
    PubMed     Abstract available


  669. SHIN DW, Cho J, Noh JM, Han H, et al
    Disparities in the diagnosis and treatment of lung cancer among people with disabilities.
    J Thorac Oncol. 2018 Nov 2. pii: S1556-0864(18)33407.
    PubMed     Abstract available


  670. RICCIUTI B, Marcomigni L, Metro G, Bellezza G, et al
    Identification of EML4-ALK Rearrangement and MET Exon 14 R988C Mutation in a Patient with High-Grade Neuroendocrine Lung Carcinoma Who Experienced a Lazarus Response to Crizotinib.
    J Thorac Oncol. 2018;13:e220-e222.
    PubMed    


  671. YOSHIDA H, Ooi M, Kim YH
    Successful Treatment with Osimertinib and Chemotherapy in a Non-Small Cell Lung Cancer Patient with EGFR Mutation and Meningeal Carcinomatosis.
    J Thorac Oncol. 2018;13:e219-e220.
    PubMed    


    October 2018
  672. KIM Y, Lee B, Shim JH, Lee SH, et al
    Concurrent genetic alterations predict the progression to target therapy in EGFR-mutated advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Oct 31. pii: S1556-0864(18)33383.
    PubMed     Abstract available


  673. GELSOMINO F, Facchini G, Barbera MA, Lamberti G, et al
    Complete recalcification following arterial embolization of massive osteolytic bone metastasis from non-small cell lung cancer (NSCLC).
    J Thorac Oncol. 2018 Oct 31. pii: S1556-0864(18)33384.
    PubMed    


  674. SCHROCK AB, Welsh A, Chung JH, Pavlick D, et al
    Hybrid capture-based genomic profiling of circulating tumor DNA from patients with advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Oct 24. pii: S1556-0864(18)33205.
    PubMed     Abstract available


  675. BASU ROY U, King-Kallimanis BL, Kluetz PG, Selig W, et al
    Learning from Patients: Reflections on Use of Patient-Reported Outcomes in Lung Cancer Trials.
    J Thorac Oncol. 2018 Oct 15. pii: S1556-0864(18)33052.
    PubMed    


  676. LAMMERS A, Slatore CG, Fromme EK, Vranas K, et al
    Association of Early Palliative Care with Chemotherapy Intensity in Patients with Advanced Stage Lung Cancer : A National Cohort Study.
    J Thorac Oncol. 2018 Oct 15. pii: S1556-0864(18)33184.
    PubMed    


  677. OKAMI J, Shintani Y, Okumura M, Ito H, et al
    Demographics, safety and quality, and prognostic information in both the seventh and eighth editions of the TNM classification in 18,973 surgical cases of the Japanese Joint committee of Lung Cancer Registry database in 2010.
    J Thorac Oncol. 2018 Oct 10. pii: S1556-0864(18)33180.
    PubMed     Abstract available


  678. READY N, Farago AF, de Braud F, Atmaca A, et al
    Third-Line Nivolumab Monotherapy in Recurrent Small Cell Lung Cancer: CheckMate 032.
    J Thorac Oncol. 2018 Oct 10. pii: S1556-0864(18)33181.
    PubMed     Abstract available


  679. CHAE YK, Oh MS
    Detection of minimal residual disease using ctDNA in lung cancer: current evidence and future directions.
    J Thorac Oncol. 2018 Oct 5. pii: S1556-0864(18)33174.
    PubMed     Abstract available


  680. SCHILD SE, Fan W, Stinchcombe TE, Vokes EE, et al
    Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33173.
    PubMed     Abstract available


  681. LEVY A, Le Pechoux C, Mistry H, Martel-Lafay I, et al
    Prophylactic cranial irradiation for limited-stage small-cell lung cancer patients: secondary findings from the prospective randomized phase 3 CONVERT trial.
    J Thorac Oncol. 2018 Oct 4. pii: S1556-0864(18)33171.
    PubMed     Abstract available


  682. CHU X, Li Y, Zhu Z
    A Case of Small Cell Lung Cancer Transformation from EGFR-Mutant Lung Adenocarcinoma with Primary Resistance to Gefitinib.
    J Thorac Oncol. 2018;13:e211-e214.
    PubMed    


  683. TAKIGAWA N
    How Should We Treat Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer?
    J Thorac Oncol. 2018;13:1438-1440.
    PubMed    


  684. SHOLL LM
    Recognizing the Challenges of Oncogene Fusion Detection: A Critical Step toward Optimal Selection of Lung Cancer Patients for Targeted Therapies.
    J Thorac Oncol. 2018;13:1433-1435.
    PubMed    


    September 2018
  685. BLUMENTHAL GM, Bunn PA Jr, Chaft JE, McCoach CE, et al
    Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer.
    J Thorac Oncol. 2018 Sep 27. pii: S1556-0864(18)33129.
    PubMed    


  686. SURESH K, Voong KR, Shankar B, Forde PM, et al
    Pneumonitis in Non-Small Cell Lung Cancer patients receiving Immune Checkpoint Immunotherapy: incidence and risk factors.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33118.
    PubMed     Abstract available


  687. QIN N, Li N, Wang C, Pu Z, et al
    Association of mosaic loss of chromosome Y with lung cancer risk and prognosis in a Chinese population.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33125.
    PubMed     Abstract available


  688. TOKI MI, Mani N, Smithy JW, Liu Y, et al
    Immune marker profiling and PD-L1 expression across Non-Small Cell Lung Cancer mutations.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33124.
    PubMed     Abstract available


  689. QIN A, Johnson A, Ross JS, Miller VA, et al
    Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling.
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33126.
    PubMed     Abstract available


  690. FRUH M M, Betticher DC, Stupp R, Xyrafas A, et al
    Multimodal Treatment in Operable Stage III Non-Small Cell Lung Cancer: A Pooled Analysis on Long Term Results of three SAKK trials (SAKK 16/96, 16/00, 16/01).
    J Thorac Oncol. 2018 Sep 26. pii: S1556-0864(18)33123.
    PubMed     Abstract available


  691. TSAO AS, Lindwasser OW, Adjei AA, Adusumilli PS, et al
    Current and Future Management of Malignant Mesothelioma : A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer and Mesothelioma Applied Research Foundation
    J Thorac Oncol. 2018 Sep 25. pii: S1556-0864(18)33121.
    PubMed     Abstract available


  692. DE RUYSSCHER D, Wanders R, Hendriks LE, van Baardwijk A, et al
    Progression-Free-Survival and Overall Survival beyond 5 years of non-small cell lung cancer patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450).
    J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)30935.
    PubMed     Abstract available


  693. YU H, Chen Z, Ballman K, Watson MA, et al
    Correlation of PD-L1 expression with tumor mutation burden and gene signatures for prognosis in early stage squamous cell lung carcinoma.
    J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33116.
    PubMed     Abstract available


  694. RAMALINGAM S, Dinan MA, Crawford J
    Survival comparison in patients with Stage IV lung cancer in Academic versus Community Centers in the United States.
    J Thorac Oncol. 2018 Sep 22. pii: S1556-0864(18)33117.
    PubMed     Abstract available


  695. GANDARA DR, von Pawel J, Mazieres J, Sullivan R, et al
    Atezolizumab Treatment Beyond Progression in Advanced Non-Small Cell Lung Cancer: Results From the Randomized, Phase III OAK Study.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33043.
    PubMed     Abstract available


  696. SUN TY, Niu X, Chakraborty A, Neal JW, et al
    Lengthy progression-free survival and intracranial activity of cabozantinib in patients with crizotinib and ceritinib-resistant ROS1-positive non-small-cell lung cancer.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33046.
    PubMed    


  697. FERRER L, Giaj Levra M, Brevet M, Antoine M, et al
    A brief report of transformation from Non-small cell to small cell lung cancer: Molecular and therapeutic characteristics.
    J Thorac Oncol. 2018 Sep 11. pii: S1556-0864(18)33044.
    PubMed     Abstract available


  698. LIN JJ, Chin E, Yeap BY, Ferris LA, et al
    Brief Report: Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Sep 8. pii: S1556-0864(18)33040.
    PubMed     Abstract available


  699. DESCARPENTRIES C, Lepretre F, Escande F, Kherrouche Z, et al
    Optimization of routine testing for MET exon 14 splice site mutations in non-small cell lung cancer patients.
    J Thorac Oncol. 2018 Sep 6. pii: S1556-0864(18)33038.
    PubMed     Abstract available


  700. DENG W, Xu T, Wang Y, Xu Y, et al
    Survival Patterns for Patients with Resected N2 Non-Small Cell Lung Cancer and Postoperative Radiotherapy: A Prognostic Scoring Model and Heat Map Approach.
    J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33036.
    PubMed     Abstract available


  701. LE-RADEMACHER J, Dahlberg S, Lee JJ, Adjei AA, et al
    Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations.
    J Thorac Oncol. 2018 Sep 4. pii: S1556-0864(18)33034.
    PubMed     Abstract available


  702. SWAMI U, Smith M, Zhang J
    Central Nervous System Pseudoprogression With Nivolumab in a Patient With Squamous Cell Lung Cancer Followed by Prolonged Response.
    J Thorac Oncol. 2018;13:e183-e184.
    PubMed    


  703. MO X, Xu-Welliver M
    Response to the Letter to Editor re: The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e182-e183.
    PubMed    


  704. WALRAVEN I, Kwint M, Belderbos J
    The Additional Prognostic Value of Tumor Volume Changes during Chemoradiotherapy in Patients with Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e181-e182.
    PubMed    


  705. JIN B, Chuang X, Liu Y
    Remarkable Long-Term Efficacy of Nivolumab Immunotherapy in a Chinese Patient with Extensive-Disease Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e174-e177.
    PubMed    


  706. DENG L, Kiedrowski LA, Ravera E, Cheng H, et al
    Response to Dual Crizotinib and Osimertinib Treatment in a Lung Cancer Patient with MET Amplification Detected by Liquid Biopsy Who Acquired Secondary Resistance to EGFR Tyrosine Kinase Inhibition.
    J Thorac Oncol. 2018;13:e169-e172.
    PubMed    


  707. XU YJ, Shi ZL, Wang Z, Du L, et al
    Gefitinib in the Treatment of a Pulmonary Sequestration Patient Complicated by Large Cell Lung Carcinoma.
    J Thorac Oncol. 2018;13:e165-e168.
    PubMed    


  708. MARINO M, Visca P, Ottaviano M
    PD-L1 Testing in Lung Cancer: An International Pathologist's Initiative in an Unknown "Middle Earth".
    J Thorac Oncol. 2018;13:1239-1241.
    PubMed    


    August 2018
  709. MORO M, Caiola E, Ganzinelli M, Zulato E, et al
    Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Aug 24. pii: S1556-0864(18)32988.
    PubMed     Abstract available


  710. BORGHAEI H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, et al
    24-Month Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab As First-Line Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Aug 20. pii: S1556-0864(18)30942.
    PubMed     Abstract available


  711. LAUFER-GEVA S, Rozenblum AB, Twito T, Grinberg R, et al
    The Clinical Impact of Comprehensive Genomic Testing of Circulating Cell-Free DNA in Advanced Lung Cancer.
    J Thorac Oncol. 2018 Aug 16. pii: S1556-0864(18)30940.
    PubMed     Abstract available


  712. GUAITOLI G, Baldessari C, Tomasello C, Barbieri F, et al
    Late Gastrointestinal Toxicity During Nivolumab Therapy in Non-Small Cell Lung Cancer: A Rare Case of Inflammatory Bowel Disease.
    J Thorac Oncol. 2018;13:e152-e153.
    PubMed    


  713. FUJIOKA S, Kitajima T, Itotani R
    Myositis in a Patient with Advanced Lung Cancer Treated with Osimertinib.
    J Thorac Oncol. 2018;13:e137-e139.
    PubMed    


  714. GARCIA CA, Dacic S, Villaruz LC
    Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e135-e136.
    PubMed    


  715. HAMANN HA, Pujol JL
    Introduction to the Special Section: The Experience and Impact of Lung Cancer Stigma.
    J Thorac Oncol. 2018;13:1053-1054.
    PubMed    


    July 2018
  716. SU S, Dong ZY, Xie Z, Yan LX, et al
    Strong PD-L1 expression predicts poor response and de novo resistance to EGFR TKIs among non-small cell lung cancer patients with EGFR mutation.
    J Thorac Oncol. 2018 Jul 26. pii: S1556-0864(18)30811.
    PubMed     Abstract available


  717. ROACH MC, Robinson CG, DeWees TA, Ganachaud J, et al
    Stereotactic body radiation therapy (SBRT) for central early stage non-small cell lung cancer: results of a prospective phase I/II trial.
    J Thorac Oncol. 2018 Jul 26. pii: S1556-0864(18)30812.
    PubMed     Abstract available


  718. ZHANG M, Wang Q, Ding Y, Wang G, et al
    Brief Report: CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Jul 13. pii: S1556-0864(18)30785.
    PubMed     Abstract available


  719. KATO R, Hayashi H, Sano K, Handa K, et al
    Nivolumab-induced hemophilia A presenting as gastric ulcer bleeding in a patient with non-small cell lung cancer.
    J Thorac Oncol. 2018 Jul 11. pii: S1556-0864(18)30779.
    PubMed    


  720. OCCHIPINTI S, Dunn J, O'Connell DL, Garvey G, et al
    Lung Cancer Stigma Across the Social Network: Patients' and Caregivers' Perspectives.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30766.
    PubMed     Abstract available


  721. RIESS JW, Gandara DR, Frampton GM, Madison R, et al
    Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30770.
    PubMed     Abstract available


  722. WILLIAMSON TJ, Choi AK, Kim JC, Garon EB, et al
    A longitudinal investigation of internalized stigma, constrained disclosure, and quality of life across 12 weeks in lung cancer patients on active oncologic treatment.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30769.
    PubMed     Abstract available


  723. PATIL T, Smith DE, Bunn PA, Aisner DL, et al
    The incidence of brain metastases in stage IV ROS1-rearranged non-small cell lung cancer and rate of central nervous system progression on crizotinib.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30772.
    PubMed     Abstract available


  724. SEHGAL K, Peters MLB, VanderLaan PA, Rangachari D, et al
    Activity of brigatinib in the setting of alectinib resistance mediated by ALK-I1171S in ALK rearranged lung cancer.
    J Thorac Oncol. 2018 Jul 5. pii: S1556-0864(18)30771.
    PubMed    


  725. KINSEY E, Ajazi E, Wang X, Johnston MAM, et al
    Predictors of physical and functional loss in advanced stage lung cancer patients receiving platinum chemotherapy.
    J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30676.
    PubMed     Abstract available


  726. LIU Y, Lusk CM, Cho MH, Silverman EK, et al
    Rare Variants in Known Susceptibility Loci and Their Contribution to Risk of Lung Cancer.
    J Thorac Oncol. 2018 Jul 4. pii: S1556-0864(18)30767.
    PubMed     Abstract available


  727. VELCHETI V, Madison R, Ali SM, Schrock AB, et al
    WAC/RET: A Novel RET Oncogenic Fusion Variant in Non-Small Cell Lung Carcinoma.
    J Thorac Oncol. 2018;13:e122-e123.
    PubMed    


  728. ASSALLUM H, Harris K
    The Impact of the Eighth TNM Classification for Lung Cancer on the Endobronchial Ultrasound Procedure.
    J Thorac Oncol. 2018;13:e119-e120.
    PubMed    


  729. NAVARRO A, Martinez-Marti A, Felip E
    HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?
    J Thorac Oncol. 2018;13:874-876.
    PubMed    


    June 2018
  730. WU YL, Lu S, Lu Y, Zhou J, et al
    Results of PROFILE 1029, a Phase III Comparison of First-Line Crizotinib versus Chemotherapy in East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jun 29. pii: S1556-0864(18)30721.
    PubMed     Abstract available


  731. SHIUE K, Cerra-Franco A, Shapiro R, Estabrook N, et al
    Histology, tumor volume, and radiation dose predict outcomes in non-small cell lung cancer patients after stereotactic ablative radiotherapy.
    J Thorac Oncol. 2018 Jun 26. pii: S1556-0864(18)30716.
    PubMed     Abstract available


  732. LIN JJ, Zhu VW, Schoenfeld AJ, Yeap BY, et al
    Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study.
    J Thorac Oncol. 2018 Jun 20. pii: S1556-0864(18)30714.
    PubMed     Abstract available


  733. WANG S, Yang L, Ci B, Maclean M, et al
    Development and Validation of a Nomogram Prognostic Model for Small-Cell Lung Cancer Patients.
    J Thorac Oncol. 2018 Jun 11. pii: S1556-0864(18)30687.
    PubMed     Abstract available


  734. HARATAKE N, Tagawa T, Hirai F, Toyokawa G, et al
    Stevens-Johnson syndrome induced by pembrolizumab in a lung cancer patient.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30681.
    PubMed    


  735. JONES CC, Mercaldo SF, Blume JD, Wenzlaff AS, et al
    Racial disparities in lung cancer survival: The contribution of stage, treatment, and ancestry.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30682.
    PubMed     Abstract available


  736. ROLFO C, Mack PC, Scagliotti GV, Baas P, et al
    IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30680.
    PubMed     Abstract available


  737. GERAUD A, Mezquita L, Bigot F, Caramella C, et al
    Long leptomeningeal responses with brigatinib in two heavily pre-treated ALK-rearranged non-small cell lung cancer patients.
    J Thorac Oncol. 2018 Jun 6. pii: S1556-0864(18)30683.
    PubMed    


  738. PARK S, Ahn BC, Lim SW, Sun JM, et al
    Characteristics and outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
    J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30673.
    PubMed     Abstract available


  739. YEGYA-RAMAN N, Wang K, Kim S, Reyhan M, et al
    Dosimetric Predictors of Symptomatic Cardiac Events after Conventional-Dose Chemoradiation Therapy for Inoperable Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jun 5. pii: S1556-0864(18)30675.
    PubMed     Abstract available


  740. WOZNIAK AJ, Schwartz AG
    Risk of Second Lung Cancer in Patients With Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology, and End Results Data.
    J Thorac Oncol. 2018;13:e106-e107.
    PubMed    


  741. MASCALCHI M, Sali L
    Risk of Second Lung Cancer in ITALUNG LDCT Screening.
    J Thorac Oncol. 2018;13:e105-e106.
    PubMed    


  742. WU CK, Kao SJ, Lai HC
    Targeted Therapy and Immunotherapy Lead to Rapid Regression of Advanced Non-Small Cell Lung Cancer with Multiple Driver Mutations.
    J Thorac Oncol. 2018;13:e103-e105.
    PubMed    


  743. BONOMI P, Blumenthal G, Ferris AS, Stewart DJ, et al
    Making Lung Cancer Clinical Trials More Inclusive: Recommendations for Expanding Eligibility Criteria.
    J Thorac Oncol. 2018;13:748-751.
    PubMed    


  744. TSENG D, Padda SK, Wakelee HA
    Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:741-744.
    PubMed    


    May 2018
  745. GETTINGER S, Hellmann MD, Chow LQM, Borghaei H, et al
    Nivolumab Plus Erlotinib in Patients with Epidermal Growth Factor Receptor-Mutant Advanced Non-Squamous Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 May 23. pii: S1556-0864(18)30628.
    PubMed     Abstract available


  746. HAMANN HA, Ver Hoeve ES, Carter-Harris L, Studts JL, et al
    Multilevel Opportunities to Address Lung Cancer Stigma across the Cancer Control Continuum.
    J Thorac Oncol. 2018 May 22. pii: S1556-0864(18)30627.
    PubMed     Abstract available


  747. FEHRENBACHER L, von Pawel J, Park K, Rittmeyer A, et al
    Updated efficacy analysis including secondary population results for OAK: a randomized phase III study of atezolizumab vs docetaxel in patients with previously treated advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 May 16. pii: S1556-0864(18)30611.
    PubMed     Abstract available


  748. GADGEEL SM, Pennell NA, Fidler MJ, Halmos B, et al
    Phase II study of maintenance pembrolizumab in patients with extensive-stage small cell lung cancer (SCLC).
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30600.
    PubMed     Abstract available


  749. SPIGEL DR, Chaft JE, Gettinger S, Chao BH, et al
    FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30603.
    PubMed     Abstract available


  750. WALTER JE, Heuvelmans MA, Yousaf-Khan U, Dorrius MD, et al
    New subsolid pulmonary nodules in lung cancer screening: a brief report of the NELSON trial.
    J Thorac Oncol. 2018 May 15. pii: S1556-0864(18)30605.
    PubMed     Abstract available


  751. KARANTH S, Rajan SS, Sharma G, Yamal JM, et al
    Racial-Ethnic Disparities in End-of-Life Care Quality among Lung Cancer Patients: A SEER-Medicare-Based Study.
    J Thorac Oncol. 2018 May 10. pii: S1556-0864(18)30540.
    PubMed     Abstract available


  752. CODONY-SERVAT J, Garcia-Roman S, Molina-Vila MA, Bertran-Alamillo J, et al
    Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer Cells.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30592.
    PubMed     Abstract available


  753. SMYTH RJ, Toomey SM, Sartori A, Hanrahan EO, et al
    Brief report on the detection of the EGFR-T790M mutation in exhaled breath condensate from lung cancer patients.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30595.
    PubMed     Abstract available


  754. NAKAMURA R, Inage Y, Tobita R, Yoneyama S, et al
    Sarcopenia in resected non-small cell lung cancer: Effect on postoperative outcomes.
    J Thorac Oncol. 2018 May 8. pii: S1556-0864(18)30597.
    PubMed     Abstract available


  755. KATZ SI, Hammer M, Bagley S, Aggarwal C, et al
    Radiologic pseudoprogression during anti-PD1 therapy for advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 May 5. pii: S1556-0864(18)30536.
    PubMed     Abstract available


  756. VOKES EE, Govindan R, Iscoe N, Hossain AM, et al
    The Impact of Staging by Positron Emission Tomography on Overall Survival and Progression-free Survival in Patients with Locally Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 May 4. pii: S1556-0864(18)30589.
    PubMed     Abstract available


  757. GARASSINO MC, Gelibter AJ, Grossi F, Chiari R, et al
    Italian nivolumab expanded access program in nonsquamous non-small-cell lung cancer patients: results in never-smokers and EGFR-mutant patients.
    J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30553.
    PubMed     Abstract available


  758. TAMURA T, Akimoto E, Matsumoto C, Mori S, et al
    Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 May 3. pii: S1556-0864(18)30554.
    PubMed    


  759. SAFIRI S, Ashrafi-Asgarabad A
    Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab: Methodological Issues.
    J Thorac Oncol. 2018;13:e85-e86.
    PubMed    


  760. WU B
    Response: Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small Cell Lung Cancer after Progression following First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2018;13:e84-e85.
    PubMed    


  761. HOYLE C, Dyer M
    Comments on Cost-Effectiveness of Osimertinib for EGFR Mutation-Positive Non-Small-Cell Lung Cancer after Progression during First-Line EGFR Tyrosine Kinase Inhibitor Therapy.
    J Thorac Oncol. 2018;13:e83-e84.
    PubMed    


  762. MARTINEZ VILA C, Garcia Garcia Y, Carcereny Costa E
    Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e77-e79.
    PubMed    


  763. DRESLER C, Warren GW, Arenberg D, Yang P, et al
    "Teachable Moment" Interventions in Lung Cancer: Why Action Matters.
    J Thorac Oncol. 2018;13:603-605.
    PubMed    


  764. HERMAN M, Warkentin MT, Shepshelovich D, Latifovic L, et al
    Heritable Germline Variation and Lung Cancer Susceptibility: One Size Does not Fit All.
    J Thorac Oncol. 2018;13:601-602.
    PubMed    


  765. TANIZAKI J, Chiba Y, Haratani K, Hayashi H, et al
    In Reply.
    J Thorac Oncol. 2018;13:e86-e87.
    PubMed    


  766. RANGACHARI D, VanderLaan PA, Costa DB
    Updated Correlation of 22C3-PD-L1 >/=50% Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting.
    J Thorac Oncol. 2018;13:e81-e83.
    PubMed    


  767. MIYAWAKI E, Murakami H, Takahashi T
    Correlation between 22C3-PD-L1 Expression and EGFR Mutations in Japanese Patients with Advanced Lung Adenocarcinoma.
    J Thorac Oncol. 2018;13:e79-e81.
    PubMed    


  768. ROSSI A, Novello S
    The Tradition of the Rising Sun: When Geography Counts.
    J Thorac Oncol. 2018;13:598-600.
    PubMed    


  769. HO C
    Anticipating the Next Step in the Management of ALK-Positive NSCLC.
    J Thorac Oncol. 2018;13:595-597.
    PubMed    


    April 2018
  770. DUDNIK E, Peled N, Nechushtan H, Wollner M, et al
    BRAF mutant lung cancer: PD-L1 expression, tumor mutational burden, microsatellite instability status and response to immune check-point inhibitors.
    J Thorac Oncol. 2018 Apr 30. pii: S1556-0864(18)30552.
    PubMed     Abstract available


  771. ANDREANO A, Peake MD, Janes SM, Valsecchi MG, et al
    The Care and Outcomes of Older Persons with Lung Cancer in England and the United States, 2008-2012.
    J Thorac Oncol. 2018 Apr 26. pii: S1556-0864(18)30550.
    PubMed     Abstract available


  772. VAN KEMPEN LC, Wang H, Aguirre ML, Spatz A, et al
    Afatinib in Osimertinib-Resistant EGFR ex19del / T790M / P794L mutated Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30548.
    PubMed    


  773. LI Z, Shen L, Ding D, Huang J, et al
    Efficacy of Crizotinib Among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-small-cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30542.
    PubMed     Abstract available


  774. MUNARI E, Zamboni G, Lunardi G, Marchionni L, et al
    PD-L1 expression heterogeneity in non-small cell lung cancer: defining criteria for harmonization between biopsies and whole sections.
    J Thorac Oncol. 2018 Apr 25. pii: S1556-0864(18)30543.
    PubMed     Abstract available


  775. VAN VEGGEL B, de Langen AJ, Hashemi S, Monkhorst K, et al
    Brief report: Afatinib and cetuximab in four patients with EGFR exon 20 insertion positive advanced non-small-cell lung cancer.
    J Thorac Oncol. 2018 Apr 24. pii: S1556-0864(18)30538.
    PubMed     Abstract available


  776. SCHILD SE, Fan W, Stinchcombe TE, Vokes EE, et al
    Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30537.
    PubMed     Abstract available


  777. WADE S, Weber M, Caruana M, Kang YJ, et al
    Estimating the cost-effectiveness of lung cancer screening with low dose computed tomography for high risk smokers in Australia.
    J Thorac Oncol. 2018 Apr 21. pii: S1556-0864(18)30531.
    PubMed     Abstract available


  778. DONINGTON JS, Kim YT, Tong B, Moreira AL, et al
    Progress in the management of Early Stage Non-Small Cell Lung Cancer in 2017.
    J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30508.
    PubMed     Abstract available


  779. OWADA-OZAKI Y, Muto S, Takagi H, Inoue T, et al
    Prognostic Impact of Tumor Mutation Burden in Patients with Completely Resected Non-Small Cell Lung Cancer: Brief Report.
    J Thorac Oncol. 2018 Apr 11. pii: S1556-0864(18)30509.
    PubMed     Abstract available


  780. OSTIOS-GARCIA L, Faig J, Leonardi GC, Adeni AE, et al
    Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients with Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30270.
    PubMed     Abstract available


  781. SANDBERG Y, den Bakker MA
    Small cell lung cancer presenting as carcinocythemia.
    J Thorac Oncol. 2018 Apr 6. pii: S1556-0864(18)30269.
    PubMed    


  782. MA Y, Zheng X, Zhao H, Fang W, et al
    First-in-Human Phase I Study of AC0010, a Mutant-Selective EGFR Inhibitor in Non-Small Cell Lung Cancer: Safety, Efficacy, and Potential Mechanism of Resistance.
    J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30264.
    PubMed     Abstract available


  783. CARR SR, Akerley W, Cannon-Albright L
    Genetic Contribution to Non-Squamous, Non-Small Cell Lung Cancer in Non-Smokers.
    J Thorac Oncol. 2018 Apr 4. pii: S1556-0864(18)30263.
    PubMed     Abstract available


  784. WATANABE J, Furuya N, Fujiwara Y
    Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion.
    J Thorac Oncol. 2018;13:e66-e69.
    PubMed    


  785. MORMILE R
    Metformin and Lung Cancer: The Final Blow to the Obesity Paradox?
    J Thorac Oncol. 2018;13:e65-e66.
    PubMed    


  786. SAFIRI S
    Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity.
    J Thorac Oncol. 2018;13:e61.
    PubMed    


  787. SANDFELD-PAULSEN B, Aggerholm-Pedersen N
    Response to Safri: "Comments on Comorbidity in Lung Cancer: A Prospective Cohort Study of Self-Reported versus Register-Based Comorbidity".
    J Thorac Oncol. 2018;13:e61-e62.
    PubMed    


  788. MASAI K, Motoi N
    Response to Letter to the Editor Titled "Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer".
    J Thorac Oncol. 2018;13:e58-e59.
    PubMed    


  789. MANSORI K, Ayubi E, Safiri S
    Comments on Prognostic Impact of Margin Distance and Tumor Spread through Air Spaces in Limited Resection for Primary Lung Cancer.
    J Thorac Oncol. 2018;13:e57-e58.
    PubMed    


  790. SUN JM
    Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer".
    J Thorac Oncol. 2018;13:e56-e57.
    PubMed    


  791. COSTANTINI A, Cadranel J
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e55-e56.
    PubMed    


  792. LEVY A, Hendriks LE, Faivre-Finn C
    Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?
    J Thorac Oncol. 2018;13:475-477.
    PubMed    


  793. SENAN S, Rusthoven CG, Slotman BJ, Siva S, et al
    Progress in Radiotherapy for Regional and Oligometastatic Disease in 2017.
    J Thorac Oncol. 2018;13:488-496.
    PubMed     Abstract available


    March 2018
  794. GAJRA A, Zemla TJ, Jatoi A, Feliciano JL, et al
    Time-to-Treatment-Failure and Related Outcomes among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients.
    J Thorac Oncol. 2018 Mar 30. pii: S1556-0864(18)30254.
    PubMed     Abstract available


  795. LI Y, Liu B, Connolly ID, Kakusa BW, et al
    Brief Report: Recurrently Mutated Genes Differ between Leptomeningeal and Solid Lung Cancer Brain Metastases.
    J Thorac Oncol. 2018 Mar 28. pii: S1556-0864(18)30222.
    PubMed     Abstract available


  796. SHIBAHARA D, Tanaka K, Iwama E, Kubo N, et al
    Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Mar 26. pii: S1556-0864(18)30215.
    PubMed     Abstract available


  797. LEE CK, Lord S, Marschner I, Wu YL, et al
    The value of early depth of response in predicting long-term outcome in EGFR-mutant lung cancer.
    J Thorac Oncol. 2018 Mar 23. pii: S1556-0864(18)30212.
    PubMed     Abstract available


  798. FLORES R, Taioli E, Yankelevitz DF, Becker BJ, et al
    Initiative for Early Lung Cancer Research on Treatment: Development of Study Design and Pilot Implementation.
    J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30211.
    PubMed     Abstract available


  799. GETTINGER SN, Wurtz A, Goldberg SB, Rimm D, et al
    Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in Twenty-Six Patients with Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Mar 22. pii: S1556-0864(18)30210.
    PubMed     Abstract available


  800. MAENG CH, Song JU, Shim SR, Lee J, et al
    The Role of Prophylactic Cranial Irradiation in Patients with Extensive Stage Small Cell Lung Cancer: A Systematic Review and Meta-Analysis.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30180.
    PubMed     Abstract available


  801. PARRA ER, Villalobos P, Zhang J, Behrens C, et al
    Immunohistochemical and Image Analysis-based Study Demonstrate that Several Immune Checkpoints are Co-expressed in Non-Small Cell Lung Carcinoma Tumors.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30182.
    PubMed     Abstract available


  802. ROCCO G, Pennazza G, Santonico M, Longo F, et al
    Breathprinting and early diagnosis of lung cancer.
    J Thorac Oncol. 2018 Mar 8. pii: S1556-0864(18)30183.
    PubMed     Abstract available


  803. SPIGEL DR, Reynolds C, Waterhouse D, Garon EB, et al
    Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-line Treatment of ALK Translocation-Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370).
    J Thorac Oncol. 2018 Mar 5. pii: S1556-0864(18)30176.
    PubMed     Abstract available


  804. TOYOOKA S, Okumura N, Nakamura H, Nakata M, et al
    A multi-center randomized controlled study of paclitaxel plus carboplatin versus oral uracil-tegafur as the adjuvant chemotherapy in resected non-small cell lung cancer.
    J Thorac Oncol. 2018 Mar 2. pii: S1556-0864(18)30168.
    PubMed     Abstract available


  805. YASUDA Y, Ozasa H, Kim YH
    PD-L1 Expression in Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e40-e41.
    PubMed    


  806. CHO JH, Sun JM, Lee SH, Ahn JS, et al
    Late-Onset Cholecystitis with Cholangitis after Avelumab Treatment in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018;13:e34-e36.
    PubMed    


  807. RANDHAWA S, Moore RF, DiSesa V, Kaiser L, et al
    Role of Thoracic Surgeons in Lung Cancer Screening: Opportune Time for Involvement.
    J Thorac Oncol. 2018;13:298-300.
    PubMed    


  808. FAN J, Dai X, Nie X
    Concomitant Epidermal Growth Factor Receptor Mutation and EML4-ALK Fusion in a Patient with Multifocal Lung Adenocarcinomas.
    J Thorac Oncol. 2018;13:e45-e48.
    PubMed    


  809. YIN J, Zhang Y, Zhang Y, Peng F, et al
    Reporting on Two Novel Fusions, DYSF-ALK and ITGAV-ALK, Coexisting in One Patient with Adenocarcinoma of Lung, Sensitive to Crizotinib.
    J Thorac Oncol. 2018;13:e43-e45.
    PubMed    


  810. RIHAWI K, Cinausero M, Fiorentino M, Salvagni S, et al
    Co-alteration of c-Met and ROS1 in Advanced NSCLC: ROS1 Wins.
    J Thorac Oncol. 2018;13:e41-e43.
    PubMed    


  811. RAEZ LE, Pinto JA, Schrock AB, Ali SM, et al
    EGFR-RAD51 Fusion: A Targetable Partnership Originated from the Tumor Evolution?
    J Thorac Oncol. 2018;13:e33-e34.
    PubMed    


    February 2018
  812. GIROUX DJ, Van Schil P, Asamura H, Rami-Porta R, et al
    The IASLC Lung Cancer Staging Project: A Renewed Call to Participation.
    J Thorac Oncol. 2018 Feb 21. pii: S1556-0864(18)30131.
    PubMed     Abstract available


  813. WEN J, Liu H, Wang L, Wang X, et al
    Potentially Functional variants of ATG16L2 predict radiation pneumonitis and outcomes in patients with non-small cell lung cancer after definitive radiotherapy.
    J Thorac Oncol. 2018 Feb 15. pii: S1556-0864(18)30103.
    PubMed     Abstract available


  814. VAN DE GOOR R, van Hooren M, Dingemans AM, Kremer B, et al
    Training and validating a portable electronic nose for lung cancer screening.
    J Thorac Oncol. 2018 Feb 6. pii: S1556-0864(18)30093.
    PubMed     Abstract available


  815. EATON KD, Romine PE, Goodman GE, Thornquist MD, et al
    Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility.
    J Thorac Oncol. 2018 Feb 2. pii: S1556-0864(18)30090.
    PubMed     Abstract available


  816. MORGENSZTERN D, Samson P, Waqar SN, Devarakonda S, et al
    Early mortality in patients undergoing adjuvant chemotherapy for non-small-cell lung cancer.
    J Thorac Oncol. 2018 Feb 1. pii: S1556-0864(18)30036.
    PubMed     Abstract available


  817. ASHRAFI-ASGARABAD A, Safiri S
    Prognostic Value of Primary Tumor Volume Changes on Kilovoltage Onboard Cone Beam Computed Tomography during Definitive Chemoradiotherapy for stage III Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2018;13:e26-e27.
    PubMed    


  818. LEONE A
    C797S and T790M EGFR Mutations in Non-Small Cell Lung Cancer: In Trans or in Separate Clones?
    J Thorac Oncol. 2018;13:e21-e22.
    PubMed    


  819. GAZDAR AF
    Morphologic and Other Forms of Heterogeneity in Small Cell Lung Cancer: What Can We Learn from Them?
    J Thorac Oncol. 2018;13:148-150.
    PubMed    


    January 2018
  820. KATZMAN D, Wu S, Sterman DH
    Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review.
    J Thorac Oncol. 2018 Jan 29. pii: S1556-0864(18)30079.
    PubMed     Abstract available


  821. WOLFF HB, Alberts L, Kastelijn EA, Lissenberg-Witte BI, et al
    Differences in longitudinal health utility between stereotactic body radiation therapy and surgery in stage I non-small cell lung cancer.
    J Thorac Oncol. 2018 Jan 29. pii: S1556-0864(18)30083.
    PubMed     Abstract available


  822. HUBBELING HG, Schapira EF, Horick NK, Goodwin KEH, et al
    Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2018 Jan 26. pii: S1556-0864(18)30039.
    PubMed     Abstract available


  823. STONE E, Jett J, Warren G, Cummings KM, et al
    Cannabis Use, Lung Cancer, and Related Issues.
    J Thorac Oncol. 2018 Jan 24. pii: S1556-0864(18)30038.
    PubMed     Abstract available


  824. LINDEMAN NI, Cagle PT, Aisner DL, Arcila ME, et al
    Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and
    J Thorac Oncol. 2018 Jan 23. pii: S1556-0864(17)33071.
    PubMed     Abstract available


  825. HOUSTON KA, Mitchell KA, King J, White A, et al
    Histologic Lung Cancer Incidence Rates and Trends vary by Race/Ethnicity and Residential County.
    J Thorac Oncol. 2018 Jan 19. pii: S1556-0864(18)30003.
    PubMed     Abstract available


  826. NYGARD L, Vogelius IR, Fischer BM, Kjaer A, et al
    A competing risk model of first failure site after definitive (chemo) radiation therapy for locally advanced non-small cell lung cancer.
    J Thorac Oncol. 2018 Jan 18. pii: S1556-0864(18)30006.
    PubMed     Abstract available


  827. MAROM EM, Ofek E, Bekker E, Onn A, et al
    Tattoo Induced False Positive FDG PET-CT Interpretation while Staging for Lung Cancer.
    J Thorac Oncol. 2018 Jan 17. pii: S1556-0864(18)30005.
    PubMed    


  828. RICCIUTI B, Metro G, Brambilla M, Ludovini V, et al
    Acquired Resistance to Afatinib Due to T790M-Positive Squamous Progression in EGFR-Mutant Adenosquamous Lung Carcinoma.
    J Thorac Oncol. 2018;13:e9-e12.
    PubMed    


  829. MCCANN B, Clark B
    Four-Year Complete Remission in a Patient with Metastatic Epidermal Growth Factor Receptor-Mutated Lung Cancer Treated with Two Cycles of Erlotinib.
    J Thorac Oncol. 2018;13:e7-e8.
    PubMed    


  830. ZHANG X, Zheng X
    Reply to "Obesity Paradox in Lung Cancer Prognosis: Is MiR-26b the Achilles Heel?"
    J Thorac Oncol. 2018;13:e16.
    PubMed    


  831. MORMILE R
    Obesity Paradox in Lung Cancer Prognosis: Is MiR-26b the Achilles Heel?
    J Thorac Oncol. 2018;13:e15.
    PubMed    


  832. DONG ZY, Zhang C, Li YF, Su J, et al
    Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
    J Thorac Oncol. 2018;13:85-96.
    PubMed     Abstract available


  833. BUCCIARELLI PR, Tan KS, Chudgar NP, Brandt W, et al
    BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis.
    J Thorac Oncol. 2018;13:73-84.
    PubMed     Abstract available


  834. PATIL NS, Righi L, Koeppen H, Zou W, et al
    Molecular and Histopathological Characterization of the Tumor Immune Microenvironment in Advanced Stage of Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2018;13:124-133.
    PubMed     Abstract available


  835. NOONAN SA, Patil T, Gao D, King GG, et al
    Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung.
    J Thorac Oncol. 2018;13:134-138.
    PubMed     Abstract available


  836. SALVI S, Ravetti JL, Arena G, Musso C, et al
    Evaluation of RET Gene Rearrangement by Fluorescence In Situ Hybridization in Malignant Mesothelioma.
    J Thorac Oncol. 2018;13:e12-e14.
    PubMed    


  837. AHN MJ
    Cell-free DNA Analysis in SCLC: Ready for Clinical Practice?
    J Thorac Oncol. 2018;13:10-11.
    PubMed    


    December 2017
  838. PILOTTO S, Sperduti I, Leuzzi G, Chiappetta M, et al
    Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33101.
    PubMed     Abstract available


  839. WU SP, Liao RQ, Tu HY, Wang WJ, et al
    Stromal PD-L1+regulatory T cells and PD-1+CD8+ T cells define the response of different subsets of non-small-cell lung cancer to PD-1/PD-L1 blockade immunotherapy.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33102.
    PubMed     Abstract available


  840. ROBIN TP, Camidge DR, Stuhr K, Nath SK, et al
    Excellent Outcomes with Radiosurgery for Multiple Brain Metastases in Oncogene-Addicted Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33107.
    PubMed     Abstract available


  841. MILLER ED, Fisher JL, Haglund KE, Grecula JC, et al
    The addition of chemotherapy to radiation therapy improves survival in elderly patients with stage III non-small cell lung cancer.
    J Thorac Oncol. 2017 Dec 18. pii: S1556-0864(17)33108.
    PubMed     Abstract available


  842. FELIP E, Barlesi F, Besse B, Chu Q, et al
    Brief Report: Phase 2 Study of the HSP-90 inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 13. pii: S1556-0864(17)33083.
    PubMed     Abstract available


  843. TSENG YH, Ho HL, Lai CR, Luo YH, et al
    Brief Report: PD-L1 expression of tumor cells, macrophages, and immune cells in non-small cell lung cancer patients with malignant pleural effusion.
    J Thorac Oncol. 2017 Dec 12. pii: S1556-0864(17)33079.
    PubMed     Abstract available


  844. AOKAGE K, Miyoshi T, Ishii G, Kusumoto M, et al
    Influence of Ground-Glass Opacity and the Corresponding Pathological Findings on Survival in Patients with Clinical Stage I Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 12. pii: S1556-0864(17)33080.
    PubMed     Abstract available


  845. STIEFEL F, Bourquin C
    Adverse Effects of "Teachable Moment" Interventions in Lung Cancer: Why Prudence Matters.
    J Thorac Oncol. 2017 Dec 11. pii: S1556-0864(17)32862.
    PubMed    


  846. STABILE LP, Farooqui M, Kanterewicz B, Abberbock S, et al
    Preclinical Evidence for Combined Use of Aromatase Inhibitors and NSAIDs as Preventive Agents of Tobacco-Induced Lung Cancer.
    J Thorac Oncol. 2017 Dec 9. pii: S1556-0864(17)33076.
    PubMed     Abstract available


  847. FUJIMOTO D, Sato Y, Uehara K, Ishida K, et al
    Predictive performance of four programmed cell death ligand 1 assay systems on nivolumab response in previously treated patients with non-small cell lung cancer.
    J Thorac Oncol. 2017 Dec 9. pii: S1556-0864(17)33072.
    PubMed     Abstract available


  848. HOTTA K, Aoe K, Kozuki T, Ohashi K, et al
    A Phase II Study of Trastuzumab Emtansine in HER2-positive Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Dec 4. pii: S1556-0864(17)33065.
    PubMed     Abstract available


  849. BOLZACCHINI E, Tuzi A, Gobba S, Pinotti G, et al
    Impressive Response to Tyrosine Kinase Inhibitors in a Patient with Respiratory Failure for EGFR-Mutated Metastatic Lung Cancer.
    J Thorac Oncol. 2017;12:e208-e210.
    PubMed    


  850. GU F, Cheung L, Katki H, Caporaso N, et al
    Response to Safiri et al. "Comments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screening".
    J Thorac Oncol. 2017;12:e208.
    PubMed    


  851. SAFIRI S, Mansourpour H, Ayubi E
    Comments on Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers For Lung Cancer Screening.
    J Thorac Oncol. 2017;12:e207.
    PubMed    


  852. NAKANISHI Y, Masuda S, Iida Y, Takahashi N, et al
    Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.
    J Thorac Oncol. 2017;12:e202-e204.
    PubMed    



  853. Erratum to: Pyo KH, Lim SM, Kim HR, Sung YH, Yun MR, Kim S-M, et al. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Postive Human Non-Small Cell Lung Cancer. J Thorac Oncol. 2017;12(3):491-500.
    J Thorac Oncol. 2017;12:1859.
    PubMed    


  854. WATZA D, Schwartz AG
    Addressing Underrepresented Populations in Lung Cancer Research: The Hispanic/Latino Lung Cancer Registry Identifies Distinct Mutation Profiles for NSCLC.
    J Thorac Oncol. 2017;12:1744-1745.
    PubMed    


    November 2017
  855. SOCINSKI MA, Obasaju C, Gandara D, Hirsch FR, et al
    Current and Emergent Therapy Options for Advanced Squamous-Cell Lung Cancer.
    J Thorac Oncol. 2017 Nov 23. pii: S1556-0864(17)33053.
    PubMed     Abstract available


  856. HENDRY S, Byrne DJ, Wright GM, Young RJ, et al
    Comparison of four PD-L1 immunohistochemical assays in lung cancer.
    J Thorac Oncol. 2017 Nov 23. pii: S1556-0864(17)33054.
    PubMed     Abstract available


  857. TANIZAKI J, Haratani K, Hayashi H, Chiba Y, et al
    Peripheral blood biomarkers associated with clinical outcome in non-small cell lung cancer patients treated with nivolumab.
    J Thorac Oncol. 2017 Nov 20. pii: S1556-0864(17)33008.
    PubMed     Abstract available


  858. YANKELEVITZ DF
    CT Screening for Lung Cancer: Successful Trial, but Failed Understanding.
    J Thorac Oncol. 2017 Nov 18. pii: S1556-0864(17)32767.
    PubMed    


  859. RECK M, Taylor F, Penrod JR, DeRosa M, et al
    Impact of Nivolumab Versus Docetaxel on Health-Related Quality of Life and Symptoms in Patients With Advanced Squamous Non-Small Cell Lung Cancer: Results From the CheckMate 017 Study.
    J Thorac Oncol. 2017 Nov 9. pii: S1556-0864(17)32878.
    PubMed     Abstract available


  860. FERRARA R, Auger N, Auclin E, Besse B, et al
    Clinical and translational implications of RET rearrangements in non-small cell lung cancer.
    J Thorac Oncol. 2017 Nov 8. pii: S1556-0864(17)32866.
    PubMed     Abstract available


  861. RICORDEL C, Llamas-Gutierrez F, Chiforeanu D, Lena H, et al
    Large Cell Neuroendocrine Lung Carcinoma Transformation as an Acquired Resistance Mechanism to Osimertinib.
    J Thorac Oncol. 2017;12:e184-e186.
    PubMed    


  862. LEE JS, Hur JY, Kim HJ, Lee KY, et al
    A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non-Small Cell Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e179-e181.
    PubMed    


  863. HENNINGFIELD MF, Adjei AA
    Lung Cancer Awareness Month-A Lot of Progress, But More Work Needs to Be Done.
    J Thorac Oncol. 2017;12:1603-1605.
    PubMed    


    October 2017
  864. PARK SE, Lee SH, Ahn JS, Ahn MJ, et al
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32850.
    PubMed     Abstract available


  865. WU B, Gu X, Zhang Q
    Cost-effectiveness of osimertinib for EGFR-mutation-positive non-small-cell lung cancer after progression of first-line EGFR TKI therapy.
    J Thorac Oncol. 2017 Oct 31. pii: S1556-0864(17)32851.
    PubMed     Abstract available


  866. SANDFELD-PAULSEN B, Meldgaard P, Aggerholm-Pedersen N
    Comorbidity in lung cancer: A prospective cohort study of self-reported versus register-based comorbidity.
    J Thorac Oncol. 2017 Oct 19. pii: S1556-0864(17)32788.
    PubMed     Abstract available


  867. PINATO DJ, Newsom-Davis T
    Regression of para-neoplastic rash following lung cancer chemotherapy.
    J Thorac Oncol. 2017 Oct 14. pii: S1556-0864(17)32786.
    PubMed    


  868. TOKACA N, Barth S, O'Brien M, Bhosle J, et al
    Molecular adequacy of image-guided rebiopsies for molecular retesting in advanced non-small cell lung cancer: a single centre experience.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32760.
    PubMed     Abstract available


  869. THAKUR MK, Ruterbusch JJ, Schwartz AG, Gadgeel SM, et al
    Risk of Second Lung Cancer in Patients with Previously Treated Lung Cancer: Analysis of Surveillance, Epidemiology and End Results (SEER) Data.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32766.
    PubMed     Abstract available


  870. SHUKUYA T, Patel S, Shane-Carson K, He K, et al
    Lung Cancer Patients with Germline Mutations detected by next generation sequencing and/or liquid biopsy.
    J Thorac Oncol. 2017 Oct 5. pii: S1556-0864(17)32764.
    PubMed    


  871. SHOLL LM
    Next-Generation Sequencing from Liquid Biopsies in Lung Cancer Patients: Advances in Comprehensive Biomarker Testing.
    J Thorac Oncol. 2017;12:1464-1466.
    PubMed    


    September 2017
  872. SUN JM, Noh JM, Oh D, Kim HK, et al
    Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 Sep 26. pii: S1556-0864(17)32708.
    PubMed     Abstract available


  873. MEYER M, Vliegenthart R, Henzler T, Buergy D, et al
    Management of progressive pulmonary nodules found during and outside of CT lung cancer screening studies.
    J Thorac Oncol. 2017 Sep 26. pii: S1556-0864(17)32713.
    PubMed     Abstract available


  874. BOYER MJ, Williams CD, Harpole DH, Onaitis MW, et al
    Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis.
    J Thorac Oncol. 2017 Sep 23. pii: S1556-0864(17)32706.
    PubMed     Abstract available


  875. ALMODOVAR K, Iams WT, Meador CB, Zhao Z, et al
    Longitudinal cell-free DNA analysis in patients with small cell lung cancer reveals dynamic insights into treatment efficacy and disease relapse.
    J Thorac Oncol. 2017 Sep 22. pii: S1556-0864(17)32705.
    PubMed     Abstract available


  876. TERAOKA S, Fujimoto D, Morimoto T, Kawachi H, et al
    Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study.
    J Thorac Oncol. 2017 Sep 19. pii: S1556-0864(17)30825.
    PubMed     Abstract available


  877. HIGGINS KA, Pillai RN, Chen Z, Tian S, et al
    Concomitant chemotherapy and radiotherapy with SBRT Boost for Unresectable, Stage III Non-small Cell Lung Cancer: A phase I Study.
    J Thorac Oncol. 2017 Sep 12. pii: S1556-0864(17)30734.
    PubMed     Abstract available


  878. GIMBRONE NT, Sarcar B, Gordian ER, Rivera JI, et al
    Brief Report: Somatic Mutations and Ancestry Markers in Hispanic Lung Cancer Patients.
    J Thorac Oncol. 2017 Sep 11. pii: S1556-0864(17)30731.
    PubMed     Abstract available


  879. MASAI K, Sakurai H, Sukeda A, Suzuki S, et al
    Prognostic Impact of Margin Distance and Tumor Spread Through Air Spaces in Limited Resection for Primary Lung Cancer.
    J Thorac Oncol. 2017 Sep 4. pii: S1556-0864(17)30727.
    PubMed     Abstract available


  880. RUSTHOVEN CG, Kavanagh BD
    Prophylactic Cranial Irradiation (PCI) vs Active MRI Surveillance for Small-Cell Lung Cancer: The Case for Equipoise.
    J Thorac Oncol. 2017 Sep 4. pii: S1556-0864(17)30728.
    PubMed     Abstract available


  881. SEPESI B, Correa AM, Dmitrovsky E, Liu X, et al
    Reply to "Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues".
    J Thorac Oncol. 2017;12:e150-e151.
    PubMed    


  882. SAFIRI S, Khazaei S, Ayubi E
    The Influence of Body Mass Index on Overall Survival following Surgical Resection of Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2017;12:e149-e150.
    PubMed    


  883. KHUNGER M, Calabrese C, Kontzias A, Velcheti V, et al
    To Treat or Not to Treat: Role of Immunotherapy in Patients with Concomitant Diagnosis of Advanced-Stage Non-Small Cell Lung Cancer and Psoriasis.
    J Thorac Oncol. 2017;12:e147-e149.
    PubMed    


  884. KOMATSU T, Nakamura K, Kawase A
    Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer.
    J Thorac Oncol. 2017;12:e143-e144.
    PubMed    


  885. FUNAZO T, Nomizo T, Kim YH
    Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non-Small Cell Lung Cancer Treated with Nivolumab.
    J Thorac Oncol. 2017;12:e140-e141.
    PubMed    


  886. GORTAIS H, Daniel C, Bidard FC, Jeannot E, et al
    T790M EGFR Mutation Detection in Cerebrospinal Fluid and Response to Osimertinib in a Lung Cancer Patient with Meningeal Carcinomatosis.
    J Thorac Oncol. 2017;12:e138-e139.
    PubMed    


  887. EZE C, Roengvoraphoj O, Manapov F
    Prophylactic Cranial Irradiation in Resected Small Cell Lung Cancer: Comprehensive Staging, Adjuvant Chemotherapy, and Strict Stratification of Pathological Stage Play a Role.
    J Thorac Oncol. 2017;12:e137-e138.
    PubMed    


  888. VAN SCHIL PE
    Optimal Treatment of Stage IIIA-N2 Non-Small Cell Lung Cancer: A Neverending Story?
    J Thorac Oncol. 2017;12:1338-1340.
    PubMed    


    August 2017
  889. WALD P, Mo X, Barney C, Gunderson D, et al
    Prognostic value of primary tumor volume changes on kV-CBCT during definitive chemoradiotherapy for stage III non-small cell lung cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30685.
    PubMed     Abstract available


  890. ARULANANDA S, Do H, Musafer A, Mitchell P, et al
    Combination osimertinib and gefitinib in C797S and T790M EGFR mutated non-small-cell lung cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30681.
    PubMed     Abstract available


  891. DAVID EA, Clark JM, Cooke DT, Melnikow J, et al
    The Role of Thoracic Surgery in the Therapeutic Management of Metastatic Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Aug 23. pii: S1556-0864(17)30683.
    PubMed     Abstract available


  892. GU F, Cheung LC, Freedman ND, Katki HA, et al
    Potential impact of including Time to First Cigarette into risk models for selecting ever-smokers for lung-cancer screening.
    J Thorac Oncol. 2017 Aug 14. pii: S1556-0864(17)30664.
    PubMed     Abstract available


  893. LIN JJ, Shaw AT
    Recent Advances in Targeting ROS1 in Lung Cancer.
    J Thorac Oncol. 2017 Aug 14. pii: S1556-0864(17)30668.
    PubMed     Abstract available


  894. KONO M, Allen PK, Lin SH, Wei X, et al
    Incidence of Second Malignancy after Successful Treatment of Limited-Stage Small-Cell Lung Cancer and Its Effects on Survival.
    J Thorac Oncol. 2017 Aug 10. pii: S1556-0864(17)30661.
    PubMed     Abstract available


  895. XIZHAO S, Wei J, Haiqing C, Fan Y, et al
    Validation of the stage groupings in the 8th edition of the TNM classification for lung cancer.
    J Thorac Oncol. 2017 Aug 3. pii: S1556-0864(17)30659.
    PubMed     Abstract available


  896. SAFIRI S, Ayubi E
    Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-Small Cell Lung Cancer: Methodological Issues.
    J Thorac Oncol. 2017;12:e130-e131.
    PubMed    


  897. KIMURA H, Tounai Y, Nagato K, Morimoto JI, et al
    A Case of Heart Failure after Treatment with Anti-PD-1 Antibody Followed by Adoptive Transfer of Cytokine-Activated Killer Cells in a Recurrent Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e128-e130.
    PubMed    


  898. YANAGISAWA S, Miyauchi E, Ichinose M
    Numb Chin Syndrome: An Ominous Sign of Lung Cancer.
    J Thorac Oncol. 2017;12:e114-e116.
    PubMed    


  899. SHOJAEE S, Vachani A, Nana-Sinkam P
    The Financial Implications of Lung Cancer Screening: Is It Worth It?
    J Thorac Oncol. 2017;12:1177-1179.
    PubMed    


  900. STONE E, Slatore CG
    The Obesity Paradox-What Does It Mean for Lung Cancer Surgery?
    J Thorac Oncol. 2017;12:1174-1176.
    PubMed    


    July 2017
  901. FURUTA H, Yoshida T, Shimizu J, Tomita N, et al
    Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Jul 31. pii: S1556-0864(17)30656.
    PubMed    


  902. ZHANG X, Liu Y, Shao H, Zheng X, et al
    Obesity paradox in lung cancer prognosis: evolving biological insights and clinical implications.
    J Thorac Oncol. 2017 Jul 27. pii: S1556-0864(17)30619.
    PubMed     Abstract available


  903. LI C, Huang C, Mok TS, Zhuang W, et al
    Comparison of 22C3-PD-L1 expression between surgically resected specimens and paired tissue microarrays in non-small cell lung cancer.
    J Thorac Oncol. 2017 Jul 24. pii: S1556-0864(17)30612.
    PubMed     Abstract available


  904. NORSKOV MS, Dahl M, Tybjaerg-Hansen A
    Genetic variation in GSTP1, lung function, risk of lung cancer and mortality in 66,000 individuals.
    J Thorac Oncol. 2017 Jul 21. pii: S1556-0864(17)30605.
    PubMed     Abstract available


  905. LOGANADANE G, Hendriks L, Le Pechoux C, Levy A, et al
    The current role of whole brain radiation therapy in non-small cell lung cancer patients.
    J Thorac Oncol. 2017 Jul 18. pii: S1556-0864(17)30585.
    PubMed     Abstract available


  906. CHO BC, Kim DW, Bearz A, Laurie SA, et al
    ASCEND-8: A Randomized Phase 1 Study of Ceritinib 450 mg or 600 mg Taken With a Low-Fat Meal Versus 750 mg in Fasted State in Patients With Anaplastic Lymphoma Kinase (ALK)-Rearranged Metastatic Non-Small Cell Lung Cancer (NSCLC).
    J Thorac Oncol. 2017 Jul 17. pii: S1556-0864(17)30578.
    PubMed     Abstract available


  907. SHLOMI D, Abud M, Liran O, Bar J, et al
    Detection of Lung Cancer and EGFR Mutation by Electronic Nose System.
    J Thorac Oncol. 2017 Jul 11. pii: S1556-0864(17)30573.
    PubMed     Abstract available


  908. YANG JC, Ou SI, De Petris L, Gadgeel S, et al
    Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small-Cell Lung Cancer.
    J Thorac Oncol. 2017 Jul 5. pii: S1556-0864(17)30570.
    PubMed     Abstract available


  909. YOSHIDA R, Sasaki T, Ohsaki Y
    EGFR and KRAS Mutations in Triple-Mutated Lung Cancer.
    J Thorac Oncol. 2017;12:e92-e93.
    PubMed    


    June 2017
  910. GORE EM, Hu C, Sun AY, Grimm DF, et al
    Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone To Prophylactic Cranial Irradiation And Consolidative Extra-Cranial Irradiation For Extensive Disease Small Cell Lung Cancer (ED-SCLC): NRG Oncology RTOG 0937.
    J Thorac Oncol. 2017 Jun 22. pii: S1556-0864(17)30468.
    PubMed     Abstract available


  911. GUPTA A, Saltarski JM, White MA, Scaglioni PP, et al
    Therapeutic Targeting of Nuclear Export Inhibition in Lung Cancer.
    J Thorac Oncol. 2017 Jun 21. pii: S1556-0864(17)30466.
    PubMed     Abstract available


  912. BARON AE, Kako S, Feser WJ, Malinowski H, et al
    Clinical Utility of Chromosomal Aneusomy in Individuals at High Risk of Lung Cancer.
    J Thorac Oncol. 2017 Jun 17. pii: S1556-0864(17)30461.
    PubMed     Abstract available


  913. EDELMAN MJ, Hu C, Le QT, Donington JS, et al
    Randomized Phase II Study of Preoperative Chemoradiotherapy +/- Panitumumab Followed by Consolidation Chemotherapy in Potentially Operable Locally Advanced (Stage IIIa, N2+) Non-small Cell Lung Cancer: NRG Oncology RTOG 0839.
    J Thorac Oncol. 2017 Jun 16. pii: S1556-0864(17)30459.
    PubMed     Abstract available


  914. EVISON M, Clive A, Castle L, Powell H, et al
    Resectable clinical N2 non-small cell lung cancer; what is the optimal treatment strategy? An update by the British Thoracic Society Lung Cancer Specialist Advisory Group.
    J Thorac Oncol. 2017 Jun 14. pii: S1556-0864(17)30448.
    PubMed     Abstract available


  915. AOKAGE K, Miyoshi T, Ishii G, Kusumoto M, et al
    Clinical and Pathological Staging Validation in the Eighth Edition of TNM Classification for Lung Cancer: Correlation Between Solid Size on Thin-section Computed Tomography and Invasive Size in Pathological Findings in the New T Classification.
    J Thorac Oncol. 2017 Jun 13. pii: S1556-0864(17)30444.
    PubMed     Abstract available


  916. SACHER AG, Komatsubara KM, Oxnard GR
    Application of plasma genotyping technologies in non-small cell lung cancer: a practical review.
    J Thorac Oncol. 2017 Jun 10. pii: S1556-0864(17)30441.
    PubMed     Abstract available


  917. RANGACHARI D, Le X, Shea M, Huberman MS, et al
    Cases of ALK-rearranged lung cancer with 5-year progression-free survival with crizotinib as initial precision therapy.
    J Thorac Oncol. 2017 Jun 10. pii: S1556-0864(17)30440.
    PubMed    


  918. LEVENTAKOS K, Peikert T, Midthun D, Molina JR, et al
    Management of multifocal lung cancer: Results of a survey.
    J Thorac Oncol. 2017 Jun 2. pii: S1556-0864(17)30421.
    PubMed     Abstract available


  919. CHIC N, Mayo-de-Las-Casas C, Reguart N
    Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
    J Thorac Oncol. 2017;12:e78-e80.
    PubMed    


  920. HSU CL, Chen KY, Kuo SW, Chang YL, et al
    Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
    J Thorac Oncol. 2017;12:e75-e76.
    PubMed    


  921. CHEN CW, Kuo CW, Chen YL, Ho CL, et al
    Successful AZD9291 Therapy in Advanced Non-Small Cell Lung Cancer after Failure of HM61713.
    J Thorac Oncol. 2017;12:e72-e74.
    PubMed    


  922. UGUEN A, Schick U, Quere G
    A Rare Case of ROS1 and ALK Double Rearranged Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e71-e72.
    PubMed    


  923. THUNNISSEN E, Witte BI, Noguchi M, Yatabe Y, et al
    Reply to Letter "The Use of Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer and Its Differential Diagnosis. An International Reproducibility Study in a Demanding Set of Cases."
    J Thorac Oncol. 2017;12:e70-e71.
    PubMed    


  924. SABOUR S
    Immunohistochemistry Improves the Diagnosis of Small Cell Lung Cancer; Statistical Issue on Reproducibility Analysis.
    J Thorac Oncol. 2017;12:e69.
    PubMed    


  925. GREEN S, Dawe DE, Banerji S
    Immune Signatures of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:913-915.
    PubMed    


  926. FARUKI H, Mayhew GM, Serody JS, Hayes DN, et al
    Lung Adenocarcinoma and Squamous Cell Carcinoma Gene Expression Subtypes Demonstrate Significant Differences in Tumor Immune Landscape.
    J Thorac Oncol. 2017;12:943-953.
    PubMed     Abstract available


  927. SHAIKH F, Zauderer MG, von Reibnitz D, Wu AJ, et al
    Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma.
    J Thorac Oncol. 2017;12:993-1000.
    PubMed     Abstract available


  928. SCHROCK AB, Li SD, Frampton GM, Suh J, et al
    Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    J Thorac Oncol. 2017;12:932-942.
    PubMed     Abstract available


  929. VERRI C, Borzi C, Holscher T, Dugo M, et al
    Mutational Profile from Targeted NGS Predicts Survival in LDCT Screening-Detected Lung Cancers.
    J Thorac Oncol. 2017;12:922-931.
    PubMed     Abstract available


    May 2017
  930. SEPESI B, Gold KA, Correa AM, Heymach JV, et al
    The Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 May 25. pii: S1556-0864(17)30390.
    PubMed     Abstract available


  931. WAN R, Wang Z, Lee JJ, Wang S, et al
    Comprehensive analysis of the discordance of EGFR mutation status between tumor tissues and matched circulating tumor DNA in advanced non-small-cell lung cancer.
    J Thorac Oncol. 2017 May 25. pii: S1556-0864(17)30391.
    PubMed     Abstract available


  932. KARLSSON A, Brunnstrom H, Micke P, Veerla S, et al
    Gene expression profiling of large cell lung cancer links transcriptional phenotypes to the new histological WHO2015 classification.
    J Thorac Oncol. 2017 May 20. pii: S1556-0864(17)30388.
    PubMed     Abstract available


  933. FELLER-KOPMAN D, Liu S, Geisler BP, DeCamp MM, et al
    Cost-Effectiveness of a Bronchial Genomic Classifier for the Diagnostic Evaluation of Lung Cancer.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30364.
    PubMed     Abstract available


  934. CRESSMAN S, Peacock SJ, Tammemagi MC, Evans WK, et al
    The cost-effectiveness of high-risk lung cancer screening and drivers of program efficiency.
    J Thorac Oncol. 2017 May 9. pii: S1556-0864(17)30354.
    PubMed     Abstract available


  935. ADAMS MN, Burgess JT, He Y, Gately K, et al
    Expression of CDCA3 is a prognostic biomarker and potential therapeutic target in non-small cell lung cancer.
    J Thorac Oncol. 2017 May 6. pii: S1556-0864(17)30351.
    PubMed     Abstract available


  936. GONG X, Li X, Jiang T, Xie H, et al
    Combined Radiotherapy and anti-PD-L1 antibody Synergistically Enhances Anti-tumor Effect in Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017 May 3. pii: S1556-0864(17)30343.
    PubMed     Abstract available


  937. MIYAUCHI E, Ichinose M, Inoue A
    Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non-Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease.
    J Thorac Oncol. 2017;12:e59-e61.
    PubMed    


  938. DAHELE M, Damhuis R
    The Relationship between Histology, Stage, and Type of Treatment in Patients with Early-Stage Lung Cancer.
    J Thorac Oncol. 2017;12:e58-e59.
    PubMed    


  939. RICCIUTI B, Metro G, Baglivo S, Colabrese D, et al
    Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.
    J Thorac Oncol. 2017;12:e51-e55.
    PubMed    


  940. OGATA H, Yamamoto Y, Harada T, Nakanishi Y, et al
    Severe Aplastic Anemia during Osimertinib Therapy in a Patient with EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:e46-e47.
    PubMed    


  941. ABDUL KARIM L, Wang P, Chahine J, Kallakury B, et al
    Harmonization of PD-L1 Immunohistochemistry Assays for Lung Cancer: A Working Progress.
    J Thorac Oncol. 2017;12:e45.
    PubMed    


  942. THORNE-NUZZO T, Williams C, Catallini A, Clements J, et al
    A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib.
    J Thorac Oncol. 2017;12:804-813.
    PubMed     Abstract available


  943. ZHAO ZR, Situ DR, Lau RWH, Mok TSK, et al
    Comparison of Segmentectomy and Lobectomy in Stage IA Adenocarcinomas.
    J Thorac Oncol. 2017;12:890-896.
    PubMed     Abstract available


  944. RANGACHARI D, VanderLaan PA, Shea M, Le X, et al
    Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 >/=50% Expression in Lung Adenocarcinoma.
    J Thorac Oncol. 2017;12:878-883.
    PubMed     Abstract available


  945. SAXON JA, Sholl LM, Janne PA
    EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
    J Thorac Oncol. 2017;12:884-889.
    PubMed     Abstract available


  946. REULING EMBP, Dickhoff C, Daniels JMA
    Treatment of Bronchial Carcinoid Tumors: Is Surgery Really Necessary?
    J Thorac Oncol. 2017;12:e57-e58.
    PubMed    


  947. LANTUEJOUL S, Le Stang N, Damiola F, Scherpereel A, et al
    PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better?
    J Thorac Oncol. 2017;12:778-781.
    PubMed    


  948. SAVIC S, Rothschild S, Bubendorf L
    Lonely Driver ROS1.
    J Thorac Oncol. 2017;12:776-777.
    PubMed    


  949. BOTLING J, Sandelin M
    Immune Biomarkers on the Radar-Comprehensive "Immunograms" for Multimodal Treatment Prediction.
    J Thorac Oncol. 2017;12:770-772.
    PubMed    


    April 2017
  950. CHANSKY K, Detterbeck FC, Nicholson AG, Rusch VW, et al
    The IASLC Lung Cancer Staging Project: External Validation of the Revision of the TNM Stage Groupings in the Eighth Edition of the TNM Classification of Lung Cancer.
    J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30340.
    PubMed     Abstract available


  951. RECK M, Blais N, Juhasz E, Gorbunova V, et al
    Smoking History Predicts Sensitivity to PARP Inhibitor Veliparib in Patients with Advanced Non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Apr 28. pii: S1556-0864(17)30338.
    PubMed     Abstract available


  952. JENKINS S, C-H Yang J, Ramalingam SS, Yu K, et al
    Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced non-small Cell Lung Cancer.
    J Thorac Oncol. 2017 Apr 17. pii: S1556-0864(17)30280.
    PubMed     Abstract available


  953. SOO RA, Adjei AA
    Predicting Clinical Outcomes Using Proteomics in Non-Small Cell Lung Cancer-The Past, Present, and Future.
    J Thorac Oncol. 2017;12:602-606.
    PubMed    


  954. GARDNER EE, Poirier JT, Rudin CM
    Histone Code Aberrancies in Small Cell Lung Cancer.
    J Thorac Oncol. 2017;12:599-601.
    PubMed    


  955. PETERS MLB, Costa DB, Rangachari D
    Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies.
    J Thorac Oncol. 2017;12:e35-e36.
    PubMed    


  956. LAINE A, Choy H
    Single-Fraction Carbon Ion Radiotherapy for Early-Stage NSCLC-The Future Is Now.
    J Thorac Oncol. 2017;12:610-611.
    PubMed    


  957. JOHN T, Russell PA, Thapa B
    Is Mesothelioma in China Rare or Misdiagnosed?
    J Thorac Oncol. 2017;12:607-609.
    PubMed    


    March 2017
  958. SENAN S, Louie AV
    Correlation, Causation and Confounding-What Is the True Risk of Lung Cancer following Breast Cancer Radiotherapy?
    J Thorac Oncol. 2017 Mar 22. pii: S1556-0864(17)30127.
    PubMed    


  959. YANAGAWA N
    The Clinical Impact of Solid and Micropapillary Patterns in Resected Lung Adenocarcinoma: Author's Reply.
    J Thorac Oncol. 2017;12:e25-e26.
    PubMed    


  960. MAO R, Chen C, Fei K
    The Clinical Implications and Thoughts on Different Patterns in Resected Lung Adenocarcinoma.
    J Thorac Oncol. 2017;12:e24-e25.
    PubMed    


    February 2017
  961. WARTH A, Beasley MB, Mino-Kenudson M
    Breaking New Ground: The Evolving Concept of Spread through Air Spaces (STAS).
    J Thorac Oncol. 2017;12:176-178.
    PubMed    


  962. HEIGENER DF, Reck M
    PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?
    J Thorac Oncol. 2017;12:171-172.
    PubMed    


    January 2017
  963. BASSE C, Merveilleux du Vignaux C, Girard N
    Postoperative Radiotherapy in Completely Resected Stage II and III Thymoma: How to Translate the Potential Survival Benefit in the Setting of the Future Adoption of the IASLC-ITMIG TNM-Based Staging System.
    J Thorac Oncol. 2017;12:e8-e9.
    PubMed    


  964. RUSSO A, Franchina T, Ricciardi GRR, Adamo V, et al
    Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation.
    J Thorac Oncol. 2017;12:e6-e8.
    PubMed    


  965. LI YS, Jiang BY, Yang JJ, Tu HY, et al
    Little Influence of Bevacizumab in Diagnosis of Leptomeningeal Metastases in Current Study.
    J Thorac Oncol. 2017;12:e5-e6.
    PubMed    


  966. VENNIYOOR A
    False-Negative MRI Findings for Leptomeningeal Metastases with Use of Bevacizumab.
    J Thorac Oncol. 2017;12:e5.
    PubMed    


  967. SOLOMON B
    Trials and Tribulations of EGFR and MET Inhibitor Combination Therapy in NSCLC.
    J Thorac Oncol. 2017;12:9-11.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: